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Secreted proteins play important roles in many cellular functions and molecular 
processes. Because secreted proteins potentially enter the blood stream, they can serve 
as valuable measures of health and disease useful for disease diagnosis and prognosis, 
therapeutic target identification, and patient stratification in personalized medicine. 
Consequently, significant interest exists in secreted protein analysis within complex 
biospecimens, particularly blood but significant bioanalytical challenges including the 
wide protein dynamic range >10 orders of magnitude remain. The cellular secretome 
therefore represents a viable alternative to direct biomarker discovery in biofluids. Finally, 
cellular systems are amenable to labeling for the production of intact stable isotope 
labeled (SIL) proteins that can be used as global internal standards for quantitative 
proteomics. In this dissertation, two secretome-focused studies were undertaken. 
The first study involving candidate biomarker discovery in radiation-induced autophagy 
utilized the p53-null and inducible H1299 non-small cell lung cancer (NSCLC) secretome. 
The study identified 364 secreted proteins that were mainly associated with exosomes 
(N=224) and chaperone activity (N=21). CHGB and SCG2 were identified as potential 
population-based biomarkers (for patient stratification) due to their consistent 
overexpression in p53-null H1299 cell secretomes compared to p53-wt cells before and 
after radiation. FAM3C, CANX, EIF5A, GPI, and TXNRD1 were identified as candidate 
biomarkers for patient prognosis following radiotherapy due to their differential expression 
only in response to radiation treatment. 
In the second study, a comprehensive glycoproteomics characterization of the SILAC-
labeled HepG2 secretome was undertaken. 1635 SIL proteins, 492 of which were major 
plasma proteins including 192 cancer biomarkers were identified with high sequence 
 
 
 
 
coverage spanning six orders of magnitude. EDTA plasma spiked with the SIL 
secretomes yielded 63 proteins that were quantified with H/L ratios in all samples out of 
1405 total proteins identified. Additionally, LC-MS/MS analysis of the Con A and WGA 
enriched 72h secretome:plasma sample afforded an opportunity to clearly distinguish 
between glycoproteins in plasma and the HepG2 secretome that share/differ in N-glycan 
structures.  
Collectively, the two studies reveal the suitability of the H1299 cancer cell secretome as 
an experimental model for biomarker studies and support the HepG2 secretome as a 
viable platform for producing SIL glycoproteins.
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Chapter 1: General Introduction 
 
 
 
1.1 Mass Spectrometry-Based Proteomics 
Mass spectrometry is generally viewed as the use of the mass spectrometer in the 
determination of the molecular weight of various species via the measurement of the 
mass-to-charge ratios (m/z) of ions [1]. Mass spectrometry has also been defined by John 
Fenn, the developer of the electrospray ionization technique, as the measurement of 
atomic mass or molecular weight, which may be enough, usually necessary and always 
important for identification of different species [2]. Mass spectrometry is one of the most 
versatile analytical techniques with varied applications in physics, biology, chemistry, as 
well as medicine. The applications of mass spectrometry range from the analysis of 
chemicals and the identification of trace amounts of impurities in drug or biological 
samples to the analysis of biomolecules of which proteins form an important part.  
In the past decade or two, mass spectrometry has become the analysis technique of 
choice not only in research or industry but also in clinical analysis [3]. Mass spectrometry 
offers a number of advantages over other analytical techniques. Amongst its advantages 
are its high molecular specificity in the determination of identity, speed of analysis, wide 
dynamic signal range, quantitative ability and the possibility of coupling with different 
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separation platforms including the more popular chromatographic systems such as gas 
chromatography (GC) and liquid chromatography (LC), and capillary electrophoresis (CE) 
[4, 5].  
Proteomics, coined as an analogous term to genomics, refers to the study of the entire 
protein complement of a cell or tissue or plasma collected at a given time usually to 
determine cellular function [6, 7]. It is a broad field that encompasses many disciplines 
including microscopy, biochemical imaging, and immunoassays [7, 8]. When looked at as 
such, the development of the two-dimensional gel electrophoresis (2D-GE) technique  
that allowed for the display and identification of multiple proteins in complex matrices from 
cells, and/or tissues can be viewed as the early beginnings of proteomics [9, 10]. 
Proteomics  may be classified into qualitative proteomics involving the identification of 
proteins and post-translational modifications (PTMs), quantitative proteomics involving 
the determination of protein levels, and lastly, protein-protein interaction [9]. 
Mass spectrometry (MS)-based proteomics may therefore be defined as the large-scale 
qualitative and quantitative study of proteins using the mass spectrometer. The mass 
spectrometer has gained increasing importance as the most widely used instrument 
platform for proteomics analyses involving complex proteomes [11, 12].  
1.2 Instrumentation 
Pioneering work that formed the basis of mass spectrometry began in the 1880’s with the 
discovery of a new type of radiation that was named Kanalstrahlen, by Eugen Goldstein 
[13, 14]. Sir J. J. Thomson, whose work resulted in the discovery of electrons in 1897, 
developed the first mass spectrometer years later in 1913 by building on the 
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developments of earlier years involving cathode rays [14, 15]. He won the Nobel Prize in 
Physics for measuring the mass of the electron in 1906 [16]. Thomson’s mass 
spectrometer, referred to at the time as a parabola spectrograph, separated ions 
according to differences in the paths of travel in electromagnetic fields and the ions were 
detected by a photographic plate [15]. In the ensuing years, continuous research resulted 
in several developments to the mass spectrometer. For instance, one of the first 
improvements in mass spectrometry came by way of Francis W. Aston, a student of J. J. 
Thomson’s at the University of Cambridge, improving upon the resolving power of 
Thomson’s mass spectrometer. This led to the ability to study isotopes of the same 
element. This happened sometime after World War I around which same time the first 
electron-impact ionization source was developed by A. J. Dempster of the University of 
Chicago in a mass spectrometer with a magnetic analyzer that also improved resolution. 
The work of these scientists formed the basis of modern mass spectrometry and the 
instrumentation. 
The current mass spectrometer consists primarily of three parts, namely an ion source, a 
mass analyzer, and a detector [7]. The ion source is responsible for the conversion of 
molecules to ions that are then separated based on their mass-to-charge (m/z) ratios in 
the mass analyzer and finally detected by the detector [1].  
1.2.1 Ionization 
Ionization is the process of converting molecular analyte species into charged ions and 
is necessarily the most critical step in mass spectrometry especially as it relates to 
macromolecules such as peptides and proteins. It may also involve the transfer of already 
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charged molecules into the gaseous phase [2]. The conversion of neutral molecules into 
charged species may occur via protonation or deprotonation, electron removal or addition, 
or by cationization [2]. 
Ionization of species affords the ability to obtain information on the m/z of the intact 
molecule (precursor), and fragments of the precursor ion. These two pieces of information 
are critical in the identification and quantification of peptides and proteins in MS-based 
proteomics measurements. There have been many developments in the ionization of 
molecules since the popularization of mass spectrometry as an analytical technique. The 
revolution of ionization has gone from hard ionization sources such as electron-impact 
ionization (EI - 1918), and chemical ionization (CI - 1966) to the so-called soft ionization 
techniques such as field desorption MS of organic molecules (1969), plasma desorption 
(1974), fast atom bombardment (FAB - 1981), matrix-assisted laser desorption ionization 
(MALDI – 1983), and electrospray ionization (ESI - 1984) [15].  The “soft ionization” 
techniques are so called because of the minimum internal energy transferred to the 
analyte ions during the process. Other ionization techniques including atmospheric 
pressure chemical ionization (APCI) and atmospheric pressure photo-ionization (APPI) 
exist and have application in mass spectrometry analysis involving small molecules. 
These are often used in the analysis of small biomolecular species unlike ESI and MALDI 
despite being considered “soft ionization” techniques.  
The first and most characterized ionization method is the electron-impact ionization 
developed by A. J. Dempster. In EI, an electron beam is applied to the neutral analyte 
molecules in the gas phase causing electrons to be knocked off the neutral molecules, 
which leads to a positively charged analyte ion [13]. Alternatively, in CI, a reagent gas 
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molecule (e.g. methane, isobutene, ammonia) is ionized by electrons and the resulting 
reagent gas ions or radicals react with neutral reagent molecules to cause ionization. 
Together with electron ionization, CI has a practical mass range of up to 0.5 kDa. Samples 
amenable to EI and CI must be thermally volatile and stable. Mass spectra obtained using 
EI are very informative due to the presence of sufficient fragment information. Being also 
that EI mass spectra are very reproducible, EI is applied in the generation of spectral 
libraries for many small molecules. As a hard ionization technique, EI may result in either 
a molecular ion of the neutral molecule or fragment ions. The molecular ion is however 
hardly observed. Compared to EI, CI produces relatively simpler mass spectra due to less 
fragmentation. 
Mass spectrometers were originally employed in the study of elements and their naturally 
occurring isotopes. Hard ionization techniques were therefore sufficient for the 
applications of the instrument. Organic compound studies using mass spectrometers did 
not happen until the late 1950s and in 1959 peptides and oligonucleotides were 
sequenced [17]. By the 1980s, mass spectrometry had become routine for the analysis of 
smaller organic biomolecules. The existing ionization methods could however, not be 
used for the mass spectrometry analysis of macromolecular species such as proteins due 
to the inability to analyze intact species without extensive fragmentation. It was not until 
the development of ESI that macromolecules such as proteins were analyzed 
successfully. For these thermolabile samples (proteins and oligopeptides), successful 
proteomics analysis required “soft ionization” techniques such as FAB, ESI and MALDI in 
order to produce ions with little fragmentation [1, 18].  
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FAB, among the early “soft ionization” techniques to be developed, involves the ionization 
of analytes applied onto a target and bombarded with a continuous high current of atoms, 
neutral molecules, or ions [2]. The analyte is dissolved in a liquid matrix (e.g. glycerol, 
thioglycerol, m-nitrobenzyl alcohol) prior to bombardment by the beam of particles which 
results in the desorption of the analyte. Owing to the ability to generate multiply charged 
species, later “soft ionization” techniques such as ESI and MALDI have become the 
predominant techniques used in LC-MS/MS-based proteomics with ESI being the most 
widely used and preferred mode of ionization [18–20].  
1.2.1.1 Electrospray Ionization (ESI) 
The introduction and development of electrospray ionization is credited primarily to 
Yamashita and John B. Fenn, but the efforts of the Aleksandrov group are recognized [21, 
22]. Fenn’s efforts led to the joint award of half of the 2002 Nobel Prize in Chemistry with 
Koichi Tanaka who first reported his work with laser desorption ionization of proteins [23]. 
The pioneering work that set the stage for the possibility of electrospray ionization began 
with Malcolm Dole as Fenn himself attested to [24, 25]. 
ESI represented a huge breakthrough in the efforts to extend the applications of mass 
spectrometry to biomolecules especially proteins and large peptides. In electrospray 
ionization, a high voltage (~ 1.5 to 5 kV) is applied to a stream/aerosol of molecules 
emanating from a narrow tip resulting in charged droplets. It occurs at atmospheric 
pressure [26]. Solvents used for ESI typically combine water and a volatile organic solvent, 
which improves the sensitivity of the analysis. Low concentrations of acids such as formic 
acid may be used to enhance ionization of analytes. 
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Two major theories exist to explain the mechanism of ion production from the charged 
droplets namely the ion evaporation model (IEM) and the charge residue model (CRM) 
[21, 24–28]. In the IEM, an applied high temperature then results in the evaporation of the 
droplets until the concentration of charges on the droplets reaches a limit greater than the 
Rayleigh limit [26]. Small charged droplets are then formed and from these droplets, ions 
emerge and are directed into the mass spectrometer [21, 26]. The charged residue model 
proposes that droplets from the electrospray tip undergo shrinkage due to solvent 
evaporation. Successive fission events that ultimately result in very small droplets 
containing single ions of the analyte [21]. It is generally believed that, in ESI, the IEM 
provides a better explanation for gas phase ion production whereas for very large 
molecules, the CRM is more likely [24, 26]. 
As a “soft ionization” technique, ESI has a number of advantages including most 
importantly, the compatibility with liquid chromatography coupled to the mass 
spectrometer. Again, the formation of multiply charged ions helps to extend the mass 
range of fixed range analyzers. Furthermore, being a “soft-ionization” technique, the ions 
produced retain the structural properties of the original molecule permitting structural 
analysis. ESI is also useful in the analysis of many non-covalent complexes due to the 
relatively low energy transferred to molecules during ionization [18]. Very low detection 
limits in the femtomole range have been achieved with ESI [2, 29]. Amongst its 
disadvantages, ESI is known to be affected by ion suppression due to matrix effects and 
may not be sufficient for the efficient ionization of neutral and non-polar or low polarity 
species such as lipids [18, 29, 30].  
1.2.1.2 Matrix-Assisted Laser Desorption Ionization (MALDI) 
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MALDI, like ESI, is a “soft ionization” method used for the mass spectrometry analysis of 
macromolecules. The development of MALDI is erroneously credited to Koichi Tanaka 
citing the Nobel Prize even though the award to Tanaka and Fenn was "for their 
development of soft desorption ionization methods for mass spectrometric analyses of 
biological macromolecules" [16]. It is important to note that Karas and Hillenkamp 
contributed significantly towards what is now referred to as MALDI [31]. In Tanaka’s laser 
desorption ionization experiment, he used glycerol and an ultrafine cobalt powder (300 Å 
diameter) mixture as the matrix and showed the ionization of protein molecules up to 100 
kDa [32, 33]. Tanaka’s work was very important in showing that large biomolecules could, 
in fact, be analyzed using laser desorption. Alternatively, for their ultraviolet-laser MALDI 
work, Karas and Hillenkamp used nicotinic acid, an organic compound, as the matrix 
which was later proven to be more sensitive and produced more stable ions than Tanaka’s 
approach [16, 32]. The Karas and Hillenkamp laser desorption approach was more widely 
accepted and used by the mass spectrometry community owing to its superiority. 
In its currently used configuration, MALDI mass spectrometry involves the mixture of the 
protein or peptide sample to be analyzed with a matrix consisting of a compound able to 
absorb ultraviolet light from a laser pulse. Organic matrices such as nicotinic acid, 
sinapinic acid, α-cyano-4-hydroxycinnamic acid, or 2,5-dihydrobenzoic acid are typically 
used with sinapinic acid and α-cyano-4-hydroxycinnamic acid being the most commonly 
used matrices for protein and peptide analysis respectively [17, 30]. The mixture of the 
analyte and the matrix is transferred onto a metal plate and dried, after which the laser 
pulse is applied. The wavelength of the laser used is dependent upon the organic matrix 
being used. The matrix molecules absorb the laser and the mixture is desorbed from the 
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surface of the plate carrying analyte molecules with them into the gas phase [30]. Excited 
matrix molecules then transfer charges to the analyte molecules resulting in the ionization 
of the analyte. In addition to UV lasers, infrared lasers also find use in some MALDI 
applications. MALDI differs from FAB in that in MALDI, a pulsed laser is used to desorb 
analyte molecules from the target whereas a continuous beam of particles is used in FAB 
[2]. The use of pulsed lasers and the subsequent generation of ions in pulses has made 
MALDI most suited to time-of-flight (TOF) mass spectrometers and as a result, the 
majority of MALDI applications now are used in tandem with TOFs [32]. MALDI, as an 
ionization technique, is however capable of being coupled with other kinds of mass 
spectrometers.  
Various advantages are associated with the use of MALDI in LC-MS/MS. Unlike ESI, 
MALDI is not sensitive to the presence of salts, detergents, and contaminants at low 
concentrations [13]. MALDI also has a practical mass range up to 300 kDa but higher 
molecular weight species have been observed with MALDI and a high current detector [2]. 
In MALDI, the use of lasers may result in photodegradation of the analyte and the matrix 
may interfere with the identification of small molecules up to 0.7 kDa [2]. 
1.2.2 Mass Analyzers 
In the mass analyzer, ions from the ion source are separated and detected. The degree 
of separation and detection of ions with very close m/z ratios is denoted by the resolution 
R, of the instrument. Resolution R is calculated as the width of the ion signal peak (Δm – 
typically taken at half of the peak height) divided by the mass M of the species [30]. 
Enormous challenges occur in the analysis of various samples by mass spectrometry 
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owing to the complexity of mixtures analyzed in proteomics [7, 34, 35]. In response to the 
increasing complexity of samples in proteomics analysis, mass spectrometers continue 
to see improvements in sensitivity, selectivity, speed and resolution through development 
of mass analyzers [34, 36].  
The development of the mass-resolution double-focusing mass spectrometer by Alfred 
Nier, an engineer and physicist, contributed immensely to the advancement and 
widespread adoption of mass spectrometry. In collaboration with Enrico Ferni, Nier 
successfully separated the uranium isotopes 238U and 235U using his high-mass-resolution 
double-focusing mass spectrometer [15, 16]. Further advancements resulted in TOF 
analyzers which were developed in the 1940s but only made public after World War II 
due to issues of secrecy during the war [37]. TOFs operate under the principle that ions of 
different masses or m/z will travel at different velocities through a known distance towards 
a detector; larger ions move slower relative to smaller ions of the same charge. 
Theoretically, TOF analyzers have limitless mass range even though this is not seen in 
practice [15].  
The development of quadrupole mass analyzers and later quadrupole ion traps in the 
1950s was championed by Von Wolfgang Paul and Helmut Steinwedel [1, 15]. Quadrupoles 
currently constitute the most common mass analyzers in mass spectrometry. They 
consist of four carefully engineered parallel rods equidistant from one another. 
Quadrupoles may function as ion traps where they store ions and as mass analyzers for 
the resolution and measurement of m/z ratios of the stored ions [38]. Von Wolfgang Paul 
received a Nobel Prize in Physics in 1989 for his research on ion trapping. When 
functioning as mass analyzers, ions passing centrally through quadrupoles are separated 
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according to their m/z ratios using electric fields generated by voltages applied to the 
rods. Quadrupoles may be used to permit the passage of only ions of a given mass-to-
charge ratio by controlling the magnitude of fixed direct current and alternating radio 
frequency voltages applied to the rods. These ions subsequently move into a detector 
while ions with different m/z ratios simply collide with the rods, as they are unable to 
traverse the trajectory created by the applied voltages. The stability of quadrupoles and 
their ability to do tandem MS saw them adopted and used more than Nier’s double-
focusing mass spectrometer even though the latter was more accurate [15].  
Marshall and Comisarow, colleagues at Stanford and then at the University of British 
Columbia in Canada, were the pioneers of Fourier transform ion cyclotron resonance (FT-
ICR) mass spectrometry in 1974 [16, 39]. ICR had originally been used by J. A. Hipple and 
colleagues in the late 1940s but Marshall and Comisarow applied FT to the technique, 
truly transforming mass spectrometry [15, 16, 40]. ICR instruments operate by the application 
of a radio frequency electric field (same frequency as the ions cyclotron) under a uniform 
magnet field, which ultimately results in the oscillation of these charged species in the 
electromagnetic field [15, 16]. Detection is recorded as the current produced as rotating ions 
strike a collector. FT-ICR instruments are highly sensitive and accurate with powerful 
resolution and large dynamic range of detection and quantitation [7]. Resolution in the sub-
ppm range is possible with FT-ICR [15]. ICR instruments and quadrupoles represent 
different forms of ion traps and are also known respectively as Penning and Paul ion traps 
[39]. 
Increasing complexity of samples analyzed (e.g. cell and tissue lysates, plasma, urine, 
cerebrospinal fluid) in mass spectrometry has necessitated continuous developments in 
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mass analyzers for increased sensitivity, speed, and resolution [34]. Recent improvements 
in mass spectrometry have mainly come by way of analyzers involving different 
combinations of the four main separation principles currently in existence: quadrupole 
mass filters, time-of-flight, linear ion traps, and Orbitrap™ mass analyzers [18, 34]. 
Combinations of two or more mass analyzer types in instruments such as the triple-
quadrupole, and quadrupole/time-of-flight (Q-TOFs) mass spectrometers represent the 
early efforts at improving resolution compared to single analyzer instruments [4].  
1.2.2.1 Orbitrap-based Mass Analyzers 
The orbitrap represents the latest development in mass analyzers and was first described 
by Makarov in 2000 [41]. These mass analyzers came after the ion traps. While very 
important in mass spectrometry, ion traps have been shown to have disadvantages 
including limited range and charge capacity as well as inadequate mass accuracy.  
Developed by Makarov, the orbitrap represents an improvement in mass accuracy, 
reduced size and cost, and increased linear dynamic range as well as charge capacity. 
The orbitrap operates on the principle of orbital ion trapping where injected ions are 
trapped between a coaxial outer electrode and an axial inner spindle-shaped electrode 
[41, 42]. The trapped ions rotate around the spindle-shaped central electrode while 
oscillating along the horizontal axis. The frequency of the harmonic oscillations is directly 
proportional to the √z/m [41]. The time-domain signal current produced on the outer 
electrodes is converted to frequency-domain and then to m/z ratio via Fourier transform 
[34, 43]. Modern orbitrap instruments are capable of resolving powers of up to 1M and mass 
accuracies in the low parts per million (ppm) [42, 44]. Different hybrid combinations of 
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orbitrap have been developed since the single orbitrap analyzer instrument was first 
developed and described including the linear ion trap-orbitrap (LTQ-Orbitrap) 
configuration [34]. The Q-Exactive is a tandem mass spectrometer that combines a 
quadrupole mass filter with Orbitrap mass analysis (Figure 1). The unique configuration 
of the Q-Exactive affords it the ability to develop new proteomics methods based on high 
resolution and accurate mass (HR/AM) analysis including targeted analysis in both MS 
and MS/MS modes [45]. The Q-Exactive differs from the earlier LTQ-Orbitrap instruments 
due to the presence of an S-lens, which ensures the transfer of higher number of ions 
into the MS [11, 34]. Resolutions of 140K full width half maximum (FWHM) at m/z 200 can 
be achieved on the Q-Exactive [11].  
In the Q-Exactive, protein/peptide molecules ionized as they emerge from the ESI tip are 
transferred into the MS via an ion transfer tube through the S-lens. Ions then pass through 
an injection multipole into a bent flatapole configured to allow droplets to exit easily. From 
the bent flatapole, by means of a lens, ions enter the quadrupole where all ions may be 
Figure 1 - Schematic of a nanoLC coupled to a Q-Exactive Mass Spectrometer 
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transmitted directly into the adjoining octapole or only a given m/z window is isolated and 
allowed to go through. Another lens at the exit of the quadrupole transfers ions to the 
octapole from where they are sent into the C-trap. In MS mode, ions are transmitted from 
the C-trap to the orbitrap for detection; in MS/MS mode, ions are transferred into the 
higher-energy collision-induced dissociation (HCD) cell where they are fragmented by 
manipulating the radiofrequency rods and then sent back into the C-trap, and transmitted 
into the orbitrap for detection [34]. Trapping of fragmented ions in the HCD cell requires 
that the offset of the radiofrequency rods in the HCD cell make the cell negative relative 
to the C-trap and the HCD exit lenses [34]. This also permits the entry of other precursor 
ions for fragmentation and transfer of all fragment ions to the C-trap and then to the 
orbitrap for detection. 
The complexity of the proteomics samples analyzed using mass spectrometers such as 
the Q-Exactive necessitates the separation of the component species prior to MS analysis 
to allow for maximum identification and quantification. Consequently, mass 
spectrometers are coupled to many separation platforms including high performance 
liquid chromatography, gas chromatography, and capillary electrophoresis [1, 5, 18]. The 
majority of mass spectrometry-based proteomics measurements however employ 
reverse-phase high-performance liquid chromatography coupled to a high-performance 
tandem mass spectrometer (MS/MS) due to a combination of factors such as high peak 
capacity, decreased ion suppression, and compatibility of solvents with ESI [46, 47]. 
Collectively this instrument platform is referred to as LC-MS/MS. 
1.2.3 High Performance Liquid Chromatography (HPLC) 
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The Russian botanist Mikhail Tswett is acknowledged as the pioneer of liquid 
chromatography based on his separation of various plant pigments from a petroleum-
ether extract by passing the extract through a powdered calcium carbonate glass column 
[48]. Tswett’s work did not gain much interest until the 1930s when chromatography was 
employed for biochemical separations.  
Liquid chromatography now represents one of the most popular and important analytical 
tools in science. The technique involves the separation of samples based on their 
differential interactions between the components of the sample and two phases: a solid 
support called the stationary phase and a liquid called the mobile phase. Csaba Horváth’s 
work in the 1960s with capillary columns of 276 µm internal diameter (I.D.) to separate 
nucleotides formed the foundation for the development of high performance liquid 
chromatography which greatly improved the separation capability and analysis time of 
liquid chromatography [24, 49]. Previously referred to as high-pressure liquid 
chromatography, HPLC involves the use of high pressures to generate the flow of liquid 
necessary to allow for chromatographic analysis involving packed columns. 
Developments in instrumentation (such as increased pressure up to 6,000 psi) that 
consequently resulted in higher performance of the technique prompted the change of 
the name to high performance liquid chromatography.  
Chromatographic sample separation can be done via one of three major separation 
mechanisms. These mechanisms include polarity, charge, and size. In HPLC/UPLC, four 
modes of separation are employed namely normal phase (polarity), reverse phase 
(polarity), ion exchange (charge), and size exclusion/gel permeation (size). Size exclusion 
chromatography is usually employed for the separation of species based on weight. 
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Stationary phases have pores into which smaller species go and are retained, therefore 
eluting much later than larger species, which move around the particles and are not 
retained. In ion exchange chromatography, samples are separated based on their charge. 
The stationary phase is usually a charged resin that attracts and retains species of 
opposite charge. The mobile phase comprises solutions with increasing concentration of 
salts with oppositely charged species that displace tightly retained or bound species. 
Normal and reverse phase HPLC, the most common separation technique used in LC-
MS/MS, involve the separation of species based on polarity (hydrophilicity or 
hydrophobicity). In normal phase, a polar (hydrophilic) stationary phase, usually free 
silica, and a non-polar (hydrophobic) mobile phase are employed. Hydrophilic samples 
have higher affinity for and partition more into the hydrophilic stationary phase. They are 
therefore bound more tightly to the stationary phase and elute later than hydrophobic 
species that partition more into the mobile phase, and are eluted much earlier. Reverse 
phase HPLC employs the opposite configuration where the stationary phase is usually a 
hydrophobic support of alkyl-chain molecules (e.g. butyl, pentyl, octadecylsilane, octyl, 
cyclohexyl etc.) bonded to silica, and the mobile phase is hydrophilic [43]. Long-chain 
carbon, usually, C-18 (octadecyl) is used for most proteomics applications involving 
peptide and oligopeptide analysis while shorter chains such as butyl and octyl are typically 
used in intact protein analysis [43]. This is the most commonly employed mode of HPLC 
for tandem mass spectrometry-based proteomics analysis. 
1.2.1.1 Principles of Nanoscale Liquid Chromatography (nano-LC) 
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Conventional HPLC typically involves the use of large columns with internal diameters 
ranging from 3.5 – 4.6 mm and the flow rates employed in separation using these columns 
are usually in the mL per minute range [50]. In nano-LC, internal column diameters range 
from 10 – 150 µm with 75 µm being the most common while typical flow rates in the 10 – 
1000 nL per minute range are routinely used [50–52]. The use of micro- and nanoscale 
columns and flow rates have become increasingly routine, due primarily to applications 
in biomolecule analysis carried out with MS-based proteomics due to a combination of 
many advantages of nano-flow chromatography systems. These include the increased 
efficiency of separation, increased sensitivity, considerable decrease in sample quantity 
requirement, and decrease in stationary and mobile phase volumes necessary for 
effective separation [47, 50, 53]. Importantly, the compatibility with nano-ESI introduced by 
Wilmar and widely employed in mass spectrometry has been very instrumental in the 
current widespread adoption of nanoscale liquid chromatography in proteomics [47, 50]. 
This compatibility has contributed to the detection and quantitation of very low 
concentrations of peptides possible [21, 22, 46]. 
In liquid chromatography, the efficiency of separation and length of time that a component 
molecule spends on the column interacting with the stationary phase are affected by a 
number of factors. These include the dimensions of the column (length, internal diameter 
I.D.), stationary phase particle size, porosity of the stationary phase packing, and the 
composition and flow rate of the mobile phase [54]. The efficiency of the chromatographic 
separation process is dependent on the degree of dilution of the analyte by the mobile 
phase (chromatographic dilution) during the separation process. Chromatographic 
dilution (D) is related to the column I.D. as shown in the equation below [50]. 
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𝐷 =  
𝐶𝑜
𝐶𝑚𝑎𝑥
=  
𝜋𝑑𝑐
2𝜀(1 + 𝑘)√2𝐿𝐻𝜋
4𝑉𝑖𝑛𝑗
 
where 𝐶𝑜 and 𝐶𝑚𝑎𝑥  are the initial and final concentrations of the analyte respectively, 𝑘 is the retention factor 
(k = 0 for a non-retained analyte), 𝐿 the column length, 𝐻 is the theoretical plate height, 𝑉𝑖𝑛𝑗 is the volume 
of sample injected, and dc is the internal diameter (I.D.) of the column. 
From the equation, it is evident that decreasing column diameter and length results in a 
consequent decrease in chromatographic dilution, which ultimately leads to increased 
analyte concentration and a consequent increase in instrument sensitivity. The use of 
increasing mobile phase strength in gradient elution may compensate for the loss of 
sensitivity that results from high chromatographic dilution but this is less than the effect 
of column diameter on the sensitivity [52]. Furthermore, in nano-LC, peak broadening 
which is related to both the column I.D. and length may present issues with separation 
efficiency and lead to poor chromatographic resolution. Peak broadening decreases with 
decreasing column I.D. and length which is positive for resolution [50]. This also has 
implications on quantification of analytes since better-resolved peaks allows for more 
accurate quantification of the component species of the sample. Other factors that may 
affect resolution due to peak broadening include pre- and post-column dead volume [50, 
52]. The effect of dead volume on peak broadening is more pronounced in shorter 
columns, all other factors being kept constant. To decrease the effect of dead volume on 
the efficiency of nano-LC chromatographic separation, low volume tubing together made 
of fused silica with short and tight fittings, usually made of polyetheretherketone (PEEK) 
are employed [50, 52]. Alternatively, some applications employ nano-ESI emitters with 
stationary phase material which considerably decreases dead volume [52].  
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Other factors that influence the degree and quality of separation achieved in 
chromatographic separation and hence peak capacity are column length and gradient 
time. In principle, with all other factors kept constant, longer gradients results in less 
interaction time between sample and stationary phase resulting in faster elution and 
consequently decreased retention time.  
1.3 Approaches to Protein Identification 
There are four different technological platforms necessary for mass spectrometry-based 
protein identification. These include platforms for the isolation, extraction, or separation 
of proteins from complex mixtures/matrices and instrumental analysis of the separated 
proteins to obtain structural information [7, 55]. The results of the instrumental analysis then 
need to be compared to an available gene and/or protein database, and lastly 
bioinformatics platforms usually involving computer programs and complex algorithms for 
matching raw data to the database information to give protein identification and 
quantification [56].  
Before the widespread use of mass spectrometry for protein identification and 
quantitation, techniques such as one and two dimensional gel electrophoresis (1DE/2DE), 
Western blots, were the major methods for molecular weight determination as well as 
comparative proteomics [30]. Edman degradation was used in sequencing peptides and 
proteins by cleaving amino acids from the N-terminus [57]. The techniques use protein 
migration differences resulting from differences in size and charge to separate proteins; 
the same protein from different samples may then be compared using different 
visualization strategies including fluorescence staining. 2DE is now used for protein 
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separation following which isolated proteins may be analyzed either via top-down or 
bottom-up proteomics [43, 55]. To extract proteins, gels are excised and solvents applied to 
the gel to dissolve the protein of interest. 
There are two main approaches in mass spectrometry-based proteomics namely top-
down and bottom-up strategies. In top-down proteomics, intact proteins are isolated or 
extracted and analyzed by mass spectrometry whereas in bottom-up proteomics, 
proteolytic peptides that result from digestion of intact proteins are analyzed by mass 
spectrometry [55, 58]. The limited fixed mass range of most commercial mass 
spectrometers makes top-down proteomics rather limited in its routine application in many 
proteomics labs. While large proteins may be capable of carrying more charge, it is more 
difficult to ionize them [55]. Again, separation of macromolecules is more challenging 
compared to the bottom-up approach using conventional modes of separation such as 
reverse phase chromatography. Furthermore, the effect of analyzer resolution is more 
apparent with higher molecular weights making it necessary for instruments used in top-
down proteomics to be capable of very high resolution [55]. Higher energy is also needed 
for fragmentation of higher molecular weight species. In spite of the stated challenges, 
top-down proteomics is useful for a number of reasons. It allows for the characterization 
of many properties of a protein relating to structure e.g. PTMs [43]. Moreover, since the 
analysis is of intact proteins, major issues associated with inferring protein presence from 
peptides are avoided. Top-down proteomics may also be better suited for the 
characterization of protein-protein interactions. Advancements in mass spectrometry from 
sample preparation to analyzer m/z range, sensitivity, and resolution present hope for the 
imminent adoption and routine use of the top-down approach for proteomics studies. 
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Of the two approaches, bottom-up proteomics also called shotgun proteomics is currently 
the most widely used by proteomics researchers for protein identification and 
quantification [6].  
1.3.1 Bottom-Up Approach 
In bottom-up or shotgun proteomics, proteins are digested into peptides using chemicals 
or enzyme; enzymes used are specific in their proteolytic activity [43]. The most commonly 
used enzyme is trypsin, which being specific in its cleavage of the peptide bond, cleaves 
only at the C-terminal of arginine and lysine residues unless these are C-linked to proline 
or N-linked to aspartic acid. Trypsin is also used due to the ability of tryptic peptides to be 
charged positively at both N- and C-termini. Due to the specificity of the enzyme, an in 
silico digestion of all proteins in the database may be carried out using the specific rules 
of cleavage and a list of the theoretical m/z ratios of the resulting peptides generated. In 
the identification of proteins, the m/z values should fall within a given range of the 
theoretical or in silico generated m/z values. It is therefore very essential that the charge 
states of the ions be accurately determined as this provides an accurate starting point for 
the identification process. High-throughput protein identification relied on the use of the 
Peptide mass fingerprinting (PMF) for quite a long time. PMF is a technique in which a 
single, usually unknown, protein is digested and the masses of the resulting peptides 
determined experimentally and compared to a database of proteins and their 
corresponding peptides [56]. 
Despite being the most commonly used proteomics approach, various issues associated 
with the use of peptides to make inferences on the presence and quantities of proteins in 
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an analyte mixture remain. Peptides that are not specific to a given protein may be 
wrongly assigned which affects protein identification. In addition to potential wrong 
assignment of peptides to proteins, not all peptides coming from a digest protein may be 
observed or identified in the mass spectrometry analysis resulting in lost information 
which may be important, necessary even, for the identification of possible PTMs, 
sequence variation, or domains for binding etc. [43].   
1.3.2 Fragmentation 
Tandem MS information obtained from fragmentation of peptides is the backbone of some 
of the search algorithms used in protein identification. Many fragmentation methods exist 
but the most predominantly used method in many mass spectrometers including the triple 
quadrupoles, the Q-TOF, and the LTQ-Orbitrap is collision induced dissociation (CID) [34, 
59]. In CID, precursor molecular ions are accelerated and made to collide with the 
molecules of an inert gas (e.g. nitrogen, helium, or argon) which results in bond cleavage 
through the conversion of kinetic energy into internal energy [59]. CID usually involves the 
use of low energy gas molecules (less than 100 eV) for the collision. This produces 
cleavage of amino acids predominantly along the peptide bond and yields b-ions, y-ions, 
and neutral water or ammonia losses. Many search algorithms therefore use b- and y-ion 
information in identification of peptides (Figures 2 & 3) [59]. 
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A higher energy variation of CID known as higher energy collisional dissociation (HCD) 
is used in orbitrap-based systems including the Q-Exactive [34]. Other fragmentation 
methods used in mass spectrometry include electron capture dissociation (ECD), surface 
induced dissociation (SID), and electron transfer dissociation (ETD) [59, 60]. 
1.3.3 Database Searching for Protein Identification 
Proteins are identified by one of three main methods including database searching using 
a database of proteins of the relevant species, de-novo sequencing, or tag-based 
algorithms [61]. Database searching is by far the most popular method. 
There are three main database searching approaches to protein identification including 
the use of only peptide (precursor) masses, the use of tandem MS information from one 
or more peptides of a protein, or the use of both mass data and amino acid sequence 
information or physicochemical data directly related to the amino acid composition [59, 62]. 
Figure 2 - Tandem MS fragmentation of a generic 
dipeptide 
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The main aim of database searching in protein identification is to correctly identify proteins 
in the experimental data that are in the database or in the case of proteins which are not 
in the experimental database, identify the proteins that are closest in sequence homology 
to the experimental proteins [62]. There are a number of protein databases, the most 
popular amongst them being the Uniprot, human IPI, and NCBI databases. The Uniprot 
database uses the Fasta format, which comprises amino acid sequence represented by 
single letters and written as a string of characters usually 60 characters per line and never 
exceeding 80. The databases consist of all experimentally identified and validated 
proteins (and sometimes, theoretical proteins based on mRNA expression). 
Figure 3 - Intact Peptide Identification and Fragmentation 
The monoisotopic peak 587.3092 of the intact peptide ITSEIPQTER was identified around ~ 35 mins and picked for 
MS/MS fragmentation and analysis. Many y-ions and a couple of b-ions were identified from the MS/MS spectrum of 
the fragmented peptide. 
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The acquisition software of an LC-MS/MS system produces a chromatogram of both 
peptide and fragment ions (Figure 3) from the raw data obtained from the instrument. 
Within the chromatogram are the spectra (represented by single peaks positioned at the 
center of the mass to charge ratio distribution and referred to as centroids) of all identified 
precursor and fragment ions. The spectra are identified and converted to m/z ratio data 
by complex deconvolution algorithms within the various software packages. The accurate 
estimation of the m/z ratio of a precursor ion is predicated upon the correct determination 
of the charge of that precursor. Using the isotopic peak distribution of a precursor ion, 
deconvolution algorithms are used to determine the charge states of a peptide and hence, 
the m/z ratio [59].  
In-silico peptides are generated through the digestion of all proteins in the database using 
computer algorithms. The in-silico peptides are then fragmented by the program and the 
similarities between these theoretical computer-generated spectra compared to the 
experimental spectra generated on the instrument [61]. The quality of the spectra 
generated by the mass spectrometer therefore plays a key role in correct matching of 
sequences and subsequent identification. The quality of the experimentally generated 
spectra is therefore very important; the poorer the quality of a spectrum, the higher the 
likelihood of false identifications based purely on chance. Algorithms assessing spectral 
quality therefore exist to help eliminate poor quality spectra. Some of these algorithms 
use statistical regressions to determine the quality of spectra and hence determine which 
spectra to eliminate [59, 63]. 
Various models also exist which are used by different programs or algorithms to predict 
the fragment ions and spectra of a given peptide against which to search the experimental 
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data [59]. The fragment ions are usually predicted to be mostly composed of b- and y-ions, 
which result from breaking the amide bond between amino acids in the peptide structure. 
Other ions such as a-, x-, c-, and z-ions may arise but these are not normally used [59]. 
The MS/MS spectra of all experimental peptides that were within the allowed mass range 
of a given precursor mass are matched to theoretical fragment spectra and scores 
assigned to all the matching spectra using a model [59, 64]. The score is a function of the 
calculated probability that the match is a true match or happened by chance [59, 62, 64]. A 
program such as Mascot uses this probability scoring to filter out the candidate precursor 
masses [64]. The highest scoring matches, which have the lowest probability of being 
chance events, are then used to estimate the protein scores. The precursor m/z values 
are compared to the in-silico or predicted values and a list of candidate proteins generated 
by the algorithm. The candidate precursors (peptides) are validated according to a 
number of criteria which may include, for instance, the number of fragment ion matches 
[59, 65]. Unique peptides are more easily matched to their respective proteins. For the 
peptides that are not unique, a program like MaxQuant employs the “Occam’s Razor” rule 
and assigns non-unique peptides to the protein with the most identified peptides. Mascot 
uses the “Principle of Parsimony” and chooses the protein ID with the simplest and most 
reasonable justification [64]. Some algorithms (such as Percolator in Proteome Discoverer) 
employ a target-decoy search tool in the protein identification sequence, which reveals 
the number of false identifications and hence sets the false discovery rate (FDR). The 
decoy databases comprise ‘nonsense’ protein sequences (reverse or random protein 
sequences of the actual database). The decoy database may be concatenated with the 
actual database and searched as one or the actual and decoy databases may be 
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searched individually against the experimental data. Any hits in the decoy database 
represent false identifications or false positives which are then used to determine the FDR 
calculated as the ratio of false positives to total number of identifications [61]. Percolator 
employs an iterative machine learning algorithm to learn different features of correct and 
incorrect identifications in the actual and decoy databases respectively [61]. The target 
decoy database searching which provides the FDR may be a limitation in analyzing lots 
of different datasets of the same proteome as opposed to one or a few [58]. It is important 
to note however, that when analyzing many datasets, there is a disproportionate increase 
in true positives versus false positives owing to the duplication or repeated sampling of 
the same proteome. The independence of false positives on the proteome against which 
the data is searched may give rise to this [58]. Again, some search algorithms such as 
Mascot employ probability scoring and rely on the size of the database to set the FDR 
threshold. Accordingly, the use of concatenated decoy databases increases the size of 
the database and therefore raises the FDR which translates into fewer peptide 
identifications or hits [61]. A workaround is to keep target and decoy databases separate 
and searching the data against them separately. 
The identification of non-unique proteins by the programs is a limitation of current 
methods. Proteins with significant sequence homology, such as isoforms of the same 
protein, may not be correctly separately identified by the program and such proteins are 
usually put into one protein group when they may in fact be different proteins. Again, the 
accuracy of protein identifications may be further complicated by the presence of 
modifications on the proteins. Modifications may be PTMs or have occurred during the 
sample processing steps. This introduces a complexity into the identification process 
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seeing as the modifications may increase exponentially the number of possible hits for a 
given mass to charge ratio. The software and the user may not be able to provide a list 
of all these modifications to accurately determine the exact sequence matches for the 
proteins in the experimental data. One other limitation of protein identification using 
database searching is the limited number of proteins available in the protein databases. 
However, until there is a comprehensive and exhaustive list of all possible proteins, there 
is always the possibility of missing important information in the mass spectra generated 
by the instrument. An exhaustive protein database seems an impossible feat right now 
considering all the possible PTMs and SNP/splice variants that may exist for each protein. 
In organisms with incomplete genome sequences where proteomics studies may seek to 
identify novel proteins, this is particularly problematic.  
De-Novo sequencing algorithms attempt to circumvent this problem of limited databases 
but that has its own challenges. In de-novo sequencing, algorithms extract information on 
the (partial) sequence of peptides using tandem MS information. Fragmentation produces 
successive fragment ions (and corresponding peaks) from which the sequence may be 
constructed. For two consecutive fragments, the difference in mass (distance between 
the peaks on the m/z scale) represents the mass of an amino acid residue. This can be 
done for all peaks in the series and used to generate the (partial) sequence that may be 
blasted against the genome database of better-characterized species to find sequences 
with appreciable homology. 
1.4 Quantitative Approaches 
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Quantitative proteomics is an essential component of mass spectrometry-based 
proteomics studies and provides information to augment identification of 
proteins/peptides in complex mixtures. Many approaches exist but these are broadly 
grouped into label-free and labeling strategies. The label-free approach involves the 
quantitation of proteins/peptides without the need for tags whereas labeling approaches 
use different labels/tags to enable comparative analysis between samples in the same 
workflow. Quantitative approaches may be absolute or relative [66]. Figure 4 is a summary 
of the major quantitative strategies currently used in the majority of proteomics studies. 
1.4.1 Label-free Strategies 
Label-free proteomics is possibly the simplest and fastest form of quantitative proteomics 
owing to the absence of extra labeling steps [67–69]. Here, different samples are analyzed 
separately and not mixed together with each sample going through the same processing 
steps. There is inherently less sample ‘complexity’ in label-free quantitation relative to 
labeled samples, which are always a combination of differentially labeled proteomes. By 
virtue of its simplicity and the fact that no special reagents have to be purchased, label-
free strategies are also the least costly protein quantification strategies [67].  
Due to the direct analysis of proteomes without the use of labels, label-free proteomics 
can be applied to all samples whether in vitro or in vivo. In regards to the instrument 
analysis, more peptides are analyzed and detected in label-free workflows than in labeled 
workflows for the same instrument duty cycle. There is maximum amount of scanning to 
obtain more microscans per second for the same ion species than in labeling methods. 
This affords the ability to obtain the maximum amount of data in label-free analysis since 
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the instrument scans multiple species (e.g. heavy and light labeled) for the same ion in 
labeling strategies and ultimately results in longer scan time and less tandem mass 
spectra [60]. It can be assumed that in the time that it scans two or more differentially 
labeled species (multiplex) of the same ion in labeled workflows, it will scan two or more 
different ions in label-free workflow. This maximum scanning therefore potentially results 
in greater depth of proteome coverage in label-free proteomics [46].  
Label-free approaches are however, beset with a number of issues principal among them 
being the inherent differences in the final sample to be analyzed due to separate 
processing for different samples. There is less quantitative precision compared to labeling 
techniques due to the susceptibility of label-free quantification to pre- and post-analytical 
variability. Owing to the fact that samples are prepared separately, there is the likelihood 
of introducing bias from the analyst, or the materials used. Different tubes in which sample 
processing is carried out may have different properties, which may affect sample losses, 
for instance, through differential protein/peptide binding to the walls of the tubes. Again, 
instrument performance differences from sample to sample during analysis may affect 
quantitation. This may consequently affect reproducibility of analysis in label-free 
workflows, which significantly impacts quantification. Consequently, high reproducibility 
from sample run to run is necessary in label-free quantitation. The development of 
different software with improved algorithms for normalization and data analysis such as 
LFQ in the MaxQuant platform seek to combat the effect of pre-analytical variability in 
label-free workflows [67].  
Label-free quantification of peptides and/or proteins is done using one of two approaches: 
spectral-based methods or intensity-based methods [69–71].   
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1.4.1.1 Spectral Counting 
In spectra-based methods, the number of experimental MS/MS spectra of a given 
peptide/protein that match with known spectra in the database is used to quantify 
peptides/proteins. The number of matched spectra is referred to as a spectral count. 
Spectral count methods rely on the assumption that the more abundant a protein is in a 
mixture, the greater the number of peptides it will produce and hence the more spectra it 
will generate [60, 72]. Various studies have demonstrated a strong relationship between the 
spectral counts and relative abundance of peptides/proteins [60]. There are however, 
problems with spectral counting methods that should prompt caution in interpreting 
results. For example, the size of a protein largely determines how many peptides can be 
produced from it. Consequently, for two proteins with equimolar amounts in a matrix, the 
larger protein tends to produce more tryptic peptides and hence, more MS/MS spectra 
[60]. Further, a number of factors including ionizability of peptides and efficiency of peptide 
fragmentation affect MS signal intensity, which affects the selection of precursor masses 
for fragmentation [60]. These issues tend to introduce bias into peptide/protein 
quantification. Spectral counting methods have also been found in some studies to 
provide less precise quantitative information and be less likely to detect small changes in 
protein abundance compared to labeled methods [73].  
To attenuate the problem arising from large proteins having more spectra, normalized 
spectral counts have been developed and used with success [6, 74]. This notwithstanding, 
spectral methods are generally not as commonly used as intensity-based methods for 
protein quantification. 
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1.4.1.2 Intensity-based Methods 
Intensity-based methods use the height or area under the curve in the chromatogram as 
a quantitative measure of how much peptide or protein there is present in a sample. There 
are a host of intensity-based label-free quantification tools currently in use in proteomics 
amongst which is MaxLFQ [67], an algorithm proposed and used by the Mann group at the 
Max Planck Institute of Biochemistry in Germany. In MaxLFQ, the problem of differences 
resulting from separate sample treatments is solved by a concept the authors term 
‘delayed normalization’. This concept involves keeping normalization coefficients (factors) 
as free variables under the assumption that the proteome of a cell or organism remains 
largely unchanged between conditions [67]. The response (intensity) of a peptide in a 
fraction is multiplied by an unknown normalization coefficient. This is done for all peptides 
in all fractions. The differences between the logarithms of each product for all possible 
fraction pairs is then squared for each peptide and the results summed up. The algorithm 
then determines the values of the coefficients as those values, which produce the least 
value of the sum of the logarithmic fold changes. These values consequently translate 
into the least differences in peptide abundances across the various fractions, which 
constitutes the basic assumption underlining the LFQ algorithm.  
1.4.2 Labeling Strategies 
Sample labeling is one of the more important strategies in quantitative mass 
spectrometry. Labeling approaches do not only enable the multiplexing of samples, which 
reduces analysis times, but also ensure the elimination of the effects of bias in the sample 
preparation steps. There are two major approaches to labeling in proteomics studies 
including metabolic labeling and chemical labeling. 
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1.4.2.1 Metabolic Labeling 
Metabolic labeling involves the introduction of stable isotope labeled amino acids into 
protein structure using the metabolic machinery of cells and/or whole organisms. This 
approach to stable isotope labeling has achieved high rates of success, particularly in cell 
culture but also in whole organisms such as Caenorhabditis elegans and the fruit fly, 
Drosophila melanogaster [75–77]. Among the currently used metabolic labeling approaches 
(i.e. Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC), Biorthogonal Non 
Canonical Amino Acid Tagging (BONCAT), and 15N labeling), SILAC is the most 
commonly used. 
Figure 4 - Quantitative Proteomics Approaches 
A) Label-free quantitative proteomics involving separate sample prep for each sample. B) Click Reaction involving 
metabolic labeling using the methionine mimetic, azidohomoalanine (AHA). C) Typical workflow for Stable Isotope 
Labeling by Amino Acids in Cell Culture involving 1:1 w/w sample mixing before sample prep. D) Chemical tagging 
approach (TMT, iTRAQ) involving chemical labeling of samples following trypsin digestion 
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SILAC, together with the other stable isotope-based labeling strategies, currently 
represent the gold standard in quantitative proteomics [67]. SILAC involves the 
supplementation of cell culture media with 13C- and 15N-labeled amino acids (arginine and 
lysine) which are taken up by cells for use in protein formation [78, 79]. Two sets of cells (or 
more depending on the number of treatments and cell types being studied) are therefore 
cultured, one with regular (light) arginine and lysine and the other with the ‘heavy’ labeled 
forms. Lysates from the different cell cultures are mixed in equal proportion, digested, 
and analyzed via LC-MS/MS. Heavy and Light labeled peptides, having similar 
physicochemical properties, elute from the HPLC column at the same time and are 
analyzed by the mass spectrometer but are differentiated by the mass spectrometer by a 
constant mass difference between these peptides due to the different stable isotope 
labels. 
More recently, the applications of SILAC have been extended to biospecimen, including 
patient tumor tissues, in what has been termed Super SILAC [80, 81]. In the Super SILAC 
approach, a master sample of proteins is generated by combining lysates from different 
SILAC heavy-labeled cell lines of a given cancer or tumor type. The master sample 
contains a near-exhaustive mixture of proteins expected to be present in the tumor cells. 
This is then spiked into different samples (e.g. patient tumor before and after radiation 
treatment) and serves as an internal standard to measure changes in protein types and 
quantities in the samples. In a recent proof of concept study, our lab has been able to 
demonstrate the applicability of the Super SILAC approach to study the plasma proteome 
in human plasma samples [82]. 
 
 
35 
 
BONCAT, another metabolic labeling technique uses the copper-catalyzed azide-alkyne 
cycloaddition reaction known mostly as click chemistry [83, 84]. In the application of this 
technique in cell culture, an amino acid analog of methionine bearing an azide group (that 
can be ‘clicked’ with an alkyne functional group) is fed to cells as part of the culture media. 
In the absence of methionine in the culture media, cells incorporate this analog into 
protein formation resulting in proteins having this azide functional group, which can then 
be pulled down with the alkyne (clicking reagent). This strategy is particularly useful in 
secretome studies in which only proteins secreted by the cells are wanted. An added 
advantage of this strategy in secretome studies is the use of serum in the labeling media, 
which ensures that cells have requisite nutrients to grow as they normally would. Unlike 
other labeling strategies, BONCAT is not inherently quantitative. BONCAT is typically 
used to facilitate protein identification rather than quantification.   
Metabolic labeling including SILAC, has the advantage of avoiding bias due to pre-
analytical variability since samples are mixed early in the sample preparation protocol and 
undergo essentially the same treatment steps [85]. Other advantages of SILAC include 
being robust, simple to perform, and the ability to fully label whole proteomes without the 
need for chemical reactions [79, 85]. 
Labeling strategies, however, are generally more expensive than label-free strategies and 
require more steps before sample analysis [67]. Relative to chemical labeling strategies, 
metabolic labeling also has the disadvantage of being limited in the number of labels that 
can be used (usually 3) as well as being unsuitable for labeling clinical and animal-based 
samples or cells that do not grow very well in labeled media [60, 67, 70]. Researchers, 
including our lab, have faced a problem with BONCAT where the cells were unable to 
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grow in the media containing the labeled methionine (azidohomoalanine, AHA) past a few 
hours. The workaround for this method is therefore to employ short labeling times [86, 87] 
where the cells are grown in regular media till desired confluency and exchanged with 
AHA containing media for 30 – 60 minutes and the media collected after. This makes the 
BONCAT approach mainly useful for studying short-term secretory profiles instead of 
long-term secretion. 
1.4.2.2 Chemical Labeling 
Chemical labeling techniques, unlike metabolic labeling, involve the labeling of proteins 
or peptides following protein extraction and/or digestion. Isotope Coded Affinity Tags 
(ICAT) have been used in the past but Isobaric Tagging for Relative and Absolute 
Quantification (iTRAQ) and Tandem Mass Tags (TMT) represent the two main isobaric 
chemical labeling tags currently used routinely in quantitative proteomics [66, 88]. N,N-
Dimethyl leucine (DiLeu) and Deuterium isobaric Amine Reactive Tag (DiART) are two 
less commonly known and less frequently used isobaric tags [89]. 
Isobaric tags are chemical species of identical mass and chemistry that permit these tags 
to co-elute at the same retention times when bound to peptides to be analyzed by mass 
spectrometry [90]. There are three regions of isobaric tags, four with the peptide included. 
The regions are the reporter region which is the tag (consists of varying 13C substitutions 
depending on the intended tag mass), a mass normalization region that is synthesized to 
balance the tag mass and ensure that all tags have the same mass regardless of label, 
and a peptide/protein reactive group that reacts with the peptide [90]. Tags are 
manufactured to ensure that cleavage from CID yields reporter ions of different masses 
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that are used to quantify the peptides to which they were bound and from which they were 
cleaved. 
Isobaric tags have the advantage of being used simultaneously with multiple samples; up 
to 8 or 10 samples can be multiplexed in iTRAQ or TMT respectively and this affords a 
very precise way to determine expression differences between large sample numbers [91]. 
This ability to combine many unique samples increases sample throughput and can 
permit the analysis of many more samples per unit time compared to label-free strategies. 
In isobaric tagging, same peptides (from different samples) labeled with different tags 
have the same mass regardless of which sample they come from unlike SILAC where 
labeled peptides from different samples have different masses. Peptides labeled with the 
different isobaric tags therefore arise as one peak in the MS precursor ion scan [89]. This, 
in fact, increases the precursor ion intensity and decreases sample complexity relative to 
SILAC, which may further increase depth of proteome coverage. Duty cycles may thereby 
be higher than in SILAC. Quantification is done by a direct comparison of the reporter ion 
intensities in the MS/MS spectrum. Peptide identifications are done with the fragment ion 
information obtained in the high m/z region of the product ion spectrum. Peptides which 
did not pick up the tags/labels are not quantified as there are no reporter ions from the 
CID events in MS/MS [90]. The labeling efficiency of the tagging therefore plays a very 
important role in protein identification and by extension differential abundances observed. 
Isobaric tags can be used on in vitro as well as in vivo samples because the peptides are 
labeled after digestion unlike in classical SILAC where proteins are labeled inside the 
cells. 
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Pre-analytical variability may not be entirely avoided in isobaric tagging techniques 
because samples are labeled after enzymatic digestion. Any variations resulting from 
reagents, materials, or analyst may therefore affect the results. In spite of these potential 
issues, iTRAQ has been shown to give accurate and very reproducible results with mean 
CVs of 0.09 in one study [88, 92]. Furthermore, because the samples are labeled before 
analysis in the mass spectrometer, post-analytical variability, including differential 
instrument performance from sample to sample, is avoided. However, pre-analytical 
variability may persist owing to the separate tryptic digestion of samples; differences in 
digestion efficiency may bias results. The overall reproducibility of isobaric tagging 
workflows may not be as good as with SILAC but certainly more so than label-free 
approaches.  
1.5 The Secretome 
First publicly used by Tjalsma et al., the term secretome represents the complement of 
all proteins secreted into the extracellular environment by cells, tissues, or organisms [93, 
94]. It is estimated that about 10 – 15% of known and predicted human proteins are soluble 
and may be secreted. Protein secretion constitutes a part of the natural mechanism of 
homeostasis. Cells also secrete proteins and other macromolecules in the body as a 
response to injury. For example, inflammatory cells secrete various factors as part of the 
immune response while tumor cells may secrete factors to promote their growth or in 
response to treatment [95].  
Due to the vast amounts of information contained in cell secretomes, they have generated 
interest as important resources for many MS-based proteomics studies. The cancer 
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secretome in particular has been shown to contain microvesicles and exosomes which 
contain proteins that play vital roles in tumor progression in vivo [96, 97]. Protein secretion 
may occur via one of two broad secretory mechanisms – the classical/conventional 
secretory pathway or the non-conventional pathways.  
1.5.1 Classical/Conventional Protein Secretory (CPS) Pathway 
Conventional protein secretion refers to the secretion of proteins involving transport 
through the endoplasmic reticulum (ER) to the Golgi Apparatus and ultimately to the cell 
membrane from where the proteins are secreted into the extracellular environment [98]. 
Proteins secreted via the CPS pathway have N-terminal secretory signal peptides, usually 
about 16-30 amino acids, or transmembrane domains that direct them to the membrane 
of the ER where they are translocated into the lumen [96, 98–100]. In the lumen of the ER, 
signal peptides are cleaved off and the proteins transported to the Golgi Apparatus in coat 
protein II (COPII)-coated vesicles [99].  
1.5.2 Non-Classical/Unconventional Secretory Pathways 
The long held belief in the scientific community was that protein secretion only occurred 
via the classical pathway and a signal peptide was necessary for protein targeting to the 
secretory pathway. It is now widely believed, however, that alternative pathways exist for 
protein secretion, broadly classified as unconventional protein secretion (UPS). Recent 
research in different labs have delineated the molecular processes involved in different 
aspects of UPS. 
Proteins that go through the UPS pathway may be subdivided into two subgroups 
including those that have a signal peptide and enter the ER but do not go through the 
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Golgi Apparatus prior to secretion and those that have no signal peptide popularly 
referred to as leaderless proteins [98]. Proteins without signal peptides may reach the 
extracellular environment through one of three mechanisms namely pore-mediated 
translocation (Type I), ABC transporter mediated transfer (Type II), or 
autophagosome/endosome-associated transport (Type III) [98]. Types I and III involve 
translocation across the cell and autophagosomal membranes respectively while Type II 
typically involves acylated peptide and yeast mating peptides. The secretion of proteins 
with secretory signal peptides via the UPS pathway is referred to as Type IV UPS.  
UPS pathways are believed to be stress-induced especially in situations where stress 
results in an impairment in the classical pathway. For instance, Type IV protein secretion 
via the Golgi bypass mechanism involving proteins of the Golgi re-assembly and stacking 
protein (GRASP) family constitutes one of the major consequences of ER stress 
induction. Similarly, autophagosome-mediated protein secretion (Type III) of proteins 
such as interleukin 1-β (IL1- β) and acyl-CoA-binding protein (ACBP)  has been shown to 
be GRASP-dependent [98, 99, 101].  
1.5.3 Approaches and Challenges in Secretome Analysis  
The use of immortalized cancer cells as experimental models for studying cancer has 
become the mainstay of cancer research in vitro [102]. Cell lines represent a readily 
available model that can be studied under carefully controlled experimental conditions. 
Cell lines are also relatively easy to grow and manipulate genetically. In spite of the merits 
of using cell lines as experimental models for basic or applied research, limitations exist 
including the lack of a tumor microenvironment associated with 2D cell cultures. Howe 
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ver, the imminent rise of 3D cell cultures seeks to make cell cultures more representative 
of what goes on in vivo while retaining the ease of growth and amenability to 
manipulation[102]. 
Cell secretomes have emerged as viable alternatives to the use of plasma in the discovery 
of proteins that may serve as important biomarkers of disease. This is in part due to the 
difficulties observed in direct plasma-based biomarker studies including the vast 
abundance of only a minority of proteins and the large dynamic range (~10 orders of 
magnitude) therein [102]. Furthermore, being representative of proteins likely to be found 
in biological fluids (e.g. plasma, cerebrospinal fluid), the secretome represents an 
important surrogate with the potential for use in biomarker discovery studies [103]. Cancer 
Figure 5 - Conventional and unconventional protein secretion 
Classical secretion is depicted as 1; processes 2 – 6 depict the different types of unconventional secretion. Image 
taken from https://www.omicsonline.org/articles-images/JPB-05-Editorial16-g001.html 
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cell secretomes are very likely to contain proteins involved in key functional activities in 
vivo owing to the dysregulation of various pathways in cancer.  
Typically, cell and tissue culture media is supplemented with up to 10% serum (e.g. fetal 
bovine serum - FBS, or fetal calf serum - FCS). The high protein and amino acid content 
of serum necessitates the use of serum-free media in efforts to circumvent the high 
protein background. Cells are therefore grown in serum containing media for some time 
following which the media is removed and the cells washed extensively to remove the 
serum. However, it is known that despite the washing, some serum persists. Being 
necessary therefore to be able to distinguish between proteins secreted from cells and 
proteins already present in culture media from serum, labeling strategies such as SILAC 
and/or Click Chemistry are sometimes employed.  
In SILAC, proteins made by the cell and secreted into the media will contain labels (13C 
and/or 15N) not present in FBS-derived proteins. Similarly, in Click Chemistry, secreted 
proteins from the cell will expectedly contain either an azide or an alkyne group 
(depending on the labeling agent used) that should be absent in serum-derived proteins. 
Most labeled secretome studies also use dialyzed serum, which consists of serum in 
which small molecules particularly amino acids together with hormones and cytokines 
have been significantly depleted. Depletion of amino acids ensures that protein 
production in cells only utilizes supplemented labeled amino acids used. 
The use of dialyzed serum and/or serum-free media may present biological issues in 
proteomics studies. It is believed that cell culture in serum-free media for extended 
periods may result in changes in cell protein dynamics as well as apoptosis, senescence, 
or autophagy. Where apoptosis is induced by the use of serum-free media, secretion of 
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proteins from the lysed or dead cells may contribute to the secretome measured. To 
ensure that the contribution of apoptotic cells to the secretome is insignificant or minimal, 
we and other labs conduct apoptosis assays to determine the percentage of apoptotic 
cells following secretome collection. Using the apoptosis assays, different labs may 
decide how long it is appropriate to culture cells in serum-free conditions while 
maintaining the integrity of the secretome. Some groups have used very low serum (~1% 
FBS) to avoid substantial cell death in their secretome studies. 
Another issue often encountered in secretome studies is the lack of proteins with equal 
rates of secretion in “all” cells to be used for normalization of samples similar to the 
housekeeping proteins used in Western Blotting. This is important especially following 
identification of candidate potential biomarkers from secretome proteomics experiments 
where further tests using Western blots, ELISAs etc. are warranted [103]. 
1.6 Protein Glycosylation 
Glycosylation refers to the addition of glycan groups to different residues on proteins 
through the activity of glycosyltransferases [104]. Typically, glycosylation occurs in the 
ER/Golgi but it has been known to sometimes take place in the cytoplasm or nucleus [105]. 
Glycosylation is the most predominant protein PTM and has been demonstrated to have 
very pertinent effects on protein function (e.g. receptor interactions, immune response 
mechanisms, secretion, and transport) and physicochemical properties (e.g. solubility, 
stability, and folding) [104, 106, 107]. For instance, glycoproteins with a mannose-6-phosphate 
group are known to be targeted to lysosomes and one such glycoprotein, tripeptidyl-
peptidase 1, is implicated in classical late-infantile neuronal ceroid lipofuscinoses (LINCL) 
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[96, 108]. In addition, cancers have been found to commonly present with changes in 
glycosylation [105]. 
Up to 50% of all proteins are estimated to have one or more glycoforms particularly 
proteins that are secreted or targeted to the cell surface [105, 109]. Among the notable 
plasma proteins known to be glycosylated are antithrombin III, fibrinogen, alpha-1-acid 
glycoprotein, alpha-1-antitrypsin, apolipoproteins B-100, D, and F [106, 110]. The abundance 
of glycoproteins coupled with the many roles they play in cellular function and disease 
makes glycoproteins well suited for investigation as potential biomarkers of early 
diagnosis or treatment prognosis [111]. 
Glycoproteins may have more than one site of glycosylation and that site may be occupied 
by more than one glycan resulting in different glycoforms of the protein. While 
glycosylation patterns may differ between people depending on genetic differences, diet, 
disease, and lifestyle, it has proven to be very stable in individuals [106, 111, 112]. Additionally, 
age and sex have been shown to correlate with the glycosylation status such as the 
increased bisection and decreased galactosylation of immunoglobulin G (IgG) with age 
[106, 113].  
The central dogma of molecular biology is the formation of RNA from DNA and the 
subsequent formation of protein from the RNA template. While this process of protein 
manufacture in cells follows a template (i.e. DNA), glycosylation is very complex and not 
template-driven, making glycoprotein analysis such as sequence determination a huge 
analytical challenge.  
1.6.1 Glycans 
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Glycans are carbohydrate moieties typically found in the body attached to proteins or 
lipids, as mono-, di-, or oligosaccharides, but they may also exist as free molecules. The 
molecule to which the glycan (glycone) is bonded is referred to as an aglycone. Glycans 
have been known to be involved in different cellular functions facilitating cell-cell, cell-
matrix, or cell-molecule interactions such as pathogen recognition and inflammation [111, 
114]. 
Glycans exist as polyhydroxy molecules of aldehydes or ketones and may be 
monosaccharides referring to the simplest glycan consisting of only one sugar unit (e.g. 
glucose shown in Figure 6) or oligosaccharides comprising many sugar units. Multiple 
oligosaccharide units bonded together are referred to as polysaccharides. An aldose 
refers to a monosaccharide with an aldehyde group whereas one with a ketone group is 
referred to as a ketose. In the free state, monosaccharides exist as ring or open chain 
molecules whereas oligosaccharides exist primarily as ringed structures. 
Glycans have two ends – the reducing end containing the aldehyde or ketone functional 
group and the opposite non-reducing end. Single glycan units may be bonded to each 
Figure 6 - Different forms of D-glucose 
The image on the left panel is the open form of D-glucose whereas the middle image represents the ring form. The 
ring form may take two conformations – the boat or the chair conformation (shown in the image on the right panel). 
Substitution of the hydroxyl groups around the structure result in different molecules with distinct properties. 
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other via two similar but distinct linkages – α or β linkages. The two linkages have been 
demonstrated, as in the case of starch (α1-4 linkages) and cellulose (β1-4 linkages), to 
result in different structural and biological properties even though they are both polymers 
of glucose [114]. Glycans are highly complex and diverse species in that the 
monosaccharides may be linked to each other via several different hydroxyl groups in 
either the α or β conformation. For instance, three six-carbon monosaccharide units 
(hexoses) may be linked to each other in up to 27,648 different possible ways compared 
to the six tripeptides or trinucleotides possible from three amino acids or nucleotides 
respectively [114]. Increasing the number of units of a polysaccharide unit increases the 
possible number of products geometrically e.g. six hexose units can form > 1 trillion 
possible hexasaccharide structures [114, 115]. 
The most commonly occurring monosaccharide units are five-carbon (e.g. xylose Xyl) and 
six-carbon (e.g. glucose Glc, galactose Gal, and mannose Man) neutral or non-neutral 
species [114]. Glucosamine and galactosamine are six-carbon units with the hydroxyl 
group at position 2 substituted with an amino (NH2-) group. The amino group may be 
acetylated to give hexosamines such as N-acetylglucosamine (GlcNAc) and N-
acetylgalactosamine (GalNAc). The hydroxyl group at position 6 may be removed to give 
a deoxyhexose such as fucose (Fuc) or replaced with a carboxylate (COO-) group to give 
uronic acids such as glucuronic acid (GlcA) and iduronic acid (IdoA). Sialic acids (Sia) 
such as N-acetylneuraminic acid (Neu5Ac) and N-glycolylneuraminic acid (Neu5Gc) 
comprising nine carbon atoms are also common in nature.  
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Glycans are generally classified into four major types namely O-linked glycans, N-linked 
glycans, glycolipids/glycosphingolipids, and glycosaminoglycans, depending on the type 
of linkage to the aglycone [105]. 
1.6.1.1 O-Linked Glycans 
O-linked glycans are formed by the glycosidic linkage of glycans to the oxygen of the 
hydroxyl group on serine (S) or threonine (T) residues. The process of O-glycosylation 
begins in the Golgi apparatus. It is the predominant form of glycosylation found in mucins 
in the body. The glycan is covalently bonded through an α-linkage to the protein by N-
acetylgalactosamine. The resulting product is referred to as a mucin-O-glycan or O-
GalNAc [105, 116]. Mucins are found in secretions of mucosa in different epithelial cell 
surfaces and body fluids. O-glycans may also be bonded to the aglycone via a β-linkage 
using N-acetylglucosamine resulting in O-GlcNAc [105]. The GalNAc residue is extended 
by different monosaccharide units including Gal, Fuc, or Sia but not Glc, Man, or Xyl 
residues [116]. 
While there is no consensus motif for O-glycosylation, the presence of a proline at the N-
terminal side of the S/T group or three amino acid residues away from the S/T group has 
been shown to favor O-linked glycan formation. 
1.6.1.2 N-Linked Glycans 
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N-glycoproteins are formed from the covalent bonding of an N-glycan group to an 
asparagine (N) residue of a polypeptide or protein [117]. Studies have revealed an Asn-X-
Ser/Thr (N-X!P-S/T) consensus sequence that is most commonly found at N-glycosylated 
asparagine sites (Figure 7) in a polypeptide chain where X is any amino acid except 
proline. Other sequences such as the N-X-C sequon have been observed in nature to be 
N-glycosylated [117]. It must be noted however, that there are several N-X-S/T sequons in 
the human proteome that have not been shown to harbor a glycan.  
Figure 7 - N-linked glycans 
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About five different monosaccharide molecules may be found linked to the asparagine 
residue but the most common group is GlcNAc. The formation of N-glycans has been 
shown to begin with dolichol phosphate (Dol-P), a lipid polymer of five-carbon isoprene 
molecules. The entire oligosaccharide glycan molecule is synthesized on Dol-P and then 
transferred onto the aglycone unit. Synthesis of the oligomannose begins on the 
cytoplasmic side of the ER membrane where Dol-P accepts an N-acetylglucosamine-
phosphate (GlcNAc-P) group from UDP-GlcNAc to form Dol-P-P-GlcNAc catalyzed by 
GlcNAc-1-phosphotransferase [117]. Successive additions of GlcNAc and Man residues 
results in the formation of a pentasaccharide core that is common to all N-glycans. The 
common core is typically made up of two GlcNAc units and three mannose sugars [111]. 
Figure 8 - Types of N-glycans 
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The addition reactions are catalyzed by different saccharyltransferases. The N-glycan 
molecule is then translocated to the lumenal side of the ER where additional 
monosaccharide units may be added before transfer of the glycan molecule onto the 
protein structure occurs while ribosomal translation is taking place. Importantly, 
Tunicamycin, a nucleosidic antibiotic, possesses inhibitory activity against GlcNAc-1-
phosphotransferase and has been used in studies to inhibit protein glycosylation [107]. 
As depicted in Figure 8, N-glycans may be broadly divided into three types. These are 1) 
oligomannose consisting only of mannose units joined to the common core, 2) complex 
N-glycans consisting of two to three antennae starting with GlcNAc joined to the common 
core plus different monosaccharides including sialic acids, hexoses, or other 
hexosamines, and  3) hybrid N-glycans consisting of two or more “antennae” with one 
antenna having only mannose units [111, 117]. 
1.6.2 Mass Spectrometry Analysis of Glycoproteins 
The importance of protein glycosylation on cellular development and function cannot be 
overstated. From protein folding to cell proliferation and signaling, glycans have proven 
to be pertinent mediators of biological function. Furthermore, their role in cancer can 
means they can serve as biomarkers of disease where they can facilitate early disease 
diagnosis and treatment prognosis. Known to be influenced by age and being involved in 
the etiology of such diseases as Alzheimer’s, Huntington’s, and some autoimmune 
conditions, glycans may be used for the detection of these age-related diseases [111, 118].  
Mass spectrometry-based analysis has been instrumental in the recent rise in interest in 
the study of protein glycosylation and glycan differences. Together, the lack of standards, 
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high variability between different subjects, vast number of possible isomers per glycan 
structure per glycosite, and the paucity of automated tools/software for interpreting 
complex MS/MS data from fragmentation of glycoproteins/glycopeptides make the 
identification and quantification of glycans for use as disease biomarkers or therapeutic 
targets an enormous analytical challenge. The absence of chromophores or fluorophores 
also means that mass spectrometry represents one of the best analytical tools for glycan 
analysis [115]. 
MALDI-MS and ESI-MS are the two most commonly used MS platforms for glycan 
analysis. Fragmentation events in MS/MS analysis allows for structural elucidation of 
glycopeptides/glycoproteins. In ESI-MS, the separation method chosen may be reverse 
phase, normal phase, hydrophilic interaction (HILIC), porous graphitized carbon (PGC) 
chromatography, or capillary electrophoresis. In MALDI-MS analyses of glycans, labile 
sialic acid residues may be cleaved off making derivatization in order to stabilize the 
monosaccharide units essential [111].  
1.6.2.1 Derivatization of Glycans for MS Analysis 
The standard modus operandi in glycoprotein (glycan) analysis by mass spectrometry 
involves the enzymatic (N-glycans) or chemical (O-glycans) release of the glycan group, 
identification of the site of glycosylation via an analysis of the deglycosylated 
protein/peptide, and identification and quantification of the released glycans. Released 
glycans may be derivatized to make them more amenable to commonly used hyphenated 
chromatographic and mass spectrometry techniques. Glycan derivatization, extensively 
reviewed by David Harvey [115], may be done by reactions with the hydroxyl group (e.g. 
 
 
52 
 
permethylation, acetylation), reducing end (e.g. reductive amination, hydrazone 
formation), or sialic acid residues. Permethylation is the most popular derivatization 
approach involving the complete or near-complete addition of methyl groups to all 
hydroxyl and where present carboxylic acid groups [115]. The INLIGHT glycan tagging 
approach developed by David Muddiman and coworkers at the North Carolina State 
University is an example of the hydrazone formation strategy [119].  
1.6.2.2 Enrichment Strategies 
In order to increase glycoprotein and glycan identification and quantification, different 
enrichment strategies may be employed. Different strategies including 
immunoprecipitation using antibodies, covalent hydrazide derivatization, and lectin affinity 
binding exist for enriching glycoproteins/glycopeptides [118].  The most popular enrichment 
strategy currently used in glycoprotein/glycopeptides analysis is however the lectin 
enrichment approach and its applicability has been demonstrated in analysis of lung, 
breast, and liver cancers [120–122]. In hydrazide-based enrichment, 
glycoproteins/glycopeptides are immobilized by reacting the reducing end of the glycan 
(aldehyde) with a solid hydrazide support ensuring that only glycosylated proteins are 
retained on the column. Peptide-N-Glycosidase F (PNGase F) may then be used to 
cleave the glycan off and the deglycosylated protein analyzed [118]. 
Lectins are proteins known to have high affinities for carbohydrates or glycan species. 
This property of lectins is therefore exploited in the enrichment of glycoproteins in 
complex protein mixtures. A wide variety of lectins have been isolated from many different 
sources including mushrooms, legumes like beans and peanuts, garden snails, potatoes, 
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wheat, and tomatoes among others. Concanavalin A (Con A), wheat germ agglutinin 
(WGA), and Ricinus communis agglutinin (RCA) represent some of the more commonly 
used lectins in glycoproteomics studies. 
Con A and WGA have been demonstrated to have higher affinities for certain glycan units 
more than others. Con A is generally associated with higher affinities for the high 
mannose N-glycan type whereas WGA preferentially binds glycoproteins with sialic acid 
residues (e.g. N-acetylneuraminic acid) and N-acetylglucosamine residues [81, 123]. 
Hydrogen bonding and hydrophilic interactions between lectins and glycans bound to 
glycoproteins/glycopeptides accounts for the selective enrichment of 
glycoproteins/glycopeptides using lectins. 
1.7 Dissertation Objectives 
This dissertation comprises two projects dealing with the use of mass spectrometry-based 
proteomics to analyze secreted proteins. The first project is a clinical applications study 
in pursuit of candidate biomarkers for diagnostic or prognostic use in NSCLC. The second 
project discussed in this dissertation is a more fundamental proteomics study in which we 
carry out a comprehensive characterization of glycoproteins in the HepG2 cell secretome. 
1.7.1 H1299 Study 
NSCLC is responsible for more deaths worldwide than any other form of cancer due to a 
combination of late stage diagnosis and relapse following chemo/radiation combination 
therapy. One primary mechanism of post-treatment cancer cell survival is thought to be 
that of autophagy. Previous studies including studies in the Gewirtz lab have indicated a 
relationship between p53 status and the functional form of autophagy induced in response 
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to radiotherapy [124–126]. In tumor cells with functional p53, autophagy has been 
determined to be cytoprotective in response to ionizing radiation whereas in tumor cells 
without p53, non-protective autophagy is known to be induced. Where the cytoprotective 
form of autophagy is present, it can be pharmacologically inhibited to sensitize cancer 
cells to chemotherapy and ionizing radiation treatment. However, this approach is unlikely 
to be effective when the autophagy is non-protective and there are currently no available 
biomarkers to stratify patients according to whether autophagy is protective, non-
protective or, in fact, cytotoxic to the tumor cell. This also provides a plausible explanation 
for the potential failure of clinical trials exploring the inhibition of autophagy as a cancer 
treatment enhancement strategy as patients could not be stratified based on the nature 
of the autophagy exhibited by their tumor [127]. In this study, we used p53-null and p53-
inducible H1299 NSCLC cell lines as models of non-protective and protective autophagy, 
respectively, in an effort to identify candidate biomarkers.  
The overarching aim of this study is to understand the proteomic signatures involved in 
radiation-induced autophagy in NSCLC in an effort to identify candidate proteins that may 
be developed into diagnostic and/or prognostic biomarkers, as well as therapeutic targets. 
This will help to distinguish between NSCLC patient groups in which autophagy 
manipulation may or may not be a beneficial therapeutic strategy. The specific aims of 
this study are: 
1. To characterize the response of the H1299 NSCLC cells to ionizing radiation 
treatment as a function of p53 status 
2. To identify the proteomic signatures that differentiate between cytoprotective and 
non-protective autophagy. 
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1.7.2 HepG2 Study 
One of the limitations of label-free quantitative proteomics is the sensitivity to pre-
analytical variability, which affects sample-to-sample reproducibility and quantitative 
precision. The SILAC approach, initially developed as a quantitative strategy for cell 
culture analysis, was recently extended to clinical samples by Matthias Mann and 
colleagues and other groups including our lab [80, 82, 128, 129]. In this extended application, 
a library of labeled intact proteins pooled from different samples are used as spike-in 
internal standards to analyze clinical samples including tissue biopsies and plasma. With 
plasma representing the primary, and perhaps most important, clinical biospecimen [130], 
our previously published proof-of-principle study [82] demonstrated the use of the HepG2 
cell line to produce labeled plasma proteins that can then be spiked into plasma for 
comparative quantitative analysis. The overall goal of this research is therefore to develop 
the HepG2 cell secretome as an expression platform for the generation of a library of 
intact stable isotope labeled proteins to serve as internal standards in quantitative 
proteomics applications. To do this effectively, it is essential to characterize the SILAC 
labeled HepG2 secretome especially relating to plasma protein glycosylation. 
The specific aims of this study include: 
1. Quantitative analysis of temporal plasma protein secretion in HepG2 cells. 
2. Qualitative and quantitative analysis of plasma protein glycosylation in the HepG2 
secretome. 
3. Comparative plasma proteomics analysis of HepG2 secretome spiked plasma. 
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Chapter 2: 
Proteomics Insights into Autophagy 
 
 
 
This chapter is drawn from a published review article by Cudjoe EK et al. 2017 
 
2.1 Introduction 
Autophagy is one of the most widely studied cellular mechanisms owing to the myriad of 
roles it plays in the cell. Dr. Ohsumi Yoshinori, one of the pioneers in the study of 
autophagy, recently received the 2016 Nobel Prize in Physiology or Medicine for his 
seminal role and contributions to the discovery of major signaling and molecular pathways 
in autophagy [131]. Autophagy, as the name implies, is a mechanism whereby cells “eat” 
or digest the components of their cytoplasm by presenting these subcellular organelles 
to lysosomes for degradation by hydrolases [132–136]. The term was coined by Christian de 
Duve and the process is a highly conserved mechanism observed in single and 
multicellular eukaryotes [137]. Autophagy occurs in cells at basal levels and in response to 
various stimuli, notably stress triggers such as starvation, chemotherapy, and 
radiotherapy. As a basal cellular mechanism, autophagy plays a homeostatic role, 
maintaining levels of proteins and energy in the cell [134] whereas in stress-induced 
autophagy the cells use breakdown products for energy and metabolic precursor 
generation, and survival. The importance of autophagy in both health and disease, has 
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generated significant interest in defining related signaling mechanisms, sub-cellular 
location of signaling elements (e.g. proteins), and extracellular signals that affect cell-cell 
communication. Autophagy represents a primarily homeostatic mechanism. In the 
process of autophagy, cellular components that may be damaged, dysfunctional, or 
excessive are captured into double-membrane vesicles known as autophagosomes from 
where they are transported to lysosomes that degrade the contents of the 
autophagosome (Figure 9). As a homeostatic mechanism, basal autophagy is involved 
in the maintenance of cellular integrity and the generation of building blocks of energy 
and metabolism that facilitate cell survival in response to starvation and/or stress. 
As a cellular process, autophagy is primarily classified into macro-autophagy, micro-
autophagy, or chaperone-mediated autophagy based on how the substrate cargo is 
delivered to the degradation machinery [134, 137–139]. Macro-autophagy, ubiquitously used 
to mean autophagy, refers to the process wherein a double membrane phagophore is 
formed that sequesters the substrates and matures into the autophagosome. In micro-
autophagy, however, the cargo is recognized and sequestered directly by the invagination 
of the lysosomal membrane for degradation [134]. Chaperone-mediated autophagy (CMA) 
involves the delivery of selected substrates, soluble proteins, to the lysosome via 
chaperone proteins. CMA is considered to be very selective whereas micro-autophagy 
and macro-autophagy may be selective or non-selective [140, 141]. In the context of cancer, 
different forms of autophagy have been identified and have been classified as either 
cytoprotective, cytotoxic, cytostatic or non-protective [125, 142–144]. This classification 
applies primarily to the case of autophagy induced in response to therapy in the tumor 
cell. Basal autophagy is however, virtually always cytoprotective. Functionally, autophagy 
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is said to be cytoprotective when its induction, as a response to stress including chemo- 
and radiotherapy, results in cell survival [125]. Cytotoxic autophagy results in cell death, 
either directly or by facilitation of apoptosis and is considered to be a desirable outcome 
of treatment in cancer cells [145].  This form has been referred to as autophagic cell death 
in some literature and is believed to occur when autophagy is induced to excessive levels 
[134]. Cytostatic autophagy refers to induced autophagy that results in the arrest of cell 
growth but not cell death. Currently, more than 36 autophagy-related (Atg) genes have 
been identified to be involved in some capacity in the autophagic machinery [146]. Many of 
these genes have been discovered through yeast genetic screening efforts. Being a 
conserved mechanism, most of the Atg genes discovered in yeast have homologs in 
Figure 9 – The Process of Autophagy 
The process of autophagy involves the formation of a double membrane structure that matures into the autophagosome 
and fuses with the lysosome. The autophagosome may also fuse with late endosomes (from the process of endocytosis) 
into an amphisome that may fuse with a lysosome or result in protein secretion. 
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mammalian cells. Autophagy begins with the formation of the double-membrane 
autophagosome from the phagophore and continues with the fusion of the 
autophagosome with the lysosome to form the autolysosome. Autophagosome formation, 
which represents the initiation of autophagy, takes place in four main steps namely 
induction, nucleation, elongation and completion [141, 147]. Basal autophagy under normal 
nutrient conditions generally occurs at very low levels, with some exceptions such as  
pancreatic cancer cells, which tend to have endogenously high levels of autophagy [148, 
149]. Stress-induced autophagy is generally observed under nutrient or oxygen starvation 
or when the cell is challenged by chemotherapy or radiotherapy. In yeast, the target of 
rapamycin (TOR) is a key autophagy inhibitor and inhibits Atg1, a serine/threonine kinase 
which is necessary for the formation of the Atg1-Atg13-Atg17 complex [148] under normal 
nutrient conditions. In mammalian cells, mTOR inhibits the Atg1 homologs, Unc-51-like 
kinases ULK1 and ULK2. However, during nutrient and amino acid starvation, AMP-
activated protein kinase (AMPK) is activated, which inhibits mTOR [147, 148]. It should be 
noted that autophagy induction by rapamycin (dependent on mTOR signaling) is not the 
exclusive pathway for this process. As reported by Sarkar et al. there are a number of 
small molecule enhancers (SMERs) and inhibitors (SMIRs) of the cytostatic effects of 
rapamycin that may induce autophagy independently of rapamycin and mTOR [147, 150]. 
This induction step results in the activation of ULK1 and ULK2, which are known to 
phosphorylate Atg13 and FIP200, the mammalian homolog of yeast Atg17. A ULK-Atg13-
FIP200 complex localized to the phagophore is then formed; Atg 101 is believed to bind 
to and stabilize Atg13 in the complex [148, 151, 152].  
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Mercer et al. found that Atg101, a novel autophagy protein, also interacts with ULK1 in 
an Atg13-dependent manner and is a part of the ULK-Atg13-FIP200 complex [151]. This 
marks the nucleation step, which requires the phosphatidylinositol 3-kinase (PtdIns3K) 
complex comprising vacuolar sorting protein 34 (Vps34), p150, Atg14, and Beclin-1 [147, 
148]. Vps34, the only class III PI3 kinase in mammalian cells, is responsible for the 
phosphorylation of phosphatidylinositol to phosphatidylinositol-3-phosphate (PtdIns3P) 
[147, 153]. This phosphorylation process is facilitated by Beclin-1. Several proteins bind to 
Beclin-1 and may result in either promotion or inhibition of autophagy. Among the Beclin-
1 binding partners that promote autophagy are Atg14L and the UV radiation resistance-
associated gene (UVRAG) whereas binding to Bcl-2 and Bcl-XL results in inhibition of 
autophagy [147].  
Conjugation of two ubiquitin-like (Ubl) protein complexes – Atg5-Atg12-Atg16 and Atg8–
Phosphatidylethanolamine mediates the elongation and completion phases of autophagy 
which involves Atg3, Atg5, Atg7, Atg10, Atg12 and Atg16L as well as microtubule-
associated protein light chain 3 (LC3) [141, 148, 154, 155]. Yeasts have only one Atg8 protein 
whereas in mammals there are many homologs in the Atg8 family of proteins including 
LC3, GABARAP, and GATE-16 [155]. The completion of autophagosome formation is 
associated with the formation of an Atg5-Atg12-Atg16 complex that results in the 
conversion of cytosolic LC3 to the lipidated membrane-bound isoform, LC3-II [154]. It was 
previously believed that Atg5 and Atg7 are necessary for autophagy in mammalian cells 
but an alternative pathway independent of Atg5/Atg7 has been identified [156]. Autophagy 
enters into completion via the fusion of the autophagosome with the lysosome to form the 
autolysosome where the cargo (contents of the autophagosome) are broken down by 
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hydrolases to generate energy, metabolic precursors, or amino acids for protein 
synthesis.  
2.2 Proteomics Approaches to Study Autophagy 
Mass spectrometry-based proteomics has proven invaluable for studying protein 
structure, expression, sub-cellular location, protein-protein interactions and PTMs [157, 158]. 
In recent years, mass spectrometry-based proteomics technology has played a major role 
in advancing our knowledge relating to autophagy and increased our understanding of 
the content of autophagic structures such as autophagosomes and lysosomes. While 
some of these studies have focused on autophagy-related mechanisms, other studies 
reflect global proteomics analysis to investigate cells and disease states, which provide 
insight into known and/or novel functions of various proteins linked to the autophagic 
machinery. A variety of proteomics approaches, including labeling (e.g. Stable Isotope 
Labeling by Amino Acids in Cell Culture (SILAC), biorthogonal noncanonical amino acid 
tagging (BONCAT), and isobaric tagging for relative and absolute quantification (iTRAQ)) 
and label-free methods, have been used in combination with immuno-based techniques, 
among others, in exploring autophagy [149, 159–165]. In this review, we will cover proteomics 
studies focused on autophagy in the context of the cell compartments analyzed and 
shown in Figure 10. A brief summary of each study including the cell and/or animal 
models, treatment conditions, and analytical approaches used as well as key regulated 
proteins is provided in Table 1. 
2.2.1 Whole Cell Proteomics Analysis 
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Proteomics has been used successfully to screen whole cell lysates for differential protein 
expression and PTMs as a function of different stress stimuli including drug treatments 
and radiation [160, 162, 164, 166–170]. Cells exposed to exogenous stimuli are subsequently 
lysed to obtain the entire complement of proteins that may have been affected, but without 
regard to cellular compartment or function. In global studies, comparative data analysis 
reveals the effects of the stimuli on biological function relating to autophagy. Proteomics 
studies have served to reveal novel proteins or novel functions of known proteins and 
their involvement in the process of autophagy. 
Autophagy 
Whole Cell Fractionation Secretome 
Autophagosomes Lysosomes 
Bagshaw et al. Tharkeshwar et al. 
Chapel et al. Gao et al. 
Sleat et al.  Naureckiene et al. 
Kollman et al. Della Valle et al. 
Dengjel et al. Gao et al. 
Mancias et al. Suzuki et al. 
Overbye et al. Naureckiene et al. 
Zhang et al. Bertin et al. 
Kang et al.  Patella et al. 
Zhuo et al.  Mathew et al. 
Zhao et al.  Kim et al. 
Rodolfo et al. Wang et al. 
Tavera-Mendoza et al. 
Kraya et al. 
Kang et al.  
Ohman et al. 
Cudjoe et al (unpublished)
  
Figure 10 - Overview of proteomics characterization of Autophagy with respect to cellular and sub-cellular 
compartments. 
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In two recent publications, Zhang et al describe a proteomics method involving a 
combination of BONCAT labeling and iTRAQ for the detection and quantification of de 
novo protein synthesis in autophagy [166, 167]. The BONCAT approach involved introducing 
azidohomoalanine (AHA), an azide methionine mimetic, into the culture media, which 
subsequently is incorporated into newly synthesized cellular proteins. Autophagy was 
induced in AHA-treated HeLa cells via amino acid starvation (in amino acid-free media) 
followed by total cell lysis and enrichment of newly synthesized AHA-containing proteins 
via click reaction coupling of biotin-linked alkyne groups and subsequent avidin bead 
capture. Bound AHA-containing proteins were then digested and treated with iTRAQ 
reagents followed by LC-MS/MS proteomics identification and quantification. Zhang et al 
profiled 711 proteins using this method. Among the proteins identified and verified were 
ATP synthase, H+ transporting, mitochondrial F1 complex, β polypeptide (ATP5B), heat 
shock protein family E [Hsp10] member 1 (HSPE1) and solute carrier family 25 member 
3 (SLC25A3), receptor for activated C kinase 1 (RACK1/GNB2L1) and PNP (purine 
nucleoside phosphorylase) [166]. Gene knockdown (using siRNA) of ATP5B, RACK1, or 
SLC25A3 resulted in decreased autophagic flux indicating a role for these proteins in the 
promotion of autophagy. The approach used in the study is applicable to many multiple 
experimental designs and can be very useful in understanding protein synthesis during 
stress-induced autophagy. 
Kang et al. performed proteomics analysis on starvation-induced autophagy in HCT116 
cells and identified Annexin A1 (ANXA1) as a potential regulator of autophagic 
degradation [41]. 2D-gel electrophoresis and subsequent MALDI-TOF MS analysis of the 
proteins identified various proteins that were up or downregulated after autophagy 
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induction. Kang et al. reasoned that downregulated proteins following autophagy 
induction may be targets of autophagic degradation whereas upregulated proteins may 
be involved in the process of autophagy itself. ANXA1 levels increased by ~3 fold 
following the induction of autophagy and when it was knocked down by siRNA, there was 
no difference in LC3 degradation between ANXA1 siRNA and wild type cells after 
starvation. Notably, a modest decrease in p62 levels was observed which the authors 
argue may be indicative of a later role related to autophagic degradation for ANXA1 [171]. 
Zhuo et al. in an iTRAQ comparative proteomics study of autophagy in mouse embryonic 
fibroblasts (MEFs) with and without the autophagy gene Atg7 revealed a connection 
between F-actin and autophagy [172]. Functional enrichment and network analysis of the 
results indicated an upregulation of proteins in the F-actin network [172]. Further analysis 
revealed the F-actin fibers in the Atg7 -/- cells were highly disorganized compared to wild 
type cells. The functional relevance of F-actin in autophagy was investigated by inducing 
F-actin depolymerization in Atg7 wild type cells using cytochalasin D (CD) which resulted 
in increased LC3 conversion and p62 degradation following starvation. However, in CD-
treated cells following starvation, more LC3 degradation but decreased p62 degradation 
was seen implying a decrease in autophagosome degradation [172]. F-actin was therefore 
shown to be important in the maturation of autophagosomes and completion of the 
autophagy process. 
Toll-like receptors (TLRs) are immune system proteins that recognize certain microbial 
molecules. TLRs have been shown to be involved in the regulation of autophagy but the 
role of specific Toll-like receptors such as TLR-9 in autophagy remains controversial [173–
175]. Delgado et al. showed, through their comprehensive study of Toll-like receptors, that 
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CpG – a TLR-9 ligand, did not induce autophagy while Sanjuan et al. showed that CpG 
activated autophagy [173, 174, 176]. A comparative global proteomics study by Bertin et al., 
however, showed that CpG is involved in the autophagic process in tumor cells as well 
as human embryonal kidney HEK293 cells expressing murine TLR9 [175]. In their study, 
CpG-treated tumor cells showed autophagy induction characterized by LC3I conversion 
to LC3II. They also observed changes in autophagy regulated proteins such as annexin 
A1 (ANXA1). In another study, Li et al. investigated changes in the host proteome 
following infections with the rabies virus in mice brains and determined factors that may 
be responsible for different pathogenicity [177]. They used two strains of the virus and found 
one strain, CVS-11, to be more virulent than the SRV9 strain and that SRV9 infection was 
attenuated between 10 – 14 days post infection. Autophagy, together with associated 
pathways such as mTOR signaling, was one of the top 5 canonical pathways differentially 
dysregulated between CVS-11 infection and SRV9 infection in the Li et al. study [177]. Li 
et al also demonstrated that autophagy induction was not simply a result of viral infection 
but a function of viral replication. NA cells were infected with UV-inactivated rabies virus 
and they found no significant induction of LC3 conversion compared to mock-infected 
cells. Increased autophagosome accumulation was observed in attenuated SRV9-
infected samples compared to CVS-11-infected samples. The presence of viral genomic 
RNA material in the SRV9-infected cells after attenuation of infection when viral titers fell 
below detectable levels may indicate that autophagy induction is more a response to viral 
RNA than to viral particles. 
Patella et al. sought to identify changes in the proteome of endothelial cells (ECs) 
associated with the transition from sub-confluence to confluence [178]. Cultured ECs are 
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motile and proliferate when sub-confluent whereas confluent cells establish cell-cell 
adhesion and secrete various autocrine and paracrine factors into the extracellular space 
that facilitate decreased cell proliferation and permeability and promote quiescence [178, 
179]. These investigators identified proteins that were differentially regulated in sub-
confluent and confluent cells. Most of the proteins upregulated in sub-confluent cells 
compared to confluent cells were related to cell division and DNA/RNA-processes, 
suggesting decreased growth in confluent cells, which is consistent with our 
understanding of the confluent state. The proteins upregulated in confluent cells were 
mostly enriched for extracellular matrix organization, metabolic processes and vesicle 
organization. Vacuole organization was the most enriched and within this group, several 
lysosomal proteins were present. Their results also indicated that p62/SQSTM1, a protein 
that is generally reduced via autophagic degradation, was downregulated in confluent 
cells. Patella et al. further sought to identify the impact of autophagy on EC function and 
found that inhibition of autophagy via Atg5 silencing resulted in decreased cell 
proliferation while both Atg5 silencing and bafilomycin treatment impaired EC barrier 
integrity and increased EC permeability [178]. Pathway analysis was used to predict the 
factors driving the global changes in proteome induced by autophagy inhibition. Among 
the identified factors was hydrogen peroxide, a widely known inducer of reactive oxygen 
species (ROS). In autophagy-deficient cells, Rho-related GTP-binding protein (RHOB), 
which has been shown to be upregulated in response to oxidative stress in pulmonary 
endothelial cells, was found to be upregulated following autophagy inhibition suggesting 
that autophagy inhibition results in oxidative stress [178]. Treatment of bafilomycin-treated 
cells with the ROS scavengers, N-acetyl-L-cysteine and ascorbic acid, resulted in a partial 
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restoration of EC barrier integrity. This showed that the increased EC permeability 
following autophagy inhibition was a consequence of ROS generation.  
Mathew et al. carried out a comparative proteomics study to identify differences in the 
proteomes of autophagy-proficient and –deficient Ras-driven cancer cells [162]. Autophagy 
was induced in SILAC-labeled baby mouse epithelial (iBMK) cells via starvation followed 
by LC-MS/MS analysis. A total of 3181 proteins were found to be differentially expressed 
before and after starvation in the autophagy-proficient and –deficient cell comparison. 
This finding reflects the extent of protein turnover during autophagy and further provides 
insight into proteins that serve as cargo for the autophagic machinery. Autophagy was 
also determined to be largely targeted to proteins that promote cell survival. In autophagy-
deficient cells, poly(ADP-ribose) polymerase (PARP), known to be involved in single-
strand DNA repair, and STAT1, known to be involved in interferon-mediated cell death, 
were upregulated [162]. 
The EVA1A gene is necessary for autophagosome formation during autophagy via its 
interaction with Atg16L [180] and it is also reported to induce cell death [181]. Proteomics 
studies have subsequently revealed that EVA1A regulates genes that are involved in the 
pathogenesis of neurodegenerative diseases including Alzheimer’s and Huntington’s, 
thereby shedding some light on the potential involvement of autophagy in 
neurodegeneration [164]. Autophagy has also been determined to be involved in the 
metabolism of amyloid beta as well as its secretion [182]. In the study by Zhong et al, 
EVA1A homozygous knockout mice (Eva1a-/-) showed higher levels of 
neurodegeneration compared to EVA1A wild type mice [164]. This was detected by 
determining both mRNA and protein levels of the neuronal marker, β-tubulin III, which 
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showed a marked decrease in knockout mice. Fluorescence detection of β-tubulin III 
showed a similar result. The effect of EVA1A deficiency was only apparent in neurons but 
not other cell types. The proteomics analysis identified 5438 proteins of which 4462 were 
quantified in all three replicates. 28 proteins were differentially regulated by EVA1A 
knockdown and pathway analysis determined an enrichment of neurodegenerative 
disease-relevant proteins [164]. 
Further insight into the actions of certain drugs using proteomics tools have revealed the 
central role played by autophagy in drug sensitivity. Zhao et al. found that the neurotoxicity 
of bupivacaine is strongly linked to the generation of excess reactive oxygen species and 
activation of autophagy. It is also related to its inhibitory effects on PI3K [160].  The 
phosphoinositide-3-kinases (PI3Ks) represent one of the more important family of genes 
involved in autophagy. The class 1 PI3Ks are known to be inhibitory while the class III 
PI3Ks are known to be stimulatory in autophagy [148]. A phosphoproteomics study was 
carried out by Zhang et al. using 2 lung cancer cell lines H3255 and H1975 [168]. The 
H3255 cells carry a single mutation in the EGFR gene which makes them susceptible to 
EGFR-targeted tyrosine kinase inhibitors (TKIs) such as erlotinib while the H1975 cells 
carry a double mutation in the EGFR gene which makes them resistant to erlotinib. Zhang 
et al. found that in erlotinib sensitive cells but not erlotinib resistant cells, the key 
autophagy signaling protein ULK1, is not phosphorylated upon treatment. This implies 
that the sensitivity of the lung adenocarcinoma cells used in the study to erlotinib may be 
autophagy dependent [168]. The phosphorylation action of kinases is known to be 
regulated in the body by ATP binding and hydrolysis [183, 184]. Kinases are also thought to 
be involved in the ability of cancer cells to evade chemotherapy. Kim et al. therefore 
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conducted a proteomics study to determine the effects of MEK-inhibitor drug treatment 
on the ATP-binding proteome in KRAS mutant lung cancer cell lines with different 
p53/LKB1 mutation statuses including A427, A549 (p53 wild type/LKB1 mutant), Calu-1, 
Calu-6 (p53 mutant/LKB1 wild type); and H157 (p53 mutant/LKB1 mutant). Cells were 
treated with 2 MEK-inhibitors, lysed, and the ATP-binding kinome enriched, using a 
kinase enrichment kit, for subsequent digestion and LC-MS/MS analysis. The study found 
that changes in the ATP-binding proteome were cell type dependent and not KRAS 
mutation dependent [184]. Furthermore, p53/LKB1 status was not determined to be a major 
factor in changes in the ATP-binding proteome. MEK-inhibition was also determined to 
effect changes in glucose metabolism in A427, A549, and Calu-1 cells. Kim et al. found 
that ULK1, ULK3 and AMPK were upregulated in cells treated with MEK-inhibitors 
compared to untreated cells. The findings of the study by Kim et al. align with MEK-
inhibitors having been previously reported as inducing protective autophagy in KRAS 
mutant non-small cell lung cancer (NSCLC), and suggests that upregulation of autophagy 
in KRAS mutant lung cancer may be kinase dependent [184, 185]. When validated, this may 
provide a reasonable basis for combination chemotherapy with kinase inhibitors. 
Some anticancer agents including Ophiobolin A (OP-A), a fungal toxin, have been 
determined to induce autophagy [169].  Rodolfo et al. investigated the anticancer activity 
of OP-A using a human melanoma cell model (A375, and CHL-1 cell lines) [169]. A 
comparative proteomics experiment was used to determine differentially regulated 
proteins due to OP-A treatment. In the study, OP-A induced autophagy based on 
increased LC3 conversion with increasing drug concentrations as well as activating 
apoptosis. Following 2D gel electrophoresis, Rodolfo et al. used LC-MS/MS to identify 24 
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protein spots that were significantly affected by OP-A treatment. Among the differentially 
regulated proteins were fructose 1,6 bisphosphate aldolase A (ALDOA) and triose 
phosphate isomerase (TPI) [169]. These enzymes, found to be associated with autophagy, 
have been shown to be important enzymes in glycolysis in a cell type dependent manner 
[186, 187]. Wang et al [170] used proteomics to identify potential targets of the natural product 
curcumin in HCT116 colon cancer cells via an alkyne-labelled curcumin probe. The 
curcumin bound-proteins were biotinylated via azide-linked biotin tags, enriched with 
avidin beads, digested with trypsin and then labeled with iTRAQ tags, and analyzed by 
LC-MS/MS. Wang et al. identified 197 proteins with unique cellular locations and 
biological functions [170]. Among the biological pathways enriched in their data were eIF2 
signaling, eIF4 and p70S6K signaling, and the mTOR signaling pathway which is directly 
related to autophagy. Wang et al. went on to investigate curcumin treatment effect on 
protein synthesis using AHA. Newly synthesized AHA-containing proteins were 
fluorescent labeled via a click reaction and the fluorescence intensity of cells analyzed 
with flow cytometry. Curcumin treatment resulted in a decrease in protein synthesis 
evidenced by a 50% reduction in fluorescence signal following treatment. Previous 
reports in literature [188] that curcumin may inhibit mTOR phosphorylation led Wang et al. 
to determine the effect of curcumin on autophagy. The results of their immunoblotting 
work confirmed that curcumin induces autophagy, which was signaled by an increased 
autophagic flux and increased LC3 levels. The inhibitory effect of curcumin on mTOR was 
also confirmed via decreased phosphorylation of the mTOR substrate S6 [170]. 
Vitamin D, acting through activation of the vitamin D receptor (VDR), has been 
determined to induce autophagy and have anti-proliferative activity [189]. A study by our 
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group demonstrated a novel switch in autophagy function from a cytoprotective to a 
cytostatic form following vitamin D combination treatment with irradiation in non-small cell 
lung cancer cells [126]. A recent proteomics study by Tavera-Mendoza et al. also showed 
autophagy induction by vitamin D in luminal-like breast cancer cells as well as anti-
proliferative effects [190]. Tavera-Mendoza et al. used rapid immunoprecipitation mass 
spectrometry (RIME) to identify proteins associated with DNA-bound VDR. The RIME 
process followed the procedures reported by Mohammed et al [191]. Briefly, cells are 
cultured, media exchanged and crosslinked in 1% formaldehyde following which proteins 
are extracted and the lysate incubated with magnetic beads prebound with antibody for 
overnight immunoprecipitation. Beads are then washed and digested for LC-MS analysis. 
The RIME analysis by Tavera-Mendoza et al. revealed a regulatory role of vitamin D-
bound VDR for autophagy in breast cancer cells. VDR was shown to downregulate 
autophagy via constitutive LC3B repression and this repression appears to be abrogated 
by vitamin D treatment. This abrogation of LC3B repression, together with the 
upregulation of transcription of autophagy-related genes defines the regulatory role of 
vitamin D in autophagy in the breast cancer model used [190]. 
2.2.2 Subcellular Fractionation 
Proteomics studies involving subcellular fractionation of various organelles is increasing 
in popularity and application. These approaches can provide critical information relating 
to the biological functions of these organelles in the cell and the roles played by specific 
proteins. While this research strategy is useful by affording a spatiotemporal subset of the 
proteome and a less complex proteome, it suffers from the cross contamination between 
subcellular compartments during sample preparation. The subcellular fractionation 
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methods typically employ differential gradient centrifugation in sucrose or Nycodenz 
gradients and/or affinity-based immunocapture or enrichment. 
2.2.2.1 Autophagosomes 
In an effort to provide comprehensive insight as to the types and amounts of proteins 
associated with the autophagosome, a limited number of studies have isolated and 
characterized the proteome of the autophagosome [149, 159, 192, 193]. Isolation of 
autophagosomes have been carried out using Nycodenz gradient centrifugation, GFP-
tagged LC3 immunoprecipitation or immunoisolation via GFP antibody purification or a 
combination of the two. One of the earliest reported methods of autophagosome isolation 
is the study by Stromhaug et al. and forms the basis of most subsequent proteomics 
autophagosome isolation studies [194]. 
Dengjel et al. sought to generate a comprehensive list of various proteins contained in 
autophagosomes while demonstrating that different inducers of autophagy produce 
different protein dynamics within the autophagosome [159]. The study employed the protein 
correlation profile (PCP) method that involves the analysis of peptide contents in the 
various fractions of a density gradient. The PCP strategy assumes that proteins/peptides 
from the same organelle would have a largely similar profile across the various fractions 
[157, 159]. In this work, autophagy was induced via amino acid starvation using Hank’s 
Balanced Salt Solution (HBSS), rapamycin treatment, and concanamycin A (Con A - a 
lysosomal degradation inhibitor) treatment. Dengjel et al. identified 728 enriched proteins 
in their autophagosomal fractions, 94 of which were present in the context of all three 
autophagy stimuli. In contrast, proteomics studies of the autophagosome by Overbye et 
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al. and Gao et al. did not generate many autophagosome-enriched proteins; 39 and 101 
respectively [192, 193]. There was little overlap between the 3 studies which could be due to 
the fact that the experimental approaches adopted by Overbye et al. and Gao et al. were 
limited to autophagosomal membrane proteins while the Dengjel et al. study analyzed the 
entire autophagosome [159]. Also, the Overbye study was conducted in primary 
hepatocytes isolated from Male Wistar rats and autophagy induction was done via 
starvation while the Gao study was in HEK293 and HCT116 cells in which autophagy was 
induced by calcium phosphate precipitate (CPP) [192, 193]. 
To distinguish between proteins truly associated with autophagosomes and non-specific 
proteins in the Dengjel et al. study, some cells were treated with Con A during starvation. 
Autophagosome associated proteins would be expected to be enriched in Con A-treated 
starved cells (due to the accumulation of autophagosomes) compared to starvation only 
cells. Dengjel et al. showed less enrichment of known autophagy-related proteins LC3B, 
p62/SQSTM1, GABARAPL2 in starvation-induced autophagosomes signifying higher 
depletion of these proteins following stimulation of autophagy compared to rapamycin 
and Con A treatment.  
One of the very significant proteomics studies of autophagy in which autophagosomes 
were isolated was performed by Mancias et al. and resulted in the identification of nuclear 
receptor coactivator 4 (NCOA4) as a cargo receptor in iron turnover through autophagy 
[149]. In this work, autophagosomes were isolated from SILAC-labelled PANC-1 and PA-
TU-8988T pancreatic cells as well as MCF7 breast cancer cells using a density gradient. 
Autophagosome accumulation was increased by treatment with chloroquine, an 
autophagy inhibitor that acts by raising lysosomal pH and thereby preventing fusion of 
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autophagosomes and lysosomes. This was a similar strategy to the Dengjel study in 
which autophagosome accumulation was achieved via Con A treatment. The isolation of 
autophagosomes enabled the unbiased identification of 94 proteins highly associated with 
autophagosome formation or maturation and by inference with autophagy.  
These autophagosome isolation studies have not only provided insights into the protein 
composition of the autophagosomal membranes and cargo, but have further provided 
general insights into the process itself. Dengjel et al. also showed, through their mass 
spectrometry-based proteomics study, a significant association between autophagy and 
the proteasome and extended their work to probe the relationship using western blotting 
and fluorescence microscopy [159]. This research group determined that the levels of 
various proteasomal proteins decreased upon autophagy stimulation via amino acid 
starvation as well as rapamycin treatment, and this was reversed when autophagy was 
inhibited by 3-methyladenine (3-MA). Data analysis of the candidate proteins in the 
Mancias et al. study revealed NCOA4 as the most consistently enriched protein in all their 
datasets. NCOA4 was also identified in the Dengjel et al. study but was not highlighted 
as one of their cluster A proteins [149, 159]. The cluster A proteins consisted of the highly 
confident autophagosomal candidate proteins believed to not be “contaminated” with 
proteins from similar organelles such as the endoplasmic reticulum, Golgi apparatus and 
endolysosomes [159]. Mancias et al. found a novel function of NCOA4, where it is required 
in ferritin turnover in a process they termed ferritinophagy [149]. The mass spectrometry 
data from their autophagosomal fraction showed increased expression of both ferritin 
heavy (FTH1) and light (FTL) chains and affinity purification-mass spectrometry showed 
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NCOA4 to interact with FTH1 and FTL as well as HERC2 and NEURL4. Importantly, the 
latter two proteins were not found to be enriched in autophagosomes [149]. 
Other proteomics studies involving isolation of autophagosomes include the work of 
Suzuki et al [195] where various cargo proteins were identified in the autophagosomes of 
Saccharomyces cerevisiae. Suzuki et al. optimized autophagosome isolation by 
monitoring GFP-labeled aminopeptidase 1, which represents a selective cargo in the 
yeast Saccharomyces cerevisiae. It appeared that some of the cargo proteins are 
delivered to the vacuole, where degradation takes place in yeast, independent of the 
essential autophagy-related protein Atg11 [195].  
2.2.2.2 Lysosomes 
Lysosomes are single membrane organelles within the cytoplasm involved in one of two 
main degradation mechanisms employed by eukaryotic cells [157, 196]. The lysosomes play 
a major role in autophagy by fusing with autophagosomes and supplying hydrolases for 
the degradation of the inner membrane and contents of the autolysosome. The 
hydrolases found in the lysosome function at an optimum acidic pH, which may be 
inhibited with agents that raise luminal pH. Lysosomes also play a role in the endosomal 
pathway [196]. Lysosomes have been found to affect many human disease pathologies 
particularly the lysosomal storage diseases (LSDs) but also other diseases including 
neurodegenerative disorders such as Alzheimer’s disease, the neuronal ceroid 
lipofuscinoses (NCLs) and some cancers [196, 197]. Understandably, many LSDs have also 
been shown to have attendant defects in the autophagy pathway [198]. To know the protein 
content of the lysosome would be to understand the possible range of functions the 
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organelle controls or is associated with in the cell and human body. Studying the 
lysosomal proteome under different conditions of stress or stimuli may also help to shed 
some light on the protein dynamics in response to the various stimuli [197]. Using classical 
biochemical approaches, lysosomal protein content had been studied but the full 
complement of the lysosome was not known [199]. However, the combination of mass 
spectrometry-based proteomics, affinity-based purification techniques, and subcellular 
fractionation has resulted in an increase in the number of proteins identified in the 
lysosomes [197]. Kieffer-Jaquinod et al. outline an affinity-based method for the purification 
of lysosomal proteins that involves the isolation of these soluble proteins on the basis of 
their mannose-6-phosphate content [200]. This isolation strategy has provided the rationale 
for many studies that have investigated soluble lysosomal proteins [108, 201–203]. 
Bagshaw et al. conducted a proteomics study to identify the proteins contained in the 
lysosomal membrane [196]. Lysosomes were isolated by the Triton WR-1339 approach 
used by Leighton et al [204] and 215 lysosomal membrane proteins were identified, some 
of which had not previously been reported as being associated with the lysosomes [196]. 
Cytochrome P450 enzymes such as CYP2A1, CYP2C13, CYP2D3, and CYP4A3 as well 
as various ATP synthase subunits including the α, f0 β, F1 complex O, and γ chain 
subunits were identified in the Bagshaw study [196]. Other lysosomal isolation proteomics 
studies have contributed to what we now know about the protein composition of 
lysosomes and their functional relevance, including autophagy. Chapel et al. identified 
734 proteins in a study in which rat liver lysosomes were isolated using differential 
centrifugation in a density gradient [205]. Of the identified proteins in the lysosomal fraction, 
207 constituted known and predicted lysosome-associated proteins whereas 527 proteins 
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were either previously reported to be associated with other cellular organelles or not 
associated with any organelle. A total of 46 potential lysosomal transport proteins were 
identified, 12 of which were validated as lysosomal proteins via overexpression in HeLa 
cells and confirmation of colocalization with lysosomal markers [205]. The authors point out 
that proteins identified in their study that had not been previously reported could be cargo 
delivered by autophagy or endocytosis to the lysosomes for degradation. Using iTRAQ 
labeling and two dimensional peptide separation involving strong cation exchange and 
reverse phase chromatography, Della Valle et al. also report the MALDI-TOF proteomics 
identification of high confident lysosomal proteins using an isolation strategy involving the 
combination of differential centrifugation with sucrose density centrifugation following 
treatment with Triton-WR1339 [206]. Among their high confident proteins were cathepsin 
D (CTSD), classical lysosomal acid phosphatases (ACP2, ACP5), and lysosomal 
associated membrane protein 2 (LAMP2). 
The identification of a glycoprotein candidate that may be responsible for classical late-
infantile NCL (LINCL) was made possible through a proteomics study [108, 197] using gel 
electrophoresis and affinity chromatography. In this work, where Sleat et al. compared 
detergent-soluble extracts of brain autopsies from LINCL patients and controls [108], 
soluble proteins with a mannose-6-phosphate (M6P) post-translational modification 
(PTM) were detected using mannose-6-phosphate receptors (MPRs). In LINCL brain 
samples, a protein that was visibly absent compared to controls was identified using 
affinity enrichment of M6P modified glycoproteins, gel isolation, and protein sequencing 
as having a molecular weight of 46-kD. The protein was determined to be resistant to 
pepstatin degradation and to have considerable sequence similarities with carboxyl 
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peptidases of both Pseudomonas and Xanthomonas [108]. The study represented the first 
report of a pepstatin-insensitive protease in mammals. A study by Vines and Warburton 
revealed substantial similarities between tripeptidyl peptidase I (TPP-I) and the pepstatin-
insensitive protease identified in the Sleat et al. work and suggested the two proteins may 
be the same [207]. 
NCL has been found to possess many common features with other mitochondrial 
disorders in which autophagy of the mitochondria, often termed mitophagy, is defective 
[208]. Other proteomics studies of the lysosome have resulted in the identification of genes 
that have been found to be pivotal in the etiology of certain LSDs. Human epididymis-
specific protein 1 (HE1), a cholesterol-binding protein was found in a proteomics study by 
Naureckiene et al. to be contained in lysosomes [201]. This discovery, together with prior 
knowledge of the involvement of this protein in cholesterol binding, led to the investigation 
of the possibility of its involvement in LSDs that involve lysosomal cholesterol storage [197, 
201]. This resulted in the discovery of mutations in the gene in Niemann-Pick disease type 
C2 (NP-C2) patients [201]. Kollman et al. employed the M6P immunoisolation strategy in 
conducting a comprehensive proteomics analysis of lysosomal matrix proteins [209]. Using 
the knowledge that M6P-deficient mouse embryonic fibroblasts secrete the lysosomal 
matrix proteins that would have otherwise been targeted to the lysosome, Kollman et al. 
isolated M6P proteins using affinity purification. The secretome of the fibroblasts was then 
analyzed which resulted in the identification of 34 known and 4 potential lysosomal matrix 
proteins [209]. Among the proteins identified were the cathepsins B, D, and Z as well as 
mammalian ependymin-related protein-2 (MERP-2), Protein CREG, and retinoid-
inducible serine carboxypeptidase (RISC). 
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In a recent proteomics study using NP-C1 as a case study, Tharkeshwar et al. 
demonstrated a novel method of isolating lysosomes for downstream proteomics 
applications [210]. The method utilizes a magnetic isolation approach with 
superparamagnetic iron oxide nanoparticles (SPIONs). These SPIONs consist of an 
organic or inorganic outer shell covering a magnetic core [210]. These investigators first 
optimized SPION preparation and found that dimercatosuccinic acid (DMSA)-coated 
SPIONs were most suited to targeting the late endosomes or lysosomes (LE/LYS). The 
SPION design and targeting efficiency was validated with proteomics and lipidomics 
profiling of plasma membranes and isolated lysosomes. The lack of proteins from 
contaminating organelles and abundance of membrane-enclosed luminal proteins was 
consistent with the isolation of very homogenous fractions of plasma membranes and 
LE/LYS. Their study also evaluated proteome and lipidome changes in HeLa cells with 
and without wild-type NP-C1. The NP-C1 protein is primarily located in the membrane of 
LE/LYS. NP-C1 and NP-C2 regulate the transport of cholesterol from lysosomes [210, 211]. 
Tharkeshwar et al. isolated plasma membranes and LE/LYS using their SPIONs and 
compared the protein as well as lipid content. The analysis showed that the plasma 
membrane proteome and lipidome remained largely the same with minor changes (6 
differentially regulated proteins) whereas the lysosomal fractions showed more variation 
in protein and lipid levels (53 differentially regulated proteins). This observation was 
consistent with the view that defects in lipid and protein transport related to lysosomes do 
not typically affect the composition of the cellular membrane but rather the intracellular 
proteins. Various autophagy-related proteins including p62/SQSTM1 and the annexins 
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A3 (ANXA3) and A5 (ANXA5) were identified and quantified in their dataset with ANXA5 
being upregulated in LYS of NP-C1 KO [210]. 
In a study by Gao et al. to determine the effect of bacterial and viral infection on global 
lysosomal function, the authors isolated lysosomes from murine RAW 264.7 macrophage 
cells [212].  Changes in the proteome as well as the glycoproteome following infection with 
Listeria monocytogenes, herpes simplex virus type 1 (HSV-1) and vesicular stomatitis 
virus (VSV) were then assessed [212]. Isolation of lysosomes was achieved via differential 
centrifugation using density gradients. Without complementing their isolation with any 
immunocapture techniques, the proteins identified in this study may not be solely 
representative of the lysosome (>80% lysosomal purity). The identification of proteins 
annotated as ER, Golgi, and mitochondrial was indicative of the effect of infection on 
protein turnover resulting in translocation of these proteins to the lysosomes. Gao et al. 
found that there was generally a decrease in lysosomal enzymes expression following 
infection except the cathepsins K and L which increased after VSV and Listeria infection 
[212]. They also found, consistent with expectation of lysosomal pH being regulated within 
very narrow limits, that proton ATPases in the lysosomal remained largely unchanged 
following infection. The TLRs were identified in the study and HSV-1 infection was 
observed to cause upregulation of TLR3 and TLR9, which has been shown to induce 
autophagy in other studies [175, 212]. 
2.2.2.3 Other Subcellular Fractionation studies 
A few other subcellular fractionation proteomics experiments have been conducted that 
have provided some insights into the process of autophagy. One such study by Yu et al. 
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examined the impact of aging on the proteome of lipid droplets in a filamentous fungus 
[165]. Lipid droplets are known to be multifunctional and are involved in many processes in 
oleaginous microbes including protein storage and autophagy [165, 213, 214]. This study 
found >400 proteins in the lipid droplets, 62 of which were significantly affected by aging. 
The authors reported the downregulation of enzymes involved in glutathione metabolism 
in the aging cells, signaling a malfunction in the antioxidant system. Autophagy has been 
shown to be involved with cellular signaling in response to reactive oxygen scavenging 
[215]. Combining findings from a previous study by their group in which mycelia were found 
to be degraded during aging, the authors then hypothesized that this malfunction resulted 
in autophagy activation by reason of an autophagy related protein that was upregulated 
in the aging sample.   
Shui et al. isolated phagosomes using latex beads incorporation into mouse 
macrophages and subsequent sucrose gradient centrifugation and carried out a mass 
spectrometry-based proteomics analysis of the isolated phagosomes [216]. In this study, 
they confirmed proteins identified in previous phagocyte isolation studies but also many 
proteins that had not been identified in phagosomes. Among the proteins identified in their 
study are Vesicle-associated membrane protein 4 (VAMP4), TLR7, TLR9, and LC3-II [216]. 
Shui et al. also studied the association between autophagy and phagosomes based, in 
part, on the presence of LC3-II in the phagosomal isolates. The authors induced 
autophagy by nutrient starvation and studied the effect of inhibiting autophagosome 
formation and autophagosome degradation on LC3-II levels in the phagosomes. Inhibition 
of autophagosome formation using 3-MA reduced LC3-II levels in phagosomes while 
inhibiting autophagosome degradation using vinblastine resulted in increased LC3-II 
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levels in phagosomes. The authors therefore hypothesized that LC3-II is transferred from 
autophagosomes to phagosomes during the process of autophagy. The increased protein 
expression in phagosomes following inhibition of autophagosome degradation was also 
evident with VAMP but not with other proteins of the phagosomal isolates including 
transferrin receptor (TfR), lysosomal-associated membrane protein-1 (LAMP1), and 
CTSD. This suggests that VAMP4 and LC3-II trafficking to the phagosomes specifically 
occurs during autophagy.  
In a proteomics study involving the purification of the coat protein II (COPII) inner coat of 
the yeast Saccharomyces cerevisiae, Davis et al highlighted the effect of phosphorylation 
on autophagosome formation [217]. Mass spectrometry-based phosphoproteomics 
analysis resulted in the identification of 27 phosphorylation sites on Sec24, a COPII cargo 
adaptor. It was found in this study that phosphorylation of Sec24 at 3 conserved amino 
acid sites (T324/T325/T328) contributes to the redirection of COPII coated vesicles to 
autophagosome formation instead of the Golgi during starvation [217]. It was also 
demonstrated that casein kinase 1 is responsible for the phosphorylation of the sites. 
2.3 The Secretome: Proteomics Biomarker Discovery 
The secretome represents one of the best opportunities for the application of proteomics 
as a tool for biomarker discovery in the study of autophagy due to the wealth of 
information resident in cellular secretomes. The cancer secretome contains various 
extracellular vesicles (EVs) such as microvesicles (MVs) and exosomes with central roles 
in tumor development and progression [218–220]. Cell secretions into culture media could 
represent a surrogate for secretion into blood/plasma, which could potentially provide a 
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rich resource for the discovery of protein markers of disease [219]. While autophagy has 
been classically known to be primarily a catabolic mechanism, recent studies have shed 
light on additional autophagic functions such as cellular protein secretion [221].  
2.3.1 Autophagy and Cellular Secretion 
Cellular secretion is known to occur either via the endoplasmic reticulum (ER) /Golgi 
pathway, which represents conventional (classical) secretion, or via alternate pathways 
that are independent of the ER/Golgi secretory machinery, representing non-conventional 
secretion. Studies have showed that about 10 – 15% of all synthesized proteins are 
eventually secreted into the extracellular environment through both classical and non-
classical secretory pathways [93, 222]. Proteins secreted via the classical pathway are 
known to have an N-terminal secretory peptide signal, which makes them recognizable 
to the secretory apparatus. During protein synthesis, the growing protein sequences are 
transported to the ER membrane where they are translocated across the membrane [223, 
224]. In the lumen of the ER, the signal peptides are cleaved before vesicles coated by 
COPII fuse with the Golgi apparatus. Proteins to be secreted are stored in vesicles within 
the Golgi and are directed to the cell membrane where secretion occurs [99].  
Non-conventional secretion occurs through various mechanisms and may or may not 
involve vesicles [99, 221, 225]. Secreted proteins may contain signal peptides but are not 
transported to the cell surface for secretion through either COPII or the Golgi machinery 
or do not contain signal peptides nor depend on the ER or Golgi machinery for delivery 
to the cell surface for secretion [99]. Non-vesicular transport may occur, among others, via 
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transporters (e.g. MATa, a yeast mating factor) or binding to macromolecules such as 
lipids (e.g. fibroblast growth factor 2, FGF2) [225].  
Autophagy has been found to have a role that interfaces with both conventional and non-
conventional secretion. The non-conventional secretion of various proteins that have 
been shown to be secreted via autophagic vesicles  in mammalian cells include high-
mobility group box 1 protein (HMGB1), amyloid beta (Aβ), and interleukin 1 beta (IL-1β) 
[182, 221, 226, 227]. The soluble yeast protein acyl-coenzyme A-binding protein (Acb1) and its 
homologs in various organisms are also known to utilize the autophagy machinery for 
secretion [99, 221, 228]. Non-conventional secretion via autophagy is mediated by 
autophagosomes and also involves the Golgi re-assembly and stacking protein, GRASP 
which makes it unique from other modes of non-conventional secretion [221, 228]. GRASP, 
while being a protein that is involved in Golgi organization, plays a role in non-
conventional secretion but not classical secretion through the ER/Golgi machinery. The 
involvement of the autophagosome in non-conventional protein secretion via autophagy 
coupled with the fact that autophagosomes are believed to possibly originate from certain 
sections of the ER gives rise to the possible interfacing with conventional secretion [180, 
221, 229]. 
2.3.2 Proteomics of Autophagy-Associated Secretion 
Mass spectrometry-based proteomics has contributed to the elucidation of the role of 
autophagy in secretion. A study by Kraya et al. assessed the role of autophagy in the 
secretion of proteins from melanoma cell lines, WM793 and 1205Lu, differing in 
metastatic ability and basal autophagy levels [161]. In the highly autophagic metastatic 
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1205Lu cell line, levels of IL-1β (interleukin 1, β), CXCL8 (chemokine C-X-C motif ligand 
8), LIF (leukemia inhibitory factor), FAM3C (family with sequence similarity 3, member C), 
and DKK3 (dickkopf WNT signaling pathway inhibitor 3) were found to be elevated. The 
expression and secretion of these proteins consequently decreased when Atg7 was 
knocked down in the highly autophagic cells while secretion increased when the low 
autophagic non-metastatic cells were treated with tat-BECN1, an autophagy inducing 
peptide. The findings were validated in melanoma patient plasma samples where serum 
levels of IL-1β, CXCL8, LIF, FAM3C, and DKK3 were found to be upregulated in patients 
with highly autophagic tumors compared to patients with low autophagic tumors. These 
results suggest a possible role for autophagy-associated protein secretion in tumor 
metastasis. The use of proteomics tools, in conjunction with other molecular approaches, 
to determine the proteins and elucidate the mechanisms involved in these roles is 
therefore warranted and important. 
A proteomics study by Kang et al. determined the effect of oxidative stress on the 
exosomes, a key component of cellular secretomes, in aqueous humor of patients with 
Neovascular Age-related Macular Degeneration (AMD). Cells were treated with Paraquat, 
an agent that induces oxidative stress which is a risk factor in AMD. Oxidative stress via 
ROS production is widely believed to be one of the major pathways of stress-induced 
autophagy [215]. The results of the study showed the upregulation of proteins associated 
with autophagy, including cathepsin D (CTSD) [230]. The cathepsins are known proteases 
found and activated in the acidic pH of the lysosome. Cathepsins were upregulated both 
in the exosomes isolated from the secretome of Paraquat-treated human retinal pigment 
epithelial ARPE-19 cells and the aqueous humor of AMD patients (relative to control cells 
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and patients respectively). In the Kang et al. study, the number of exosomes in the 
secretome correlated with oxidative stress levels.   
Ohman et al. studied the activation of unconventional protein secretion in human 
macrophages using 1,3-β-Glucans, curdlan and GBY [227]. They hypothesized that β-
Glucans, a principal component of fungal cell walls, constitute a key arm of fungi-induced 
human cell immunoactivation. Dectin-1 is the primary recognition receptor of β-Glucans 
in macrophages and dendritic cells [227, 231]. Mouse bone marrow-derived dendritic cells 
(BMDCs) with and without Dectin-1 were utilized to examine the hypothesis relating to 
the β-Glucans. Ohman et al. used iTRAQ labeling mass spectrometry to determine 
differences in protein secretion between control cells (no treatment and LPS treatment as 
negative controls) and β-Glucan-treated cells. This work determined that β-Glucan 
treatment significantly increased protein secretion and this was associated with various 
pathways including immune signaling, chemokine signaling pathway and leukocyte 
transendothelial migration [227]. The presence of many autophagy-related proteins led the 
authors to investigate the connection between autophagy and protein secretion in their 
model. Their findings indicated a strong association between autophagy and the dectin-
1-mediated regulation of protein secretion. LC3 conversion was shown to increase upon 
treatment with curdlan and inhibition of autophagy significantly diminished IL-1β secretion 
even though IL-1β mRNA levels were not affected. Similarly, total protein secretion 
decreased with Beclin-1 knockdown (50%). The secretion of CTSD, ANXA1, tubulin, and 
galectin-3 in dectin-1 activated cells were all shown to decrease upon autophagy 
inhibition via Beclin-1 knockdown [227]. 
2.4 Autophagy and Cancer Therapy: How Proteomics Could Help 
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As discussed above, autophagy has been implicated in the pathogenesis of multiple 
diseases [154, 126, 232–235]. It is also well-established that autophagy represents a pivotal 
cellular stress response to DNA-damaging cancer therapy [236]. As a survival mechanism, 
cancer therapy-induced autophagy has been studied extensively as a resistance 
mechanism by which tumor cells can thrive under unfavorable conditions [237, 238]. 
Accordingly, multiple clinical trials have been conducted with the goal of inhibiting 
autophagy in combination with conventional or targeted cancer therapy 
(www.clinicaltrials.gov). These studies have overall shown inconsistent outcomes [236, 127]. 
This is likely due in part to the heterogeneous roles that autophagy can play. As 
mentioned earlier, autophagy is not always cytoprotective, and we and others have 
identified different functions of autophagy where it can facilitate cell death rather than 
survival [125]. In addition, the classical protective function of autophagy can be diminished 
under certain circumstances and autophagy inhibition may fail to influence tumor cell 
survival, a form we have termed non-protective autophagy [233]. Collectively, this 
inconsistency in the functions of autophagy provides a challenge to autophagy modulating 
therapy which is largely directed to inhibit autophagy induction or completion.  
Despite the increased understanding of what dictates the function of autophagy, this field 
is critically lacking in biomarkers that might predict how autophagy will affect tumor cell 
response to therapy, which consequently would determine whether pharmacological 
autophagy inhibition would result in desirable outcomes. It is quite feasible that 
proteomics could prove to be a rigorous tool for the identification of novel markers that 
would allow for clinical evaluation of autophagy function in patients [239].  The primary goal 
is to be able to predict when chemotherapy-induced and/or radiation-induced autophagy 
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will be cytoprotective, based on specific serum markers secreted by tumor cells that are 
dependent on autophagy for survival. The compelling need for such markers provides an 
ideal opportunity for the application of mass spectrometry-based proteomics. To this end, 
our group has carried out an initial exploratory study of the secretome of p53 wild type 
(p53wt) and p53-null H1299 (NSCLC) cells as a function of radiation-induced autophagy 
(manuscript in preparation). This is an effort to identify potential blood based biomarkers 
that may be useful in distinguishing between NSCLC patients on the basis of response to 
radiation therapy during cancer treatment.  
The study was carried out with the knowledge that about half of all cancers have 
mutations in p53 which may impact prognosis during treatment [240–242]. We also used the 
inducible H1299 cell line as a model of NSCLC because our previous studies had shown 
that in p53wt cells, autophagy was protective whereas autophagy was non-protective in 
p53-null cells [126, 233]. By exploring the secretome of these cells with differing p53 status 
using mass spectrometry-based proteomics, we identified differences due to p53 status 
as well as changes in secretion following ionizing radiation treatment. The proteins, 
regulated by p53 and/or radiation treatment, included chromogranin B (CHGB), 
secretogranin 2 (SCG2, glucose phosphate isomerase (GPI), thioredoxin (TXNRD1), 
protein FAM3C, calnexin (CANX), and eukaryotic translation initiation factor 5A-1 
(EIF5A). By this study of secretion differences due to p53 status as a function of radiation 
treatment in NSCLC, we have demonstrated the potential of mass spectrometry to 
provide plausible leads in biomarker discovery efforts towards being able to predict 
whether the response to radiation in the context of autophagy would be beneficial. 
2.5 Conclusions 
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We have discussed the process of autophagy and its signaling machinery from a mass 
spectrometry-based proteomics perspective in this review. The proteomics studies that 
have been described and discussed highlight the usefulness of mass spectrometry for 
global and targeted analysis of the autophagy process and its role on various cellular 
processes ranging from cell signaling to response to infections and drug action. 
Improvements in mass spectrometry instrumentation as well as continuous analytical 
software developments have enhanced the ability to measure qualitatively and 
quantitatively proteome changes with high accuracy and reproducibility. Autophagy is a 
potential mechanism of cellular resistance to therapy. However, in the absence of 
biomarkers that might predict benefit from autophagy modulation as a clinical strategy to 
complement chemotherapy and/or radiotherapy, proteomics studies that probe the cell 
and secretome in a largely unbiased approach could provide the avenue for identification 
and clinical application of such biomarkers.
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Table 1 - Summary of reviewed proteomics studies on autophagy 
Authors Reference 
Number 
Type of study/Cell 
compartment 
Cells used Treatment 
Conditions 
Analytical 
Approach 
No of 
proteins 
Proteins of 
Interest 
Some Key 
Proteins of 
Interest 
Mancias et al 20 Autophagosomes PANC-1, PA-
TU-8988T, 
MCF7 
Wortmannin, 
Chloroquine 
SILAC-based 
density gradient 
centrifugation, 
LC-MS/MS  
>2000 33 NCOA4, FTH1, 
FTL, MAP1LC3B, 
SQSTM1, 
CALCOCO1, 
SLC38A2, 
SLC7A1 
Dengjel et al. 30 Autophagosomes MCF7-eGFP-
LC3, Yeast 
(Saccharomyc
es cerevisiae) 
Amino acid 
starvation, 
rapamycin, 
concanamycin 
A 
Iodixanol density 
centrifugation, 
Protein 
correlation profile 
(PCP)-SILAC, 
LC-MS/MS 
7935 94 CAP1, VPS35, 
EEF1G, LC3, NP, 
RHEB, GNB2L1 
Zhao et al. 31 Whole cell SH-SY5Y Bupivacaine iTRAQ, SCX, LC-
MS/MS 
4139 241 PIK3CB, PIK3R2 
Kraya et al. 32 Secretome WM793, 
1205Lu, WM9, 
WM1346, 
WM1361A, 
WM164, 
WM1366, 
A375 
tat-BECN1, 
ATG7 
silencing 
SDS-PAGE, 
Label-free LC-
MS/MS 
599 28 FAM3C, IL1B, 
CXCL8, LIF, 
DKK3 
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Mathew et al. 33 Whole cell iBMKs Starvation, 
ATG5 
knockout, 
Bafilomycin A1 
SILAC, SCX, Off-
gel fractionation, 
LC-MS/MS 
7184 3181 MCM3, MCM, 
LIG1, PARP, 
STAT1, AK4, 
PARG, PSMC5, 
PSMC2, SNAP29 
Zhong et al. 35 In vivo Mouse EVA1A 
knockout 
Label-free LC-
MS/MS 
5438 28 Nnt, Ugp2, Uqcrq, 
Plcb3 
Yu Y et al. 36 Lipid droplets Mortierella 
alpina 
(Filamentous 
fungus) 
Time (aging) Density gradient 
fractionation, 
SDS-PAGE, 
Label-free LC-
MS/MS 
>400 62 Histone H4, 
Histone H2B, 
Tubulin alpha-1C 
chain, Actin, 
GLELO, 
EC:2.4.1.25-
disproportionating 
enzyme, 
EC:2.5.1.6-
adenosyltransfera
se, EC:6.3.1.2-
ligase, 
EC:2.5.1.54-
synthase 
Zhang et al. 38 Whole cell HeLa Amino acid 
starvation 
AHA labeling 
(BONCAT), 
iTRAQ, LC-
MS/MS 
711 5 HSPE1, ATP5B, 
SLC25A3, 
RACK1/GNB2L1, 
PNP 
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Zhang et al. 39 Whole cell H3255, H1975 Erlotinib SILAC, TiO2 
Phosphopeptide 
enrichment, SCX, 
LC-MS/MS 
11207 
phosphosit
e (3086 
proteins) 
~ 37 ULK1, EGFR, 
MAPK3, RIPK2, 
WNK1, STAT5B, 
ATG16L1, SSH2, 
PTPN14 
Rodolfo et 
al. 
40 Whole cell A375, CHL-1 Ophiobolin A 2D Gel 
electrophoresis 
LC-MS/MS 
N/A 24 ALDOA, TPI 
Wang et al 41 Whole cell HCT116 Curcumin Click chemistry, 
AHA labeling, 
iTRAQ, LC-
MS/MS  
370 212 (197) PRDX1, TUBB, 
HS90, GAPDH, 
FASN 
Kang et al. 41 Whole cell HCT116 EBSS induced 
starvation 
2D Gel 
electrophoresis, 
MALDI-TOF 
> 1500 GE 
spots 
52 ANXA1, Hsc70, 
GRP78, PDIA3, 
ENO1, GST-P1 
Zhuo et al. 43 Whole cell MEFs Starvation, 
Cytochalasin D 
for F-actin 
depolymerizati
on 
Itraq, online 2D 
LC-MS/MS 
1234 114 F-actin network 
Bertin et al. 46 Whole cell (In vitro 
and in vivo) 
DHD/K12/RP
Ob (rat), MCF-
7, PC-3, 
HEK293 
CpG-ODN, 
Rapamycin 
2D Gel 
electrophoresis, 
LC-MS/MS 
N/A 16 ANXA1, PGAM1, 
DPYSL3, CNN3, 
TPM1, GAPDH, 
PHB, eIF4A1, PC, 
MnSOD, GRP78 
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Li et al. 48 Whole cell Mouse brain, 
NA cells 
Rabies viruses 
(CVS-11, 
SRV9) 
iTRAQ, LC-
MS/MS 
2285 265 PRDX5, mTOR, 
SOD1, SOD2, 
ATP5C1, EIF3E, 
EIF4B 
Patella et al. 49 Whole cell HUVECs siATG5, 
Bafilomycin 
SILAC spike-in, 
LC-MS/MS 
7565 2221 CD55, CRIM1, 
RHOB, ESM1, 
CTSA, CTSB, 
CTSZ, PPT1, 
TPP1 
Kim et al.  55 Whole cell A427, A549, 
Calu-1, Calu-
6,H157 
MEK-inhibitors 
(AZD6244 and 
MEK162) 
ATP-binding 
proteome labeling 
and enrichment, 
LC-MS/MS 
1925 24 JAK1, FAK1, 
MKK3, MKK6, 
PLK1, ULK1, 
ULK3, AMPK, 
AURKA 
Tavera-
Mendoza et 
al 
62 Whole cell MCF-7, MDA-
MB-231, MDA-
MB-453, ZR-
75-1, MCF-
12A 
1,25(OH)2D3 Rapid 
Immunoprecipitati
on Mass 
Spectrometry 
(RIME) 
N/A N/A LC3B, p62, 
HSP90AB1, 
EGFR, ULK2, 
CXCR4 
Overbye et al 64 Autophagosomes Male Wistar 
Rat primary 
hepatocytes 
Starvation, 
Vinblastine 
Differential 
centrifugation, 2D 
gel 
electrophoresis, 
MALDI-TOF 
> 1500 GE 
spots 
39 PEBP, COMT, 
BHMT, IPP, 
AMPK 
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Gao et al. 65 Autophagosomes HEK-293, 
HCT116 
Starvation, 
Calcium 
phosphate 
precipitate 
Immunoisolation, 
2D gel 
electrophoresis, 
MALD-MS/MS 
101 N/A LC3, ATG5, 
ATG16, ATG9, 
SQSTM1, UMP-
CMP Kinase, 
GRP-78, Rab4, 
Rab5 
Suzuki et al. 67 Autophagosomes Saccharomyce
s cerevisiae 
Starvation GFP-fuse 
aminopeptidase 
fluorescence, 
Iodixanol gradient 
centrifugation, 
LC-MS/MS 
40 N/A prApe1, Ald6, 
Pyk1, Yef3, 
Hsc82, Eft1   
Bagshaw et 
al. 
68 Lysosomes Male Sprague-
Dawley rat 
liver 
lysosomes 
Triton-
WR1339, 
Tyloxapol 
Differential 
sucrose density 
centrifugation, 
lysosomal 
subfractionation, 
sepharose cation 
exchange, 1D gel 
electrophoresis,L
C-MS/MS 
215 N/A LAMP1, LAMP2, 
LIMPII, Rab6, 
Rab7, Rab1A, 
Rab11B, VAMP8, 
CYP2A1, 
CYP2C29, 
CYP2D2, 
CYP4A3, APOA-
V, APOE, APOB, 
ST6Gal 
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Naureckiene 
et al. 
73 Lysosomes Human brain 
biopsies, rat 
liver 
NP-C2 
disease, 
Controls (No 
disease or NP-
C1 patients), 
Triton-
WR1339 
Mannose-6-
phosphate affinity 
enrichment, 2D 
SDS-PAGE, 
differential 
sucrose density 
centrifugation, 
anion exchange 
chromatography 
N/A 1 HE1 
Sleat et al. 74 Lysosomes Human brain 
biopsies 
LINCL disease 
and Controls 
(No disease) 
Mannose-6-
phosphate affinity 
chromatography 
purification, 2D 
gel 
electrophoresis, 
Edman 
degradation 
N/A 1 Pepstatin 
Chapel et al. 78 Lysosomes Rat liver 
lysosomes, 
HeLa 
- Differential 
centrifugation, 
Nycodenz density 
gradient 
fractionation, 
liquid-liquid 
extraction, SDS-
PAGE, LC-
MS/MS 
734 12 LOH12CR1, 
MFSD1, 
PTTG1IP, 
SLC37A2, 
SLC38A7, 
SLC46A3, 
SLCO2B1, 
STARD10, 
TMEM104, 
TMEM175, 
TTYH2, TTYH3 
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Della Valle et 
al 
79 Lysosomes Male Wistar 
Rat liver 
homogenates 
Triton-
WR1339 
Differential 
centrifugation, 
isopycnic sucrose 
density 
centrifugation, 
iTRAQ, 2D SCX 
and RP peptide 
separation, 
MALDI-TOF 
1273 gene 
products 
N/A CTSD, ACP2, 
LAMP2, ACP5 
Kollman et 
al. 
82 Lysosomal 
proteins/Secretome 
MEF23-1SV 
mouse 
fibroblasts 
MPR46 and 
MPR300 
deficiency, 
Pepstatin A 
and Leupeptin 
Mannose-6-
phosphate affinity 
enrichment, 2D 
gel 
electrophoresis, 
MALD-TOF, 
MudPIT 
38 N/A CTSD, CTSB, 
CTSZ, MERP-2, 
M2B2, CREG, 
RISC 
Tharkeshwar 
et al. 
83 Lysosomes HeLa NP-C1 
knockout 
SPION isolation, 
LC-MS/MS 
~ 2400 53 LIPA, IFI30, 
IGF2R, 
GABARAPL2, 
CALCOCO2, 
SQSTM1, FOLR1, 
ACKR3, RHOB, 
ITGA11, Rab5 
Gao et al. 85 Lysosomes Murine RAW 
264.7 
macrophage 
cells 
Listeria 
monocytogene
s, HSV-1, VSV 
infections 
Differential 
centrifugation, 
density gradient 
fractionation, 
TMT labeling, LC-
MS/MS 
3704 ~ 204 Fam120c, Clec4e, 
Cxcl2, Ccl9, 
Hspe1, Hspa2, 
Hmox1, Slc15a3, 
Cd274 
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Shui et al. 89 Phagosomes Mouse 
macrophages 
3-
methyladenine 
(3-MA) 
Sucrose gradient 
centrifugation, 2D 
SDS-PAGE, LC-
MS/MS 
546 N/A EEA1, TfR, CatD, 
VAMP4, TLR7, 
TLR9, LC3-II, 
LAMP1, JAK1 
Davis et al. 90 COPII coated 
vesicles 
Saccharomyce
s cerevisiae 
Nitrogen 
starvation, 
Rapamycin, 
0.5% 
galactose 
(Sec24 
induction) 
His tag protein 
purification, LC-
MS/MS 
27 
phosphosit
es 
3 
phosphosit
es 
Sec24 
(T324/T325/T328) 
Ohman et al. 102 Secretome/Exosome Human 
PMBC-derived 
primary 
macrophages, 
Mouse BMDC 
LPS, 1,3-β-
Glucans 
(Curdlan, 
GBY), 3- MA, 
SykII, Src 
inhibitor I, 
Brefeldin A, 
Dectin-
deficiency 
Exosome 
isolation via 
ultracentrifugation
, iTRAQ, SCX, 
LC-MS/MS 
1597 6 pathways Chemokine 
signaling pathway, 
cytokine- cytokine 
receptor 
interaction, and 
MAPK signaling 
pathways, 
cytosolic DNA-
sensing pathway, 
Jak-STAT 
signaling path- 
way,NOD-like 
receptor signaling 
pathways (IL-1β, 
CTSD, ANXA1, 
Tubulin, LEG3) 
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Kang et al. 105 Aqueous 
humor/Secretome/E
xosome 
ARPE-19, 
AMD patients 
and controls 
Paraquat, 
serum-free 
Exosome 
isolation via 
precipitation, 
SDS-PAGE, LC-
MS/MS, LC-MRM 
1209 6 CTSD, HSPA1, 
ACTA2, KRT8, 
KRT14, MYH9 
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Chapter 3: 
Secretome Analysis of Non-Small Cell Lung Cancer in Response to Ionizing 
Radiation and p53-status 
 
 
 
3.1 Lung Cancer Statistics: US and Worldwide 
Lung cancer refers to cancer that starts in the tissues or cells of the lungs. It is currently 
the deadliest type of cancer in both men and women, killing more people than breast, 
colorectal and prostate cancers combined and accounting for about 1.59 million deaths 
worldwide in 2012 [243]. About 159,000 estimated deaths are projected in the US in 2014 
[244]. In spite of the decreasing trends in the incidence of lung cancer amongst both males 
and females [245], it continues to be one of the most prevalent cancers both nationwide 
and around the world.  
The majority of lung cancer patients living today were diagnosed within the last 5 years 
and this is because of the low 5-year relative survival (16.8 – 17.8%) [246]. In 1977, the 5-
year relative survival for lung cancer was 12.3% [247]. The 5-year survival depends largely 
on the stage of diagnosis with early stage NSCLC patients having a survival of >50% 
compared to <5% in late stage patients [245, 248]. This relatively low survival rate is a result 
of late diagnosis for majority of cases and/or ineffectiveness of available treatments. Of 
the new NSCLC patients in the US, ~16% are found to have local or early stage while 
~57% are metastatic at diagnosis [245]. This makes early detection of lung cancer a priority 
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in cancer research in the bid to improve survival. Current standard treatment regimen 
involves the use of chemotherapy and radiation concurrently [249] but the evidence of 
relapse, disease recurrence, and/or mortality indicates then that the current treatments 
are ineffective or at best insufficient. Amongst the possible mechanisms responsible for 
the resistance and/or relapse is autophagy [161].  
3.2 Types of Lung Cancer 
Lung cancer is characterized by molecular heterogeneity, comprising of various small 
populations of cells with distinct features. This heterogeneity may be within a given lung 
tumor or between one tumor type and another [250]. 
Lung cancer pathogenesis is associated primarily with smoking even though non-
smokers do develop the disease [247, 250]. Smoking accounts for > 80% of lung cancer 
inside and outside the US [247]. Exposure to different agents including asbestos, arsenic, 
and radiation from homes and mines (radon gas) as well as air pollution constitute some 
of the other causative agents in lung cancer [247]. These causative factors may act in 
synergy to result in disease [247]. There are two main types of lung cancer depending on 
the type of cells affected in the lungs namely small cell lung cancer (SCLC ~10-15%) and 
non-small cell lung cancer (NSCLC ~ 85%) [246, 250, 251]. Some sources add a third type, 
lung carcinoid tumor estimated to be found in ~5% of lung cancer cases. It is uncommon, 
grows slower than the two major types and constitutes neuroendocrine cells [252, 253]. 
3.2.1 Small Cell Lung Cancer 
SCLC is aggressive and highly metastatic, and estimated to be responsible for ~ 250,000 
deaths throughout the world each year. The vast majority of SCLC patients currently 
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smoke or smoked heavily in the past [251]. With a 5-year survival rate of 7%, SCLC is one 
of the most aggressive tumors, being designated at one time a “recalcitrant cancer” [251, 
254]. The scarcity of tumor tissue, or the lack thereof, for scientific research greatly 
hindered advancements in the understanding of the disease. Consequently, most SCLC 
patients are still treated with only the first line platinum-based chemotherapeutic agents 
such as cisplatin with the only second line treatment option being topotecan [254]. Given 
that there is loss of the tumor suppressor genes TP53 and RB1 in almost all SCLC cases, 
it is plausible that relapse and resistance to therapy develops after the responsiveness of 
tumors to initial treatment [250, 254].  
3.2.2 Non-Small Cell Lung Cancer 
NSCLC is classified into three types namely squamous cell carcinoma (LUSC), 
adenocarcinoma (LUAD), and large cell carcinoma [246]. Despite being associated with 
SCLC, neuroendocrine features have been identified in a “fourth class” of NSCLC cells 
(~3%) referred to as large cell neuroendocrine tumors [255].  
Squamous cell carcinoma and adenocarcinoma constitute the most prevalent subtypes 
of NSCLC with LUSC making up about 25-30% and LUAD about 40% of all lung cancer 
cases [246, 250]. Of the two most common types of NSCLC, squamous cell carcinoma has 
the stronger association with smoking. Most lung cancer patients who have never 
smoked, mostly women, are usually diagnosed with adenocarcinoma [250]. LUAD is 
relatively slower growing and may be detected before it metastasizes out of the lungs; it 
is also normally associated with exposure to second-hand smoke and carcinogens like 
asbestos and radon gas [246, 250]. 
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Relative to SCLC, NSCLC has seen the most advancement particularly regarding 
treatment options. Over the past two decades, more sophisticated and individualized 
treatment options have been developed with some promising results [250]. This has been 
due to the ready availability of clinical samples for scientific studies owing to the 
significantly greater number (and percentage) of cases encountered compared to SCLC.  
This chapter focuses on NSCLC due to the aforementioned reasons together with the 
historically poor prognosis following treatment [256] and the 5-year survival rate of ~ 17%.  
3.3 NSCLC Treatment Options 
NSCLC treatment depends on the stage of the disease at diagnosis. In early disease 
where the tumor is resectable (based on imaging and biopsies), surgery is the first line of 
treatment for stage I, II, and IIIA NSCLC [246]. This initial surgery is usually followed by 
adjuvant chemo- and/or radiotherapy as well as targeted therapy [246, 257].  
3.3.1 Chemotherapy 
In about 40% of patients where diagnosis first happens at stage IV of the disease, 
combination cytotoxic chemotherapy constitutes the first line of treatment [246]. This is 
dependent upon the comorbid conditions, tumor histology, patient age, and performance 
status (PS). Frequency and types of side effects as well as patient tolerance to side 
effects of the cytotoxic agents informs the specific combination regimen selected for a 
patient [246].  
When PS ≤ 1, along with palliative care and symptomatic treatment, a platinum in 
combination with paclitaxel, gemcitabine, docetaxel, vinorelbine, irinotecan, or 
 
 
103 
 
pemetrexed is used per the American Society of Clinical Oncology treatment guidelines 
[246, 258]. Studies have shown that these combinations are similar in effect and no one is 
superior to the other with median overall survival around 8-10 months. When PS=2, only 
one chemotherapeutic agent is recommended and this treatment is stopped in the event 
of intolerable adverse effects, tumor size growth, or stable disease but no decrease in 
tumor size after four treatment cycles. For patients with PS of 3, supportive care rather 
than chemotherapy is recommended. Chemotherapy offers little to no benefit to these 
patients and may result in significant decline in patients’ quality of life. 
3.3.1.1 Advances in Chemotherapy  
There has been significant advancement in the survival stats for NSCLC patients 
following the advent of personalized medicine that targets certain gene mutations and/or 
rearrangements. Currently, targeted therapy exists for patients with mutations of the 
epidermal growth factor receptor (EGFR) (~10-15% of LUAD patients of Caucasian or 
European descent), and BRAF (1-4% of all NSCLC) genes as well as gene 
rearrangements involving the anaplastic lymphoma kinase (ALK) gene (~3-7% of usually 
younger patients) and the ROS1 gene [246, 259]. Other mutations with promising targeted 
therapy include KRAS and HER2 mutations. EGFR mutations are treated with such 
agents as erlotinib and gefitinib while crizotinib represents the treatment of choice for 
patients with previously untreated, advanced ALK mutations in non-squamous NSCLC 
[246].  
The immune system has been shown to have a dual role in cancer development; 
suppressing growth of some tumor cells while promoting the progression of other tumor 
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cells able to survive in immunocompetent hosts [260]. In its protective role in cancer, the 
immune system is able to considerably slow down or stop the growth of tumor cells and 
prevent metastases [246, 260]. Immunotherapy involving agents that are thought to enhance 
the immune system’s ability to differentiate between cancer cells and normal body cells 
is one of the advances in cancer treatment. Immunotherapy targets mechanisms through 
which cancer cells evade the immune system such as checkpoint pathways. For example, 
the protein PD-L1, a ligand for the inhibitory cytotoxic receptor programmed cell death-1 
(PD-1), is a target of the immunotherapy drugs pembrolizumab and nivolumab [246, 259, 261].  
3.3.2 Radiation Treatment 
Approximately 50% of all cancer patients receive radiation therapy at some point in their 
disease management [262]. Radiation may be used to target tumors at specific sites in the 
body and may be used alone, in combination with chemotherapy or as neo-adjuvant 
therapy to shrink tumors thereby making surgery easier and more likely to succeed. In a 
retrospective study of patients with stage III NSCLC using the Surveillance, Epidemiology, 
and End Results (SEER) database, neo-adjuvant radiotherapy was shown to be 
associated with significant increase in 3-year overall survival compared to other treatment 
regimen including surgery only, radiation only, or surgery plus postoperative radiotherapy 
[256]. In patients with advanced lung cancer that is not amenable to surgical resection, or 
patients that do not respond to surgery or chemotherapy, radiation treatment is used in 
combination with palliative care [246].  
Radiotherapy may be administered with an external radiation machine (external-beam 
radiation therapy) or internally (internal-beam radiation therapy or brachytherapy) via 
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radioactive agents, placed in or near the tumor cells inside the body [263]. In stereotactic 
body radiation therapy (SBRT), tumors are located with precision using imaging 
techniques and advanced coordinate systems in order to administer precise and 
concentrated doses of focused radiation to the tumors. This is typically used in early 
disease where tumors have not metastasized [246]. 
Radiation treatment involves the use of high-energy beams that result in DNA damage in 
cancer cells. Radiation is measured in Grays (Gy) and the dose used is dependent on the 
type, histology, and stage of cancer. Radiotherapy acts by penetrating cells and directly 
causing clustered DNA damage including double-stranded breaks (DSB) that ultimately 
results in cell death if the break is not repaired [263, 264]. Radiation also generates single-
stranded breaks as well as reactive oxygen species (ROS) that result in the oxidation of 
proteins and lipids in cells [263]. ROS generated as a by-product of aerobic metabolism 
induces about 50,000 lesions of DNA damage. This is, in fact, more than the number of 
lesions induced by ionizing radiation treatment with 2 Gy radiation therapy [264]. However, 
the major difference between endogenous ROS-induced DNA damage and radiotherapy-
induced DNA damage is the production of lethal DSB which has deleterious cytotoxic 
effects in the body [264]. The lethality of DSB is a consequence of the inherent difficulty of 
the DNA repair mechanisms to repair such breaks relative to SSBs. 
3.3.3 Limitations of Current Treatment 
Many advancements have been made in the development of new therapies for lung 
cancer, particular NSCLC. However, the fact remains that the vast majority of NSCLC 
diagnosis are often made in late disease when the tumors have grown in size and have 
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metastasized. Furthermore, in spite of increased disease- or symptom-free periods 
facilitated by the availability of newer more targeted chemotherapeutic agents, majority 
of NSCLC patients ultimately relapse or develop resistance to therapy [265]. Tumor cells 
exploit a number of mechanisms for promoting proliferation and evading cell death by 
apoptosis amongst which include the functional loss of p53 tumor suppressor activity, and 
autophagy [266–268].  
About 50% of all cancers and ~50-60% of lung cancer cases are estimated to have a loss 
of function mutation of the TP53 gene [240–242]. NSCLC tumors have been shown to  evade 
treatment-induced cell death via various strategies that include tumor heterogeneity [269], 
and autophagy [267, 270].  
3.3.4 NSCLC Tumor Response to Therapy 
Radiation-induced DNA damage induces different responses in cells including but not 
limited to apoptosis, senescence, and autophagy. When cells are exposed to such 
external stress as radiotherapy, the initial response is cell survival through mechanisms 
which include the heat shock response (HSR), unfolded protein response (UPR), the DNA 
damage response, and the oxidative stress response [271]. However, depending on the 
level and duration of the stress, these mechanisms may fail and the cell may switch to 
cell death signaling pathways, which include apoptosis, necrosis, and mitotic catastrophe. 
Tumor cells seek to disrupt the normal homeostatic balance that exists naturally between 
cell proliferation and cell death [271]. By decreasing the rate of cell death through the 
disruption of cell death signaling pathways, tumor cells are able to survive longer and 
proliferate more. 
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3.3.4.1 Apoptosis 
Apoptosis is a major cellular process and represents one of the most extensively studied 
mechanisms of cell death. Apoptosis is one of several cellular mechanisms that occur in 
response to external stress such as ionizing radiation when cell survival mechanisms fail 
to contain the stress or stop its deleterious effects. Also known as programmed cell death, 
apoptosis was first coined as a term in 1972 and refers to a highly organized intracellular 
event [272, 273].  
During apoptosis, cells undergo changes that include chromatin condensation, 
detachment from the surrounding tissue and shrinkage, as well as blebbing of their cell 
membranes [274]. Two mechanisms of apoptosis namely caspase-dependent and 
caspase-independent mechanisms have been elucidated. The classical caspase-
dependent mechanism may be initiated either by intrinsic or extrinsic factors. The intrinsic 
or mitochondrial pathway is mediated by activation of BAX and BAK of the Bcl-2 family 
proteins while the extrinsic pathway is mediated by death receptors (CD95 aka 
APO1/Fas), Tumor necrosis factor alpha (TNFα) receptors, and TNF related apoptosis 
inducing ligand (TRAIL) receptors that are stimulated by their respective ligands. When 
the intrinsic pathway is initiated via the Bcl2 family protein activation, Cytochrome C is 
released into the cytosol where it binds to apoptotic protease activating factor (Apaf1) and 
forms a complex [274–276] which activates caspase-9 that sets off the caspase cascade. 
The intrinsic pathway may however, also initiate the caspase-independent mechanism 
where it results in the release of apoptosis inducing factor and endonuclease G which 
results in chromatin condensation [275, 276].  
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In the extrinsic pathway, binding of the ligands to their receptors results in the attraction 
of adaptor molecules such as FADD which recognizes a death domain and leads to the 
activation of caspase-8 which culminates in the activation of the entire caspase cascade 
[275–277]. A consequence of apoptosis is the proteolytic cleavage of poly(ADP-
ribose)polymerase-1 (PARP-1), a DNA repair enzyme involved in transcriptional 
regulation [278]. 
In essence, apoptosis is a suicide mechanism where cells that are no longer needed by 
the organism or that are diseased beyond repair kill themselves. In normal cells, 
apoptosis represents a homeostatic process which ensures tissue growth and aging, but 
represents a response mechanism in tumor treatment therapy [271]. Apoptosis may also 
be a response to DNA double strand breaks resulting from ionizing radiation treatment 
[279] and is usually the fastest mode of cell death induced in tissues while the other forms 
such as necrosis and autophagic cell death kick in with inhibition of apoptosis [275, 278]. In 
his paper, Meyn distinguishes between two different forms of apoptosis following ionizing 
radiation treatment depending on occurrence before or after post-irradiation mitosis [273]. 
He refers to the programmed cell death observed before the first mitotic division (4 – 6 
hrs. post irradiation) as primary apoptosis whereas he terms as secondary apoptosis, the 
cell death that occurs after the first mitotic division (>24 hrs. post irradiation). He argues 
for the relevance of this observation, especially in radiotherapy, because cells that 
undergo primary apoptosis actually affect clonogenic survival compared with those that 
undergo secondary apoptosis by which time cells would have divided anyway and so 
death does not necessarily decrease the live cell number. As a cellular response to 
radiotherapy, apoptosis may likely be representative of an intrinsic sensitivity or otherwise 
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in that whereas 5 Gy of IR is usually sufficient to induce apoptosis in sensitive cells, more 
radiation is needed for secondary apoptosis and is observed much later [273].  
Apoptosis may result in decreased tumor clonogenic survival and consequently enhance 
sensitivity to chemo- and/or radiotherapy. Studies have shown that tumors with high 
apoptotic indices before treatment tend to respond better and this index has been found 
to be predictive of patient survival indicating the desirability of apoptosis as a treatment 
outcome [273, 280, 281]. It is important to note that while apoptosis may be a desirable 
outcome of treatment, it may also be a mechanism of eliminating susceptible cells so that 
the tumor can have only resistant cells, which can then mutate to result in ‘intractable’ 
tumors. 
3.3.4.2 Autophagy and Senescence 
Autophagy, as discussed extensively in chapter 2, is an intracellular mechanism in which 
cells recycle some of their cytoplasmic components, in response to stress such as 
starvation, chemotherapy or radiation, by degradation with the help of lysosomes for the 
production of energy [96, 155, 274, 282–285]. The recycling occurs via the fusion of 
autophagosomes with lysosomes, which release hydrolases to degrade the contents of 
the autophagosome.  
Autophagy was historically thought to serve a protective function; however, recent studies 
have painted a more complex picture. At least four functional forms of autophagy have 
been identified in the context of cancer cells; protective, non-protective, cytotoxic, and 
cytostatic [125]. Within these functional forms, protective autophagy holds the most 
promise for pharmacological inhibition through increased sensitization to standard of care 
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chemo-radiation treatment [126]. The identification of these four functional forms of 
autophagy also provides a plausible explanation for the potential failure of clinical trials 
exploring the inhibition of autophagy as a cancer treatment enhancement strategy as 
patients could not be stratified based on the nature of the autophagy exhibited by their 
tumor [127]. 
Senescence, on the other hand, is a growth arrest phenomenon whereby cells are alive 
and have active metabolism but cannot divide [286]. Two major forms of senescence have 
been identified, replicative senescence in which cells cannot divide anymore owing to 
reaching a length of telomere referred to as the “Hayflick Limit”, which does not permit 
further cell division and stress-induced premature senescence which does not depend on 
telomere length [287–290]. When cells reach the Hayflick Limit suggesting that the cells are 
approaching senescence, a DNA damage response is initiated and cells show foci that 
indicate the presence of γ-H2AX. The proteins – p53 binding protein 1 (53BP1), nibrin 
(NBS1), and Mediator of DNA damage checkpoint protein 1 (MDC1) which are DNA 
damage response proteins also show up and activation of ataxia telangiectasia-mutated 
(ATM) and ataxia telangiectasia and Rad3-related protein (ATR) is seen [289, 291]. ATM and 
ATR subsequently induce the activation of checkpoint kinase 1 (CHK1) and CHK, which 
may then lead to the activation of p53 and several other factors and proteins that are 
related to and regulate the cell cycle. Together with p53, activation of Rb, a tumor 
suppressor and its downstream signals including p16INK4A has also been demonstrated in 
senescence [288, 289]. Silencing p19ARF, a direct upstream regulator of p53, or p16INK4A 
resulted in a consequent prevention of Ras oncogene induced senescence [289, 292].  
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In various cancer cells, it appears as though autophagy and senescence may be induced 
concurrently or consecutively. However, reports of the relationship between autophagy 
and senescence in the literature are inconclusive at best. While some studies have 
showed autophagy and senescence to be directly related, other studies have essentially 
established that the two processes are dissociable. Young et al. showed in their work that 
autophagy was directly related to oncogene induced senescence by showing an increase 
in LC3-II levels, a marker of the initiation of autophagy, in senescent but not quiescent 
cells [286]. The association between autophagy and senescence was however, not very 
strong when autophagy genes ATG5 and ATG7 were silenced. In their silencing studies, 
the production of IL-6 and IL-8 which are senescence-associated cytokines was 
comparable in empty vector and ATG5 silenced cells albeit there was slightly more IL-6 
on day 4 in the vector. Senescence could therefore be said to have only been delayed by 
the inhibition of autophagy. This may suggest that autophagy may play a role in the onset 
of senescence but not the sustenance thereof. Progression of senescence may thus be 
independent of autophagy. Gewirtz et al. also showed, like in the Young paper, that 
senescence is reduced and/or delayed, but not entirely blocked, in MCF-7 and HCT-116 
tumor cells with pharmacological or genetic inhibition of autophagy [293]. Anna Knizhnik et 
al. have demonstrated temozolomide-induced senescence that is completely abolished 
by inhibition of autophagy with 3-methyladenine (3-MA) [294]. Considering however, that 
3-MA can have off-target effects, caution has to be exercised in assuming the complete 
inhibition of senescence was due only to autophagy. Strong evidence of a relationship 
between autophagy and senescence is also presented in a study of autophagy competent 
cells which express proteolytic Cyclin E fragment (p18-CycE) where ATG7 was silenced 
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and which resulted in a consequent decrease in senescence associated markers β-
galactosidase and HP1γ [295]. Some studies have pointed to the decrease in chaperone-
mediated autophagy in senescent cells [289]. Studies have shown a cytostatic form of 
autophagy [126] which is functionally similar to senescence in that cells are alive and 
metabolically active but do not proliferate. Regarding the signaling pathways of both 
autophagy and senescence, some overlap has been reported. Amongst the overlapping 
features of both pathways are ROS generation, activation of ATM kinase, TP53 induction, 
CDKN1A/p21 induction and dephosphorylation of Rb [283, 296]. In a study where Regulator 
of Cullins-1 (ROC-1) was knocked down, there was the induction of senescence 
(mediated by p21) and a time dependent increase in autophagy (marked by increased 
LC3-I to LC3-II conversion) [297]. This points to a strong molecular /signaling association 
between the two. These pathway signaling overlaps have however, are still undergoing 
rigorous scientific interrogation and therefore no conclusions can be made yet regarding 
the interdependence of the two processes.  
3.4 TP53 and Autophagy 
Autophagy has been considered as a central cellular response for some cancer cell types, 
including NSCLC cells, to avoid radiation-induced cell death [126, 232, 233]. The TP53 gene 
has been shown to promote cell survival via autophagy activation following starvation 
whereas autophagy suppresses the activity of p53 suggesting a negative feedback 
mechanism [298, 299].  
In a study of 188 patients with early stage NSCLC, Ahrendt et al. found that p53 mutations 
in patients’ tumors resulted in poor prognosis and significantly higher deaths [241]. Levine 
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et al. also showed that the TP53 gene plays a role in the increased cellular secretion of 
some proteins and the decreased secretion of others particularly via exosomes in NSCLC 
cell lines including H460 and H1299 [300]. Chenau et al. used the NSCLC cell line as a tool 
to investigate secreted proteins in which they found the secretion of about 91 proteins to 
be affected by the p53 status of the cell [301]. The high prevalence of TP53 mutation in 
cancers and more specifically NSCLC combined with its reported association with 
treatment resistance arising from protective autophagy makes TP53 an important gene 
for study. 
3.5 Justification and Objectives of the Study 
• Promotes cell death when induced 
• Unlikely to mediate actions of 
chemotherapy 
Cytotoxic  
Cytoprotective 
Cytostatic  Non-protective 
AUTOPHAGY 
• Does not appear to be relevant to 
resistance 
• Inhibition does not affect sensitivity 
to treatment 
• Mediates growth inhibition 
• May be associated with senescence 
• Results in reduced clonogenic 
survival 
• May confer resistance to therapy 
• Inhibition increases sensitivity 
• Possibly involved in normal 
homeostasis 
Figure 11 - Functional forms of autophagy 
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The search for biomarkers for the detection of at-risk persons and early disease diagnosis 
remains one of the major focuses of lung cancer research [97, 247]. Many potential markers 
of disease have been proposed through various studies but issues of sensitivity and/or 
specificity and selectivity affect their adaptation in clinics [247]. Blood-based markers are 
of particular interest due to the limited access to the lung, a visceral organ, except by 
direct invasive approaches [247]. Working on the hypothesis that some proteins that are 
eventually secreted into the blood are up- or downregulated due to the development of 
cancer, proteomics studies aim to detect these proteins early in disease pathogenesis in 
order to serve as biomarkers [97]. 
Several reports have shown the value of using cancer cell lines as experimental models 
for identifying potential protein biomarkers secreted and/or shed into the media (i.e., 
secretome) [161, 249, 301–304]. High resolution and accurate mass spectrometry (HRAM) LC-
MS/MS provides an unbiased method for identifying protein signatures of autophagy that 
may be useful in differentiating between different responses to radiation in NSCLC.  
Various cell lines have shown differences in response to the manipulation of autophagy 
using both pharmacological and genetic strategies. For instance, cytoprotective 
autophagy has been demonstrated following ionizing radiation (IR)  in tumor cells from a 
variety of backgrounds, including A549, H460, and CT26 [305], and HTB35 [232] cells. The 
protective function of radiation-induced autophagy has however, been observed primarily 
if not exclusively in cancer cells with functional p53, as in H1299 and H460 cells with wild-
type p53 [126]. In contrast, H1299 cells that do not express functional p53 demonstrated 
non-protective autophagy in that the cells were not sensitized to radiation when 
autophagy was blocked by pharmacologic or genetic approaches [233].  
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H1299 cells are immortalized non-small cell lung cancer cells derived from lymph nodes. 
The cells do not produce the p53 protein due to a homozygous partial deletion of the 
TP53 gene. However, H1299 cells capable of producing p53 via a tetracycline-inducible 
p53 construct were developed by Constantinos Koumenis resulting in an isogenic cell line 
with and without p53. Consequently, in the present study, we have used quantitative 
proteomics to investigate the effect of p53 expression on non-small cell lung cancer 
response to ionizing radiation, using the isogenic H1299 cell line. The H1299 secretome 
was analyzed in an effort to identify potential candidate protein biomarkers or therapeutic 
targets of cytoprotective autophagy. 
3.6 Experimental 
3.6.1 Materials and Reagents 
Chemicals were purchased from Invitrogen, Gibco, Thermo Scientific, Sigma Ultra, 
Fisher, Promega, Fluka, and Honeywell Burdick & Jackson and used as received unless 
otherwise stated. 
3.6.2 Cell Culture Conditions and Ionizing Radiation Treatment 
H1299 TP53-null (p53-null) and TP53-inducible (p53-wt) cells, originally developed by Dr. 
Constantinos Koumenis,[306] were obtained from Drs. Frank and Suzy Torti (University of 
Connecticut). H1299 cells were cultured in low glucose Dulbecco’s Modified Eagle Media 
(Invitrogen) supplemented with 10% Fetal Bovine Serum (Thermo Scientific), 1% 100 
U/ml Penicillin G sodium/1% 100 µg/ml Streptomycin sulfate (Invitrogen) at 37°C and 5% 
CO2. H1299 p53-wt cells were maintained in 1 mg/ml Doxycycline to induce tp53 
expression. H1299 p53-wt and H1299 p53-null cells were seeded in two sets of 9 × 10 
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cm dishes at 20,000 cells/mL with 10 mL of media and grown to ~85% confluency over 
48 hours. At ~85% confluency, the 10% FBS media the culture media was aspirated from 
all plates. The plates were washed once with 5 mL of Phosphate Buffered Saline 1X pH 
7.4 (Gibco) and then twice with 5 mL serum-free DMEM. A final 5 mL volume of serum-
free DMEM was added to all plates. A set of 3× p53-wt and 3× p53-null cells were then 
immediately treated with ionizing radiation (6Gy) after which all plates were incubated for 
12 hours. The serum-free media containing secreted proteins (secretomes) were 
collected into 15 mL tubes after a 12-hour incubation and stored at -80oC until processing.  
3.6.3 Western Blot 
Cells were pelleted and washed briefly with cold PBS (Gibco) after which they were lysed 
using CHAPS buffer containing protease and phosphatase inhibitors (Sigma Aldrich). 
Total protein concentration of samples was determined using the Bradford assay (Bio-
Rad Labs). Equivalent amounts of proteins were then run on an SDS-PAGE gel and 
blotted onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad Labs). The quality of 
the transfer was then determined by staining with Ponceau S stain. The blots were then 
processed and visualized as described by Sharma et al. using antibodies against p53 and 
GAPDH [126]. 
3.6.4 Proteomics Sample Preparation 
The collected media (secretomes) samples were removed from -80oC, thawed, 
centrifuged at 2500 rpm for 5 minutes at 8oC, and the supernatant concentrated in 3 kDa 
MWCO filters (Millipore Amicon Ultra) at 7500 × g for 30 minutes at 8oC. The concentrated 
secretomes were then transferred into 10 kDa MWCO filters (Millipore Amicon Ultra) and 
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washed with 3 × 500 µL Tris HCl buffer pH 8.1. Remaining solutions were made up to the 
same volume and total protein concentration for each secretome determined at 280 nm 
using a BioTek Synergy H1 plate reader fitted with a Take3 Plate. The secretomes were 
processed for proteomics analysis using the FASP method [307]. Specifically, each 
secretome sample in the 10 kDa MWCO filter was reduced using 40 µL of 50 mM 
Dithiothreitol (Fisher Scientific) by incubation for 45 mins at 56oC, alkylated at room 
temperature in the dark with 30 µL of 142 mM Iodoacetamide (SigmaUltra), and then 
rinsed with 300 µL of Tris-HCl pH 8.1 at 14,000 × g for 10 minutes. Digestion was 
performed with 6 µL of 1 µg/ µL Trypsin Gold (Promega) solution overnight at 37oC and 
then terminated with 200 µL of 0.1% acetic acid (Fluka Analytical).  
3.6.5 LC-MS/MS Analysis 
50 µL solutions of 100 ng/µL peptide sample were prepared by dilution with 0.1% Acetic 
Acid for LC-MS/MS analysis. The LC-MS/MS system consists of an Eksigent nLC 415 
(ABSciex) in a trap and elute configuration. The reverse phase trap column (75 µm x 1 
cm) and analytical column (75μm x 15cm) were both packed in-house with 5 µm Magic 
AQ C18, 200Å stationary phase. The nLC system was coupled to a Q-Exactive (Thermo 
Scientific, San Jose, CA) mass spectrometer equipped with the Nanospray-Flex 
ionization source fitted with a 10 μm ID emitter tip (New Objective). 2 µL of sample was 
loaded onto the trap column and desalted at a flow rate of 2.25 μL/min for 5 minutes using 
mobile phase A. Desalted peptides were then eluted at 300 nL/min with the following 
gradient: 5% B (0 – 4 minutes), 35% B (95 minutes), 75 % B (105 – 110 minutes), 5% B 
(115 minutes) and held for 5 minutes until the run finishes at 120 minutes. Mobile phase 
A consisted of 98% H2O/2% acetonitrile, 0.1% formic acid and mobile phase B consisted 
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of 2% H2O/98% acetonitrile, 0.1% formic acid. The electrospray emitter tip was charged 
with a voltage of 1.80 kV in positive ion mode and the Q-Exactive inlet temperature and 
S-lens setting were maintained at 250C and 62 V, respectively. Full scan (400-1600 m/z) 
resolution was set at 70,000 FWHM with an AGC target of 3 × 106. MS/MS was set to a 
resolution of 17,500 with an AGC target of 2 × 104 at 120 ms maximum inject time and 
selection of the top 12 ions at a 30 second dynamic exclusion. HCD voltage was 
maintained at 30 NCE throughout.  
3.6.6 Data Analysis 
Proteomic datasets were processed in MaxQuant (ver. 1.5.2.8) with the Andromeda 
search algorithm using the Uniprot Human proteome Fasta database (downloaded on 04-
04-2016); mass accuracies: MS = 5 ppm, MS/MS = 0.02 Da; fixed modifications: 
carbamidomethyl (C), variable modifications: acetyl (N-terminus) and methionine 
oxidation (M), and a false discovery rate (FDR) of 1%. 
Protein quantification was done in MaxQuant using the LFQ algorithm[67] and the 
threshold for quantification set to 2 or more shared peptides. Statistical analyses were 
carried out in Perseus (ver. 1.5.1.6) and JMP Pro 11 Statistical Software. One-way 
analysis of variance (ANOVA) tests were carried out followed by t-test pairwise 
comparisons to determine significant effects using the Benjamini-Hochberg correction. 
Imputation of missing values was done in Perseus by replacing with random numbers 
drawn from the lower (left) boundary of a normal distribution. Gene Ontology (GO) 
annotation enrichment analysis was performed using the Functional Enrichment 
(FunRich) Analysis Tool, a bioinformatics software tool for functional and network analysis 
 
 
119 
 
developed by the Mathivanan lab [308]. FunRich uses hypergeometric tests for significance 
testing and the Benjamini-Hochberg procedure to decrease false discovery rate.  
3.7 Results 
3.7.1 Secretome Analysis of Radiation-treated H1299 cells 
Inducible H1299 cells, with or without doxycycline treatment to induce stable p53 
expression or not (hereon referred to as p53-wt or p53-null respectively), were treated 
with or without ionizing radiation (+IR or –IR, respectively). Secretomes from the 4 
experimental conditions (p53-wt -IR, p53-wt +IR, p53-null -IR, and p53-null +IR) were 
collected 12-hours post-irradiation and then analyzed by LC-MS/MS. Prior to the 
secretome analysis, the p53 status of the cells was verified, specifically to ensure that we 
were using an isogenic paired set of H1299 cells, one of which is p53-inducible with the 
native cell line being p53-null (Figure 12). A total of 364 secreted proteins were identified 
Figure 12 - H1299 Secretome Experimental Design 
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post-filtering from the 4 experimental secretomes in triplicate (Figure 13A). Out of the 
364 identified proteins, we considered 163 proteins after filtration based on label-free 
quantification (LFQ)[67]. Thus, a protein should be quantified with an LFQ value in a 
minimum of 2 (in at least one condition) out of 12 replicates across all conditions. Out of 
the 163 quantified proteins, 123 were detected in all 4 groups (Figure 13B). Functional 
enrichment analysis was performed on the 163 quantified using the FunRich functional 
enrichment analysis tool. Enriched cellular components in the quantified secretome 
proteins included exosomes (~5.3 fold, p-value = 4.52 × 10-66), lysosomes (~4.8 fold, p-
value = 5.89 × 10-40), cytoplasm (~2.1 fold, p-value = 6.73 × 10-29), centrosome (~7.03 
fold, p-value = 9.70 × 10-28), cytoskeleton (~7.3 fold, p-value = 4.51 × 10-66), and 
mitochondria (~3.61 fold, p-value = 9.35 × 10-16) as shown in Figure 13C. The molecular 
functions most enriched in this same dataset were related to chaperone activity (~15.1 
fold, p-value = 5.12 × 10-13) which is one of the more prominent processes in autophagy, 
and lysosomal function (Figure 13D). Notable secretory proteins (GO Cellular 
Component - Figure 13C) include protein FAM3C, which has been reported in other 
works as a potential blood based marker of autophagy[103, 161], C-type lectin domain family 
11 member A (CLEC11A), Annexin A2 (ANXA2), and the heat shock protein HSP90B1. 
3.7.2 Quantitative Analysis of the Secretome 
The 163 quantified proteins from the four experimental conditions were analyzed to 
identify statistically significant changes in secretion. An analysis of variance (ANOVA) for 
the LFQ values identified 25 proteins (Table 2) that showed significant changes (p<0.05) 
in one or more of the experimental conditions tested. The data were transformed into a 
hierarchically clustered heatmap plotting the log2 LFQ protein levels in each condition 
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relative to the average log2 LFQs across all four experimental conditions (Figure 14). 
Comparing the protein intensity levels in individual samples to the average intensities 
Figure 13 - Preliminary Qualitative Data Analysis of H1299 Secretome 
(A) Summary of identified proteins and subsequent filtering Experimental Design of secretome analysis (B) Distribution of 
LFQ intensities of filtered proteins before imputation in Perseus (C) Gene Ontology Cellular Component analysis of 163 
filtered proteins (D) Gene Ontology Molecular Function analysis of 163 filtered proteins 
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across all samples rather than a baseline intensity value is deliberate. We believe it is 
essential to define upregulation or downregulation in the context of clinical samples and 
in using the average intensities, we are able to define these as protein levels above or 
below the population mean. The results of the hierarchical clustering indicates that the 
primary contributing factor to differential protein secretion is p53 expression status. 
Among the most prominent proteins in this group are Chromogranin B (CHGB), 
Secretogranin 2 (SCG2), Clusterin (CLU), and Destrin (DSTN) where protein level 
Figure 14 - Hierarchical Clustering of ANOVA significant proteins 
Hierarchical clustering and heat map analysis of 25 differentially secreted proteins shows that p53 status drives 
the major changes in the secretome whereas radiation treatment drives changes within cells of the same p53 
status.  
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differences are dictated by p53 status and irradiation has no significant effect on their 
secreted levels. Similar effects, but to a lesser extent, are observed for FAM3C, Calnexin 
(CANX), U6 snRNA-associated Sm-like protein LSm8 (LSM8), C-type lectin domain 
family 11 member A (CLEC11A), Kinectin (KTN1), Metalloproteinase inhibitor 1 (TIMP1), 
and Nucleobindin-1 (NUCB1). The levels of the remaining proteins in the secretome are 
more significantly impacted by irradiation than p53 status. These include Nucleoside 
diphosphate kinase A (NME1), Eukaryotic translation initiation factor 5A-1 (EIF5A), 
Aminopeptidase N (ANPEP), Glucose-6-phosphate isomerase (GPI), Thioredoxin 
reductase 1, cytoplasmic (TXNRD1), Adenosylhomocysteinase (AHCY), GTP-binding 
nuclear protein Ran (RAN), 14-3-3 protein eta (YWHAH), Beta-2-microglobulin (B2M), 
Stress-70 protein, mitochondrial HSPA9), Calsyntenin-1 (CLSTN1), Fructose-
bisphosphate aldolase A (ALDOA), 60 kDa heat shock protein, mitochondrial (HSPD1), 
and Actin, cytoplasmic 2 (ACTG1). We also conducted a 2-way ANOVA model to 
determine the effects of p53 status and IR treatment as well as their interaction on the 
expression of the proteins in the secretomes.  
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Table 2 - Proteins that were found to be significantly differentially expressed (using ANOVA) in the 
secretomes of p53wt and p53-null H1299 cells before and after ionizing radiation treatment. 
Gene 
names 
Protein names 
Sequence 
Coverage 
-Log ANOVA p 
value 
ACTG1 Actin, cytoplasmic 2 36.9 1.93048 
AHCY Adenosylhomocysteinase 13.4 1.59804 
ALDOA Fructose-bisphosphate aldolase A 26.6 2.73084 
ANPEP Aminopeptidase N 5.8 1.38492 
B2M Beta-2-microglobulin 28.2 2.06836 
CANX Calnexin 3 1.52497 
CHGB Secretogranin-1 5.5 3.66691 
CLEC11A C-type lectin domain family 11 member A 15.8 2.21017 
CLSTN1 Calsyntenin-1 9.2 2.11829 
CLU Clusterin 6 1.45451 
DSTN Destrin 14.2 2.47716 
EIF5A Eukaryotic translation initiation factor 5A-1 10.9 1.48163 
FAM3C Protein FAM3C 17.2 1.78124 
GPI Glucose-6-phosphate isomerase 8.6 1.9333 
HSPA9 Stress-70 protein, mitochondrial 4.4 1.85985 
HSPD1 60 kDa heat shock protein, mitochondrial 11.5 1.79067 
KTN1 Kinectin 2.9 3.76623 
LSM8 U6 snRNA-associated Sm-like protein LSm8 19.8 1.31747 
NME1 Nucleoside diphosphate kinase A 33.6 1.38612 
NUCB1 Nucleobindin-1 13.6 1.55122 
RAN GTP-binding nuclear protein Ran 12.9 1.91709 
SCG2 Secretogranin-2 7 4.41865 
TIMP1 Metalloproteinase inhibitor 1 11.2 1.58608 
TXNRD1 Thioredoxin reductase 1, cytoplasmic 4.3 2.14274 
YWHAH 14-3-3 protein eta 16.7 1.59071 
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Of the differentially secreted proteins, GPI and TXNRD1 showed an interaction effect i.e. 
the effect of p53 status on the expression of GPI and TXNRD1 in the secretome depends 
on whether or not the cells received IR treatment. 
Following the ANOVA analyses, we conducted pairwise comparisons of the secretomes 
of p53-wt and p53-null H1299 cells before and after ionizing radiation treatment using t-
tests. We sought to identify proteins with the best potential to be population-based or 
individual/personalized biomarkers.  
3.7.3 p53 Expression Status Promotes Differential Protein Secretion Before and 
After Ionizing Radiation Treatment 
3.7.3.1 p53wt-IR vs p53-null –IR 
15 proteins were found to be differentially secreted between H1299 p53-wt -IR and p53-
null -IR cells (Figure 15A) and include CHGB, SCG2, DSTN, CLEC11A, CLU, GPI, 
ANPEP, phosphoglycerate kinase 1 (PGK1), hepatoma-derived growth factor (HDGF), 
protein disulfide-isomerase A4 (PDIA4), heterogeneous nuclear ribonucleoproteins 
A2/B1 (HNRNPA2B1), nuclease-sensitive element-binding protein 1 (YBX1), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), aspartate aminotransferase 
(GOT2), and nuclear migration protein nudC (NUDC).  
Among the differentially secreted proteins, CLU, DSTN, PDIA4, YBX1, CLEC11A, 
HNRNPA2B1, NUDC, and HDGF were overexpressed by ≥ 2-fold in the secretome of 
p53-null cells compared to p53-wt cells whereas secretion of GAPDH, PGK1, GOT2, 
ANPEP, and GPI was higher in p53-wt cells by ≥ 2-fold than in p53-null cells. HDGF, also 
known as HMG-1L2, is a known repressor gene that is involved in DNA binding and cell 
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growth [309] and has been demonstrated to have the ability to stimulate growth in 
Figure 15 - Volcano Plots showing IR and TP53 effects on H1299 Secretome 
Differential protein secretion for H1299 cells (A) un-irradiated and (B) irradiated. Red data points with gene 
labels indicate proteins with log2 difference ≥ │1│ and p-value < 0.05 
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fibroblasts and some liver cancer cells [310]. 
3.7.3.2 p53wt +IR vs p53-null +IR 
In the pairwise comparison between p53-null and p53-wt cells treated with IR (Figure 
15B), proteins over-secreted in p53-null cells by ≥ 2 fold include LSM8, CANX, CHGB 
and SCG2 whereas guanine nucleotide-binding protein subunit beta-2-like 1 (GNB2L1) 
was over-expressed by >2 fold in p53-wt cell secretomes. Calnexin is known to contain a 
signal peptide (1 – 20) which by manual inference, is responsible for its secretion and is 
reported to be a molecular chaperone [311, 312]. The significant differences in CHGB and 
SCG2 secretion between p53-wt and p53-null H1299 cells were observed both before 
and after ionizing radiation, suggesting a potential role for these proteins as population 
based biomarkers for patient stratification before treatment particular as a function of 
autophagy response. 
3.7.4 Association between Significant Proteins and Patient Survival 
Kaplan-Meier plots for the significant proteins were performed using the online kmplotter 
by Gyorffy et al [313]. Of the differentially secreted proteins, TXNRD1 and GPI were found 
to be significantly associated with survival in lung cancer patients (Figure 16). 
3.8 Discussion 
Approximately 10 – 15% of all proteins are secreted into the extracellular matrix via 
classical and non-classical pathways [93, 222]. The classical pathways involve the 
endoplasmic reticulum (ER)/Golgi apparatus. Here a protein undergoing synthesis and 
having the appropriate signaling sequence, generally at the N-terminus, results in the 
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transport of the ribosome to the ER membrane where the growing peptide chain is 
Figure 16 - Kaplan Meier survival plots for selected proteins 
Association between GPI levels (A) and HSPA9 levels (B) on probability of survival plot in lung cancer patients 
with or without radiation but not chemotherapy; n=310. (C) Association between p53 levels and patient survival 
in lung cancer; n=1926. Analysis conducted using Kaplan-Meier Plotter at kmplot.com  Ref: Gyorffy B, Surowiak 
P, Budczies J, Lanczky A. PLoS One, 2013 Dec 18;8(12):e82241. 
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translocated across the ER membrane [223]. The newly synthesized proteins are mostly 
found in tiny vesicles in the ER which fuse with the Golgi apparatus where secretory 
proteins are eventually sorted into transport vesicles that migrate to the cell membrane 
and are released via exocytosis into the extracellular environment [224]. The non-classical 
secretory pathway was proposed and described due to the discovery of secreted proteins 
that lack the N-terminal secretory signal sequence, are excluded from the ER/Golgi 
machinery and are not affected by inhibition of the ER/Golgi – dependent secretory 
mechanism [314]. Both pathways are involved in cells differentially expressing p53 [300, 315] 
and under different environmental stimuli including ionizing radiation [300].  
The secretory pathways associated with autophagy have been investigated in yeast and 
in cancer cells. The role of autophagy in protein secretion borders on both classical and 
nonconventional secretion and this has potential downstream ramifications for biomarker 
discovery [161, 221, 225, 304]. In this study, we quantitatively characterized the H1299 
secretome as a function of p53 expression and ionizing radiation to potentially identify 
proteomic signatures to discriminate between the response to ionizing radiation in the 
context of protective and non-protective forms of autophagy. As demonstrated in many 
studies, proteomics affords the ability to view the entire proteome, for internal cellular 
signatures, and secretome, for surrogate plasma biomarkers [94, 103, 161, 301, 302, 316–318].  
Lung cancer has been associated with abnormal protein secretion and evidence shows 
that interactions between lung cancer cells and their microenvironment contribute to 
disease progression [302]. Such communication involves the secretion of proteins and 
exosomes, most of which contain proteins, which play a role in cancer cell – cell 
interaction and which may either promote tumor progression or serve some anti-tumor 
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capacities within the body [93, 223]. Autophagy as a cellular mechanism has been shown in 
various studies to contribute to chemotherapy resistance [270, 319]. This protective form of 
autophagy appears to be associated with the presence of functional p53 in the case of 
radiation [126]. During the course of autophagy, protein turnover occurs in response to the 
applied stress. The findings of our GO Biological Process analysis is consistent with our 
expectation of cells undergoing stress from ionization radiation and in which autophagy 
is induced. The biological processes most enriched in our dataset include protein folding 
(p-value = 0.0008) (e.g. HSPD1, CANX, and PPIA), protein metabolism (p-value = 1.0 × 
10-11) (e.g. CTSZ, FAM3C, and RAN), and energy pathways (p-value = 1.0 × 10-4) (e.g. 
NME1, GPI, PGD, and PGAM1).  
3.8.1 Cathepsin D (CTSD) 
Our current work has identified a number of proteins reported in different lung cancer 
studies and that may be closely associated with autophagy. Amongst these proteins are 
CANX, Bifunctional purine biosynthesis protein PURH (ATIC), caspase 3 (CASP3), 
cathepsin B (CTSB) and cathepsin D (CTSD). Cathepsin D (CTSD) was only quantified 
in p53-wt +IR and p53-null -IR cells meaning levels in p53-wt -IR and p53-null +IR were 
not sufficient for quantitation by the LFQ algorithm. Consistent with reports of 
cytoprotective autophagy in cells with p53, the e2levated secretion of CTSD in p53-wt 
+IR cells and its decreased presence in p53-null +IR cells  may be an indication of its role 
in protective autophagy, as reported in a study in which dichloroacetate was used to 
induce protective autophagy in LoVo cells [320]. Koukourakis et al. have also reported poor 
prognosis of NSCLC associated with increased CTSD expression [321]. CTSB was 
identified in our dataset but filtered due to our stringent criteria. It has been associated 
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with the cleavage of Disabled-2 (DAB2) to promote autophagy in cells treated with 
Transforming growth factor-β (TGF-β) and when, in that study, CTSB was inhibited cells 
became apoptotic in the long term [322]. 
In determining the potential of these differentially secreted proteins to serve as 
biomarkers to predict benefit from autophagy modulation in combination with 
chemotherapy or radiation therapy, we reasoned that proteins consistently 
overexpressed or under-expressed based on p53-status and independent of radiation 
treatment are more likely to serve as population-based biomarkers before treatment. That 
is, the secretion of these proteins may contribute to prediction of benefit from treatment 
and/or help to stratify patients in clinical trials using autophagy inhibition as a tumor 
sensitization strategy.  
We identified CHGB and SCG2 to be consistently overexpressed in p53-null secretomes 
at very high levels while GIP, and TXNRD1 were consistently overexpressed in the p53-
wt secretome. Therefore, CHGB, SCG2, GPI, and TXNRD1 with consistently high levels 
have the potential to serve as population-based markers. FAM3C, CANX, and LSM8 
levels were consistently downregulated in the p53-wt +IR secretome while EIF5A levels 
were consistently low in p53-wt –IR secretomes; therefore these proteins may serve a 
role in distinguishing between patients following radiation treatment. Patients whose 
FAM3C, CANX, and LSM8 levels decrease and those whose EIF5A levels increase 
following ionizing radiation treatment may be found to have tumors that respond to 
autophagy inhibition. The secretory profiles of these proteins are shown in Figure 17. 
3.8.2 Chromogranin B and Secretogranin 2 (CHGB and SCG2) 
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The chromogranin-secretogranin proteins are known to be associated primarily with 
neuronal cells[323]. SCG2 has been shown to be involved in angiogenesis and proliferation 
Figure 17 – H1299 secretory profile of selected proteins across the different conditions  
Log2 LFQ values were plotted across the four conditions (IR treated and untreated p53-null and p53-wt H1299 for 
proteins CHGB, EIF5A, FAM3C, GPI, TXNRD1, and SCG2  
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in endothelial cells through an anti-apoptotic mechanism[324]. SCG2 is cleaved into 2 
chains: the 33-amino acid secretoneurin and manserin. Secretoneurin has been shown 
in in vivo studies to induce neovascularization in cornea and stimulate proliferation of 
serum-starved human umbilical vein endothelial cells (HUVECs)[324]. With angiogenesis 
being a prominent feature of tumor progression, it is not unexpected that SCG2 would be 
overexpressed in the secretomes of H1299 p53-null cells which undergo non-protective 
autophagy in response to radiation. Secretoneurin has also been shown to contribute to 
the growth and protection of neuronal cells [325]. This neuroprotection has been observed 
in primary cortical cell cultures during oxygen or glucose starvation[325]. Glucose 
starvation is known to induce autophagy. Chromogranin B (CHGB) is also known to be 
cleaved into the peptides GAWK and CCB which have been found to be elevated in 
pancreatic islet-cell and bronchial tumors while secretoneurin from SCG2 has been found 
to be elevated in gastroenteropancreatic neuroendocrine tumors, small cell lung tumors 
and pheochromocytomas[323, 326, 327]. There are reports of using neuroendocrine 
differentiation as a prognostic marker of NSCLC disease response to therapy[328, 329]. 
Given that the chromogranins and secretogranins are closely related to neuroendocrine 
differentiation, CHGB and SCG2 may have potential prognostic utility in NSCLC.  
3.8.3 Glucose-6-phosphate isomerase (GPI) 
The differential levels of GPI and TXNRD1 was found to be associated with both p53 
status and radiation treatment status. GPI, also known as autocrine motility factor (AMF), 
was overexpressed in the secretomes of p53-null cells by ~2.8 fold following irradiation. 
However, in p53-wt cells, levels of GPI in the secretome were not affected by IR 
treatment, implying that p53 status impacts the response of GPI following radiation as 
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confirmed by the least squares model including the interaction of p53 status and IR 
treatment (p-value=0.0276). The level of GPI in the p53-null secretome before irradiation 
was the lowest and significantly different from the other 3 conditions. GPI has different 
functions in the intracellular and extracellular compartments. GPI  has been identified in 
various cancers including renal cell carcinoma, endometrial cancer, and breast cancer[330, 
331]. In the cytoplasm, GPI acts in glycolysis in the conversion of glucose-6-phosphate to 
fructose-6-phosphate and vice versa. In the extracellular space, it may act to induce 
secretion of immunoglobulin or facilitate neuronal survival. The differential secretion of 
GPI between p53-wt and p53-null cells pre-irradiation suggests that it could prove to be 
useful as a biomarker to predict potential patient benefit from IR and autophagy inhibitor 
combination treatment before the first dose of ionizing radiation. Using the online KM 
Plotter[313], GPI was also found to be significantly associated with probability of survival 
(log Rank p = 0.0026) in lung cancer patients who may or may not have been treated with 
IR but not chemotherapy (Figure 16).  
3.8.4 Thioredoxin reductase 1 (TXNRD1) 
Studies have shown that TXNRD1, identified in this study to be significantly differentially 
secreted only in untreated p53-wt cells, has different isoforms that may display different 
functions. Isoform 4 promotes transcription of estrogen receptors while isoform 5 is 
involved in interferon beta and retinoic acid induced apoptosis [332, 333]. We determined 
from this study that the effect of IR on TXNRD1 secretion is dependent on the p53 status 
(p-value = 0.0157). Like GPI, the significant difference in TXNRD1 secretion between 
p53-wt cells and p53-null cells before IR treatment suggests that it may be used as a 
diagnostic marker (before patients undergo radiotherapy) rather than a prognostic marker 
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given that the levels after radiation are not significantly different. TXNRD1 has been 
reported to have a prognostic association in breast cancer in a study that found that high 
levels of TXNRD1 RNA in node-negative breast tumor samples correlated with a higher 
risk of metastasis [334]. 
3.8.5 Protein FAM3C 
In our study FAM3C, also referred to as interleukin-like EMT inducer (ILEI), was 
expressed ~1.5 fold higher in p53-null cell secretomes compared to p53-wt cells before 
radiation whereas there was a ~3.2-fold increase in expression in p53-null cell 
secretomes compared to p53-wt after radiation treatment. FAM3C is a member of the 
FAM3 family of proteins and its gene codes for secreted proteins known to play a role in 
autophagy [161, 335]. A number of studies have also found the gene to be overexpressed in 
esophageal, colorectal and pancreatic cancer [103, 335, 336]. A study by Ling-Zhi et al. 
indicates that FAM3C is overexpressed in the exosomes of NSCLC patient plasma 
compared to healthy patients and is also linked to cell migration in K-ras mutant cells [337]. 
Its role in cell migration may be related to metastasis and poor prognosis [337]. 
Overexpression of FAMC3in H1299 p53-null cells, which represent the non-protective 
form of autophagy, is consistent with previous studies that have linked FAM3C to poor 
prognosis in colorectal cancer and metastasis in lung cancer cells [336, 338]. 
3.8.6 Calnexin (CANX) 
Together with FAM3C, CANX was shown to be overexpressed principally in the p53-null 
secretome following radiation treatment. Calnexin (CANX) is a calcium-binding 
membrane protein of the endoplasmic reticulum [339]. It is thought to be a chaperone in 
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protein translocatin from the ER to the extracellular membrane [339] and is known to be 
cleaved during regular growth into 2 fragments in yeasts [340]. This cleavage of calnexin 
has been found to depend on autophagy in a study that showed CANX processing to be 
defective following knockdown of autophagy-related genes [340]. In yeasts, autophagy 
occurs primarily in the vacuoles and CANX has been showed to co-localize with the 
vacuole following autophagy induction via nitrogen starvation [340]. CANX has also been 
reported in a recent study as  a  novel sero-diagnostic marker of lung cancer [341]. Its role 
as a chaperone protein is consistent with this study in which we have characterized 
autophagy associated secretion induced by ionizing radiation in the H1299 NSCLC cell 
line.  To our knowledge, this is the first report of differential secretion of calnexin in 
isogenic cell lines of  NSCLC differing only in p53 expression and functional autophagy 
status. The association of calnexin with autophagy combined with its recent report as a 
potential sero marker of lung cancer suggests that it could potentially serve as a marker 
for the autophagic response during chemo- or radiotherapy.  
3.8.7 U6 snRNA-associated Sm-like protein LSM8 
LSM8, quantified in all conditions except p53-wt -IR and overexpressed in p53-null +IR 
secretome compared to p53-wt +IR cells, is widely viewed as a component of the 
spliceosome. In a study of different cell lines including mammary and lung carcinoma 
cells, the spliceosomal machinery was demonstrated to be associated with autophagy 
where depletion of key spliceosome genes SNRPE or SNRPD1 resulted in autophagy 
induction [342]. LSM8 was found to be secreted in similar quantities in p53-null cells before 
and after radiation; however, secretion was elevated after irradiation in p53-wt cells. This 
may indicate a role of LSM8 in protective autophagy after IR treatment. LSM8 has been 
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reported to be directly involved in P-body regulation, its overexpression resulting in a 
concomittant decrease in P-body structures while depletion of LSM8 results in an 
increase in P-body structures [343]. LSM8 is believed to interact with the other LSM 
proteins in the cytoplasm [344, 345]. Persistent higher expression of LSM8 in H1299 p53-
null secretomes which represent the model of non-protective autophagy which is 
unresponsive to modulation may also imply a role in non-protective autophagy when it is 
upregulated before IR treatment. 
3.8.8 Eukaryotic translation initiation factor 5A-1 (EIF5A) 
EIF5A is the only protein in humans known to have the amino acid hypusine in its structure 
[346, 347]. The modification of lysine to hypusine has been shown to be important for cell 
viability [347]. Two gene encode for two isoforms of the protein; EIF5A1 and EIF5A2 with 
84% sequence homology. EIF5A has been shown to be directly or indirectly involved with 
the p53 signaling pathway in lung cancer cells [348] as well as the regulation of autophagy 
in drosophila [349]. EIF5A2 has also reported to be important for epithelial-mesenchymal 
transition in NSCLC and overexpressed in stage 1 NSCLC patients with poor prognosis 
[350, 351]. EIF5A has been found to promote the metastatic phenotype of pancreatic cancer 
through modulatory activity on various proteins [352]. In our study, EIF5A is virtually absent 
prior to irradiation in p53-wt cells whereas it is increased by more than 3-fold following 
irradiation. Conversely, EIF5A levels in the p53-null cells do not change in response to 
irradiation. The marked upregulation of EIF5A in p53-wt cell secretomes following 
radiation treatment suggests a role in the cellular response to radiation in p53-wt cells 
and makes EIF5A a potential predictor of functional autophagy type in response to 
radiation.  
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A comparison of our data with the protein list from the study by Daub et al [353] where 23 
NSCLC cell lines were profiled reveals overlap between proteins identified in this study 
and their study (Figure 18). We also found a number of proteins that may prove to be 
peculiar to the H1299 cell line that were not identified in the Daub et al.  study including 
H2AFV, HIST1H2BK, TMA7, PKM, SUMO2 and RHOBTB3. Similar comparisons of our 
data with the proteins in the exocarta database as well as the protein list obtained by Hu 
et al. who used TMT-labeled samples to examine the secretome of the H1993 metastatic 
NSCLC cell line shows substantial overlap between the identified proteins (Figure 18) 
[302]. The overalp between these findings supports the validity of the label-free approach 
we used in our study. 
3.9 Conclusions 
The current study has identified, among many proteins, CHGB, SCG2, GPI, TXNRD1, 
FAM3C, CANX, and EIF5A as potential diagnostic and prognostic blood based 
biomarkers in NSCLC. While FAM3C and CANX have been reported as being 
Figure 18 - Comparative Venn Diagrams 
Comparison of proteins identified in our study to the Exocarta database and a recently published study by 
Rongkuan et al. to the autophagy protein database and to a study of 23 NSCLC cell lines by Daub et al. 
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overexpressed in some cancers including NSCLC, for many of the proteins identified in 
our study, this is the first report of overexpression in a NSCLC (H1299) secretome in the 
context of autophagy and ionizing radiation treatment. We determined that CHGB, SCG2, 
GPI, and TXNRD1 have potential as population-based biomarkers (for patient 
stratification) due to their consistent overexpression as a function of p53 status and not 
radiation treatment whereas FAM3C, CANX, and EIF5A hold potential as personalized 
biomarkers to predict patient response following ionizing radiation treatment due to their 
differential secretion in radiation treated versus untreated cells. On the basis of this study, 
plans are in place to conduct larger studies to optimize the sensitivity and specificity of 
these proteins in NSCLC and the validity of using these proteins as stratification tools to 
determine which patients may benefit from autophagy modulation in combination with 
chemo- and/or radiotherapy. 
It is necessary to provide a critical caveat to these findings. Although our stated goal in 
this work was to identify proteins that could potentially be utilized as biomarkers to 
distinguish between the cytoprotective and non-protective forms/functions of autophagy, 
we fully recognize that the observed profile of proteins in the secretome may be related 
primarily to the p53 status of the tumor cell models. Identifying potential linkages to 
autophagy will require further studies where the levels of these proteins are genetically 
modulated to determine their impact on autophagic function. 
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Chapter 4: 
Glycoproteomics Characterization of the SILAC-Labeled HepG2 Secretome as a 
Platform for the Generation of Stable Isotope Labeled Plasma Proteins 
 
 
 
4.1 Introduction 
The development and implementation of untargeted (i.e., global) quantitative proteomics 
strategies has transformed the study of complex biological systems. With regard to clinical 
biospecimen analysis, label free (i.e., spectral counts, LFQ) and isobaric tagging (i.e., 
iTRAQ and TMT) have played a predominant role in comparative un-targeted proteomics 
studies. The successful implementation of both approaches requires minimal sample 
preparation variation including total protein determination, consistent digestion efficiency, 
and control of chemical modifications (e.g. alkylation, oxidation, isobaric tagging, etc.). 
Although it is possible to minimize these sources of variation, it can become increasingly 
difficult scaling up to larger numbers of samples. Finally, as the number of samples 
increases and the desire to venture outside of traditional peptide-level quantification (e.g., 
complex carbohydrates), so too does the difficulty in maintaining quantitative precision 
across samples. Furthermore, the recognition that large amounts of biologically important 
information in the form of PTMs is not captured. 
Plasma remains an important clinical biospecimen for comparative proteomics analysis 
but it is one of the most complex proteomes to quantitatively study with >1010 dynamic 
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range of concentration, disproportionate levels of high abundant proteins such as albumin 
and immunoglobulins, heterogeneous protein complexes (e.g. lipoproteins), and protein 
glycoforms [82, 130]. Although many comparative plasma proteomics studies have focused 
on identifying low abundant proteins using extensive depletion and fractionation, many of 
the major plasma proteins hold important biological functions and potential diagnostic 
value. In fact, many high- and mid-level plasma proteins have been identified as 
candidate biomarkers for cancer [354]. For instance, some of these proteins (e.g., CA-125, 
APOA1, B2M, TF, and ALB used in the OVA-1 test) have been used for FDA-approved 
diagnostics and prognostics applications. An added dimension of complexity and 
opportunity lies in plasma protein PTMs. Glycosylation is very common for PTM, 
particularly for major plasma proteins, and dysregulated forms of glycoproteins are 
believed to be potentially important. Despite their importance, there are limited 
quantitative approaches to address this potentially important aspect of comparative 
plasma proteomics measurements. 
The extension of the SILAC quantitative proteomics strategy to biological samples termed 
Super-SILAC has improved the precision and accuracy of LC-MS/MS analysis of 
biospecimen [80]. We have showed in a proof-of-principle study that this approach makes 
possible the quantitative analysis of changes in the plasma proteome [82]. In that study, 
the HepG2 cell, shown in the literature to secrete many of the major plasma proteins, was 
used [82, 355]. The use of the HepG2 cell line secretome for the generation of stable isotope 
labeled (SIL) intact proteins is however, not limited in applicability to only plasma 
analyses. There are ongoing studies in our lab in which we show extended applicability 
of the SIL labeled secretome to enzyme digestion kinetics, biospecimen degradation, and 
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interaction studies. These studies are respectively in pursuit of sequences that influence 
protein digestion and peptide formation rates, factors such as collection strategies 
affecting biospecimen integrity, and novel binding motifs of heparin and heparan sulfate. 
Glycosylation is one of the most important PTMs in cellular protein production [107, 356, 357]. 
The importance of glycosylation in normal cell function as well as in disease is well 
established in the literature [358–360]. Glycosylation introduces carbohydrate (or sugar) 
moieties onto certain amino acids in the protein structure. Glycans may be N-linked or O-
linked referring to the atom of the amino acid to which the glycan is linked to the protein. 
To use the HepG2 cell line as the platform for the generation of intact SIL proteins to be 
used as standards for mass spectrometry analyses of plasma and other biospecimens, it 
is essential to characterize the complement of secreted proteins and to determine 
similarities and differences compared to plasma especially regarding PTMs such as 
glycosylation. The results of our previous study [82] suggested potential differential 
glycosylation between plasma and the HepG2 secretome as was the case with alpha-1-
glycoprotein 2 (ORM2). In this study, we present an in-depth glycoproteomics 
characterization of the HepG2 secretome.  
4.2 Experimental 
4.2.1 Reagents  
SILAC DMEM (arginine- and lysine-free high glucose Dulbecco’s Modified Eagle Media) 
was purchased from Thermo Scientific. 13C6 L-arginine-HCl (>98%) and 13C6 L-lysine-
2HCl (>98%) were purchased from Cambridge Isotopes Laboratories. Dialyzed Fetal 
Bovine Serum was purchased from Gibco. Penicillin, streptomycin, and amphotericin B 
were obtained as a 100X solution from Invitrogen. LC-MS grade acetonitrile (ACN) and 
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water were obtained from Burdick and Jackson. LC-MS grade formic acid, Iodoacetamide 
(IAA), and Dithiothreitol (DTT) were purchased from Sigma-Aldrich. Reagent grade Tris 
base and 12 M hydrochloric acid were obtained from Fisher Scientific, and trypsin gold 
was obtained from Promega.  
4.2.2 Cell Culture Conditions 
HepG2 cells were obtained from the American Type Culture Collection (ATCC, HG-8065, 
Manassas, VA), and cultured in high glucose SILAC DMEM supplemented with 10% 
dialyzed Fetal Bovine Serum (FBS), 50 mg 13C6 L-arginine-HCl (>98%), 50 mg 13C6 L-
lysine-2HCl (>98%), and 1% 100 U/ml Penicillin G sodium/1% 100 µg/ml Streptomycin 
sulfate at 37°C and 5% CO2 for nine population doublings. Cells were then transferred 
into freeze media and stored in liquid nitrogen until needed. Heavy SILAC-labeled HepG2 
cells were seeded in three sets of 3 × 10 cm dishes at ~200,000 cells in 10 mL of media 
and grown to ~85% confluency over 48 hours. At ~85% confluency, the 10% dialyzed 
FBS culture media was aspirated from all plates, cells washed with 2 × 5 mL of Phosphate 
Buffered Saline 1X pH 7.4 (Gibco) and then once with 5 mL serum-free DMEM [361]. A 
final 10 mL volume of serum-free SILAC heavy DMEM was added to the 9 plates. All 
plates were then incubated at 37oC. The serum-free media containing secreted proteins 
(secretomes) were collected into 3 × 15 mL tubes after 24-, 48-, and 72-hour incubation 
times and stored at -80oC. Cells from the plates were then harvested, pelleted by 
centrifugation at 1500 rpm for 5 minutes at 8oC, washed with PBS, and stored at -80oC 
until use. 
4.2.3 Annexin V/Propidium Iodide staining 
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Quantification of apoptotic cells via flow cytometry was performed per the manufacturer’s 
instructions (Annexin V - FITC apoptosis detection kit, BD Biosciences, 556547). Flow 
cytometry analysis was performed using BD FACSCanto II and BD FACSDiva software 
at the Virginia Commonwealth University Flow Cytometry Core Facility. 
4.2.4 Proteomics Sample Preparation 
Secretome Only 
The collected media (secretomes) samples were removed from -80oC, thawed, and 
centrifuged at 2500 rpm for 5 minutes at 8oC to remove cellular debris. The supernatant 
was then collected and concentrated in 3 kDa MWCO filters at 6900 × g for 30 minutes 
at 8oC in 5 mL aliquots. Centrifugation was repeated until there was ~500 µL of 
concentrated secretome in the filter. To remove the phenol red color, 3 × 500 µL of Tris 
HCl buffer pH 8.1 was added to each secretome and centrifuged at 6900 × g for 30 
minutes at 8oC. The concentrated secretomes were then transferred into 10 kDa MWCO 
filters and washed with 2 × 400 µL of Protease Inhibitor (PI) in Tris HCl pH 8.1 buffer by 
centrifugation at 15,000 × g for 10 minutes. Remaining secretome in the filters were then 
made up to 300 µL with PI in Tris HCl pH 8.1 buffer and transferred into 1.5 mL centrifuge 
tubes. 300 µL of PI in Tris HCl pH 8.1 buffer was pipetted into each filter, vortexed briefly, 
and transferred into the same corresponding 1.5 mL centrifuge tube. The biological 
replicates of each time point were then pooled to give 3 samples: 24h, 48h, and 72h. Total 
protein concentration was determined at 280 nm using a BioTek Synergy H1 fitted with a 
Take3 Plate. 6 × 100 µL aliquots of each sample was then pipetted into 6 new 10 kDa 
MWCO filters secretomes and were processed for proteomics analysis using the FASP 
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method [307]. For each time point, samples in three filters were subjected to PNGase F 
digestion preceding trypsin digestion while samples in remaining three filters served as 
controls in which no PNGase F digestion was carried out before trypsin digestion. 
Samples were processed concurrently. Briefly, each filter was centrifuged at 15,000 × g 
for 10 minutes. Samples in the 10 kDa MWCO filter were then reduced with 50 µL of 50 
mM DTT (to give a final concentration of 25 mM DTT) by incubation for 45 mins at 56oC. 
Reduced samples were then alkylated with 100 µL of IAA to a final concentration of 40 
mM IAA at room temperature in the dark. Reduced and alkylated samples were 
centrifuged at 15,000 × g for 10 minutes and subsequently rinsed with 350 µL of Tris-HCl 
pH 8.1. PNGase F digestion was carried out based on protein concentration with 5 µL, 6 
µL, and 7 µL PNGase F for 24, 48, and 72 h samples respectively. Samples were 
incubated at 37oC overnight. Control samples were incubated without PNGase F. Trypsin 
digestion was performed with 5.75 µL, 6.91 µL, and 8.03 µL of 1 µg/ µL Trypsin Gold 
(Promega) solution corresponding to 50:1 protein to enzyme ratio. Samples were 
incubated overnight at 37oC and then digestion terminated with 200 µL of 0.1% acetic 
acid (Fluka Analytical). 
Secretome - Plasma Combinations 
Previously concentrated secretome samples and frozen human plasma samples were 
removed from -80oC, and thawed at room temperature. Total protein concentration was 
determined at 280 nm using a BioTek Synergy H1 fitted with a Take3 Plate. 35.6 µL 
aliquots of 24 h, 48 h, and 72 h secretomes were then combined with 22.7 µL (150 µg) of 
plasma in different centrifuge tubes. Different weight-to-weight combinations (1:1, 1:10, 
and 10:1) of 72 h secretome and plasma were also prepared. Each secretome-plasma 
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combination sample was reduced with 50 mM DTT (to give a final concentration of 25 
mM DTT) by incubation for 45 mins at 56oC. Reduced samples were then alkylated with 
80 mM IAA to a final concentration of 40 mM IAA at room temperature for 30 minutes in 
the dark. Reduced and alkylated samples were centrifuged at 15,000 × g for 10 minutes 
and subsequently rinsed with 350 µL of Tris-HCl pH 8.1. Trypsin digestion was performed 
with 5 µL, of 1 µg/ µL LC-MS/MS Trypsin (Pierce) solution. Samples were incubated 
overnight at 37oC and then digestion terminated with 200 µL of 50 mM acetic acid (Fluka 
Analytical). 
Peptides were then desalted using C18 StageTips (Thermo) according to the instructions 
in the manufacturer kit. Briefly, 24 × 10 µg capacity StageTips were washed with 20 µL 
of 80% acetonitrile in 5% formic acid by centrifugation at 500 × g for 5 minutes. The 
StageTips were then equilibrated with 20 µL of 5% formic acid. 15 µL of each peptide 
sample was loaded onto a StageTip and centrifuged at 1000 × g for 5 minutes. StageTips 
were then washed with 20 µL of 5% formic acid to remove salts. Peptides were then 
manually eluted with 2 × 20 µL of 80% acetonitrile in 5% formic acid using the CombiTips 
provided with the Thermo StageTips kit. Eluted peptides were then dried in the speedvac 
and reconstituted in 20 µL of 2% acetonitrile in 0.1% formic acid. The reconstituted 
peptide samples were then transferred into LC vials and analyzed by nanoLC-MS/MS. 
Lectin Enrichment and PNGase F Digestion 
Two 1 g solutions of a 1:1 w/w mixture of the 72 h secretome and plasma were prepared 
in two different tubes for lectin enrichment. The secretome-plasma mixtures were diluted 
with the 5X binding buffer from the Thermo glycoprotein kit in a 4:1 protein buffer ratio. 
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100 µL each of WGA and Con A lectin slurries were pipetted into separate columns, 
labeled, and centrifuged at 1000 × g for 1 minute. Unless otherwise stated, centrifugation 
of lectin columns was done at 1000 × g for 1 minute. The columns were then rinsed three 
times with 1X binding buffer via centrifugation. The diluted protein samples were then 
transferred into the labeled lectin columns and incubated at room temperature for 60 mins 
with mild shaking on a vortex. The columns were then centrifuged and the flow-through 
(FT) collected and transferred into centrifuge tubes labeled WGA FT or Con A FT. 2 × 
200 µL of 1X binding buffer was added to the columns, centrifuged and the eluates added 
to the FT tubes. The columns were then incubated with 200 µL of 1X binding buffer for 
15 mins at room temperature. Columns were centrifuged followed by a wash with 200 µL 
of 1X binding buffer. Eluates were combined in the FT tubes. 200 µL of glycoprotein 
elution buffer was then added to each column and incubated at room temperature for 20 
mins. Columns were subsequently centrifuged and transferred into tubes labeled WGA 
binders or Con A binders. Incubation with the elution buffer was repeated for 20 mins 
following which columns were centrifuged and the glycoprotein eluates transferred into 
their corresponding labeled centrifuge tubes. Flow-through proteins and the eluted lectin-
enriched glycoproteins were then reduced, alkylated, and digested with PNGase F 
overnight followed by an overnight digestion with trypsin. 
4.2.5 Gel Electrophoresis 
A 1D gel electrophoresis of concentrated secretome samples (24h, 48h, and 72 h) was 
run as previously described [82]. 20 µg aliquots of secretomes were pipetted and made up 
to 20 µL with HPLC grade water. The samples were denatured and reduced by mixing 
with 20 µL of 50 mM DTT in 2X Laemmli buffer and incubating at 100oC for 5 minutes. 
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The resulting 40 µL of each sample was then loaded onto a 10% Criterion Tris-HCl 
precast gel (Bio-Rad) and run at 200V for 1 hr. The gel was washed with distilled water 
for 3 × 10 minutes followed by Coomassie staining on an orbital shaker for 30 minutes. 
The stain was then washed with distilled water for 30 minutes. The stained gels were then 
visualized with a Bio-Rad gel imager and stored at 8oC. 
4.2.6 LC-MS/MS Method 
75 µL solutions of peptide samples were pipetted into LC vials for nLC-MS/MS analysis. 
The LC-MS/MS system consists of an Eksigent nLC 415 (ABSciex) in a vented column, 
trap and elute configuration. The reverse phase trap column (75 µm x 5 cm) and analytical 
column (75μm x 15cm) were both packed in-house with Magic AQ C18 3µm and 200Å 
material. The nLC system was coupled to a Q-Exactive (Thermo Scientific, San Jose, CA) 
mass spectrometer equipped with the Nanospray-Flex ionization source fitted with a 10 
μm ID emitter PicoFrit tip (New Objective). 2 µL of peptide sample was loaded onto the 
trap column and desalted at a flow rate of 2.25 μL/min for 5 minutes using mobile phase 
A (98% H2O/2% acetonitrile, 0.1% formic acid). Desalted peptides were then separated 
on the C18 self-pack column at 300 nL/min with increasing mobile phase B (2% H2O/98% 
acetonitrile, 0.1% formic acid) using the following gradient:  5% B (0 – 4 minutes), 35% B 
(95 minutes), 75 % B (105 – 110 minutes), 5% B (115 minutes) and held for 5 minutes 
until the run finishes at 120 minutes. The electrospray emitter tip was charged with a 
voltage of 1.80 kV in positive ion mode and the Q-Exactive inlet temperature and S-lens 
setting were maintained at 250C and 62 V, respectively. Full scan (400-1600 m/z) 
resolution was set at 70,000 FWHM with an AGC target of 3 × 106. MS/MS was set to a 
resolution of 17,500 with an AGC target of 2 × 104 at 120 ms maximum inject time and 
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selection of the top 12 ions at a 30 second dynamic exclusion. HCD voltage was 
maintained at 30 NCE throughout.  
4.2.7 LC-MS/MS Protein Identification, Quantification, and Data Analysis  
Proteomic raw files were processed in the MaxQuant computational platform (ver. 1.5.8.3) 
with the Andromeda search algorithm using the Uniprot Human proteome database 
(common contaminants were added to the search). Up to two missed cleavages, mass 
accuracies: MS = 5 ppm, MS/MS = 0.02 Da; fixed modifications: carbamidomethyl (C), 
variable modifications: acetyl (N-terminus) and methionine oxidation (M), and a false 
discovery rate (FDR) of 1% were included in the search parameters. Quantification of 
proteins was done in MaxQuant using the LFQ algorithm requiring at least 2 shared 
peptides[67]. Statistical analyses were carried out in Perseus (ver. 1.5.8.8) and JMP Pro 
13 Statistical Software. One-way analysis of variance (ANOVA) tests were carried out 
followed by t-test pairwise comparisons to determine significant effects using the 
Benjamini-Hochberg correction. Imputation of missing values was done in Perseus by 
replacing with random numbers drawn from the lower (left) boundary of a normal 
distribution. Gene Ontology (GO) annotation enrichment analysis were performed using 
the David Bioinformatics Resource (ver 6.8) [362, 363]. For the GO enrichment analysis in 
David, a term is said to be enriched if the proportion of proteins associated with the GO 
term in the data set is significantly higher (using a modified Fisher Exact test) than the 
proportion of proteins associated with the term in the human proteome. In the Perseus 
statistical analysis, protein identification lists were filtered by removing contaminants and 
reverse database sequence hits.  
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4.3 Results & Discussions 
The use of the SIL HepG2 secretome as a global internal standard for plasma versus cell 
lysates offers some critical advantages for LC-MS/MS comparative studies. The majority 
of plasma proteins are produced by liver hepatocytes. The HepG2 cell line is derived from 
liver adenocarcinoma and has been used as a model for liver hepatocyte function 
including plasma protein synthesis. Primary hepatocytes were not used due to concerns 
with the ability to continue cell propagation after stable isotope labeling that occurs in 
about nine doublings (over 2 – 3 passages). To use the HepG2 cell line to produce SIL 
plasma proteins, serum-free conditions are necessary to avoid the issue of high protein 
background from fetal bovine serum [361]. However, there are concerns regarding cell 
survival as well as the contribution, from lysed apoptotic cells, of proteins that would 
otherwise not have been secreted into the media to the total secretome [361]. In other 
Figure 19 - Protein Content of the HepG2 Secretome over 72 hours 
A) Total protein concentration determined by UV absorbance at 280nm on a plate reader. Total protein levels 
increased from 2.88 mg/mL (± 0.11) at 24 hours to 3.46 mg/mL (± 0.08) at 48 hours and 4.02 mg/mL (± 0.08) at 72 
hours. Statistical significance was determined using t-tests. B) Coomassie stained 1D-Gel image of HepG2 
secretomes at 24, 48, 72 hours relative to human plasma. 
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words, sustained incubation of HepG2 cells under serum free conditions may stress the 
cells and potentially reduce the overall number of viable cells. Thus, our initial efforts were 
focused on exploring the protein production of HepG2 cells under serum-free conditions 
over an extended period while concurrently monitoring cell viability. 
To address these issues, we measured total protein production of HepG2 cells at 24h, 
48h, and 72h under serum-free conditions while concurrently measuring cell viability 
under the same conditions. HepG2 cells were cultured in triplicate in 6-well plates in high 
glucose SILAC DMEM supplemented with 10% dialyzed FBS, 13C6 L-arginine-HCl, 13C6 
L-lysine-2HCl, and 1% 100 U/ml Penicillin G sodium/1% 100 µg/ml Streptomycin sulfate 
Figure 20 - Annexin V/PI Apoptosis Assay 
Flow cytometry of Annexin V/PI stained cells shows no significant induction of apoptosis in HepG2 cells following 
serum starvation (Serum-free) compared to serum fed (Control) cells at 24, 48, and 72 hours following initiation of 
serum-free conditions 
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at 37°C and 5% CO2. At ~ 85% confluence (after 48 hrs), the media was replaced with 
serum-free SILAC DMEM-high glucose media following which conditioned media 
(secretomes) were collected and total protein concentration measured at 280 nm on the 
BioTek Synergy Hybrid Take3 Plate Reader. The results reported in Figure 19A showed 
a sustained and statistically significant increase with time. Total protein levels increased 
from 2.88 mg/mL (± 0.11) at 24 hours to 3.46 mg/mL (± 0.08) at 48 hours and 4.02 mg/mL 
Figure 21 - Protein Distribution in the HepG2 Secretome 
Quantitative proteomics results showing the A) total LFQ intensities at 24h, 48h, and 72h and B) 
distribution of individual quantified proteins. C) Rank ordered LFQ abundance levels of plasma proteins 
(*Nanjappa et. al. 2014) and cancer biomarkers (Polanski and Anderson 2007) quantified in this study. 
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(± 0.08) at 72 hours. The distribution of secreted proteins was also assessed by 1D gel 
electrophoresis (Figure 19B). Furthermore, all time points showed similar bands to 
human plasma including the prominent albumin band at ~ 66 kDa. Concurrent with the 
secretome analysis in Figure 19, we determined the effect of serum starvation up to 72 
hours on HepG2 cells using the BD Biosciences apoptosis kit. The extent of apoptosis 
was evaluated at 24, 48, and 72 hours according to the manufacturer’s directions. The 
results revealed very low levels of apoptosis in both control cells and cells exposed to 
serum starvation (Figure 20). There were very few cells in early or late apoptosis with 
most samples in both control and serum-starved cells showing mostly no cells in late 
apoptosis. 
4.3.1 Quantitative Analysis of the SILAC HepG2 Secretome 
Pooled concentrated secretome samples were then reduced, alkylated, and digested for 
nLC-MS/MS analyses. This increasing protein concentration correlated directly with total 
LFQ intensity levels which increased from 2.38E11 (± 3.20E9) at 24 hours to 2.63E11 (± 
2.78E9) at 48 hours and then to 3.03E11 (± 2.55E9) at 72 hours in the PNGase F-treated 
secretome samples (Figure 21A). As shown in Supplementary Figure 1, increased 
protein secretion over time was not a result of increased protein from lysed apoptotic cells 
with increasing incubation time in serum-free media.  
The nLC-MS/MS analysis of the HepG2 secretome revealed the identification of 1635 
unique proteins. Using LFQ[67] quantification to filter the proteins, 1229 were identified to 
be quantified in 2 or more replicates of at least one time point. Further quantitative 
analysis showed that 1187, 1225, and 1374 proteins were quantified at least once in the 
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24h, 48h, and 72h secretomes respectively. A summary of the distribution, including 
overlap, of quantified proteins across the three time points is illustrated in Figure 21B. 
1016 proteins were quantified at least once in all time points while the 72h secretome had 
the most unique proteins quantified (283). Bioinformatics functional enrichment analysis 
was performed on the 1229 proteins using David 6.8. The results revealed the enrichment 
of cellular components including extracellular exosomes (~3.57 fold, p-value = 3.13 × 10-
257), cytosol (~2.48 fold, p-value = 7.02 × 10-115), cell-cell adherens junction (~5.87 fold, 
p-value = 1.69 × 10-65), focal adhesion (~4.16 fold, p-value = 1.92 × 10-38), membrane 
Figure 22 - Gene Ontology Cellular Component (GOCC) Analysis 
Bioinformatics functional analysis of 1229 proteins quantified in ≥ 2 replicates of one or more groups 
(secretome only analysis) revealed the Gene Ontology Cellular Component (GOCC) most enriched 
in the HepG2 secretome include extracellular exosome, cytosol, cell-cell adherens junction, focal 
adhesion, membrane, and intracellular ribonucleoprotein complex. 
 
 
155 
 
(~1.90 fold, p-value = 1.27 × 10-27), and intracellular ribonucleoprotein complex (~5.98 
fold, p-value = 1.75 × 10-27) as shown in Figure 22. 
The HepG2 hepatocarcinoma cell line has been demonstrated to secrete many proteins, 
including the major plasma proteins at levels comparable to plasma, with function in 
different physiological processes[82, 364]. Many of these plasma proteins (e.g. ORM1, TF, 
Figure 23 - Differential protein secretion over 72 hours in HepG2 cells. 
Volcano plots showing significantly different proteins (shown in red circles) between the 48 hour 
secretomes compared to the 24 hour secretome (A), the 72 hour secretome compared to the 24 hour 
secretome (B), and the 72 hour secretome compared to the 48 hour secretome (C). 
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FGA, A2M, and APOA2) serve as biomarkers of disease e.g. cancer [365]. Among the 
major plasma proteins of interest are apolipoproteins, protease inhibitors, complement 
factors, and coagulation factors. A comparison of the 1635 identified proteins in the 
HepG2 secretome with the plasma protein database curated from the Nanjapa et al 
manuscript [365] and downloaded from http://plasmaproteomedatabase.org revealed an 
overlap of 491 non-redundant proteins. Included in the 491 proteins are many 
apolipoproteins including APOA1, APOA2, APOA4, APOA5, APOB, APOC1, APOC3, 
APOE, APOH, APOL, and APOM, as well as many serine protease inhibitors (SERPINs) 
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Figure 24 – Hierarchical Clustering of Secreted Proteins in HepG2 Cells 
Heatmap of z-score normalized HepG2 protein secretion over 72 hours showing increasing and decreasing levels of different plasma proteins 
over time. Proteins corresponding to various GO terms clustered together and are colored as follows: purple – associated with complement and 
coagulation cascade, red – associated with serine-type endopeptidase inhibitor activity, brown – associated with protein binding, and green – 
associated with protein processing in the ER. 
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such as alpha-1-antitrypsin (SERPINA1), antithrombin III (SERPINC1), and heparin 
cofactor 2 (SERPIND1). Apolipoproteins are the major players in the plasma lipid 
transport system and their quantitative measurements serve important roles in 
cardiovascular disease diagnosis and prognosis. A plot of the rank ordered total LFQ 
intensity (computed by an algebraic sum of the LFQ intensity across all technical 
replicates of each sample) of the 491 plasma proteins showed quantification over six 
orders of magnitude (Figure 21C).  
Statistical analysis using t-tests were performed on the HepG2 secretome dataset to 
determine changes in the HepG2 protein secretion dynamics. Significant differences were 
found mainly to be between the 24 h secretome and 48 h or 72 h secretomes. Few 
differences in protein secretion were observed between the 48 h and 72 h secretomes. 
112 proteins were found to be significantly different between 24 h and 48 h (Figure 23A), 
while 279 proteins differed significantly between the secretomes at 24 h and 72 h (Figure 
23B), using an α value of 0.0167 for 3 pairwise comparisons and ≥ 2-fold difference. 
There were 44 significantly different proteins between the secretomes at 48 h and 72 h 
(Figure 23C).  
Additionally, we were interested in proteins with consistently increasing or decreasing 
secretory levels in the secretome from 24 – 72 hours. A z-score hierarchical cluster of 96 
plasma proteins found to be significantly decreasing or increasing over the 72-hour period 
is shown in Figure 24. Of these, 67 showed increasing levels, while 29 showed 
decreasing levels in the HepG2 secretome. 
4.3.2 N-Glycosylation of Plasma Proteins 
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To carry out N-glycosylation analysis of HepG2 secreted proteins, the concentrated 
secretome was treated with PNGase F prior to trypsin digestion. Following PNGase F 
treatment to cleave N-glycans from asparagine residues and generation of tryptic digests, 
the deglycosylated peptides were analyzed by LC-MS/MS and raw data processed.  
Manual data analysis via a cross reference of the 491 identified plasma proteins against 
the Uniprot database indicated 163 of them were N-glycosylated and represented 707 
unique N-glycosites. Among the 163 Uniprot plasma N-glycoproteins, 76 were identified 
with deglycosylated peptides in the PNGase F-treated HepG2 secretome (Figure 25A). 
Further analysis revealed that plasma N-glycoproteins in the HepG2 dataset with 
Figure 25 - Plasma N-glycoproteins in the HepG2 Secretome 
A) Bar graph showing the distribution of Uniprot-verified plasma N-glycoproteins and the corresponding number of N-
glycosites found in the HepG2 Secretome. B) Scatter plot of the 163 plasma glycoproteins with identified and 
unidentified glycosites in the PNGase F-treated HepG2 secretome. Glycoproteins with identified sites of glycosylation 
had a greater mean LFQ value than those with unidentified glycosites. C) N-glycosite analysis of  293 proteins 
corresponding to 621 glycosites identified in the PNGase F-treated HepG2 secretome showed 34% consensus with 
the N-X-T/S motif  D) N-glycan motif analysis of the 76 plasma glycoproteins with 283 identified glycosites showed 143 
glycosites (~50%) consistent with the N-X-T/S motif.  
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identified N-glycosites had a higher mean LFQ intensity across all time points compared 
to N-glycoproteins with unidentified glycosites (Figure 25B).  
An illustration of the most highly represented sequence motifs in the glycoproteins 
identified in the HepG2 secretome data is displayed in Figures 25C-D. PNGase F 
treatment revealed the presence of 621 sites of N-glycosylation in the HepG2 secretome, 
~ 34% of which were consistent with the conserved N-X-T/S motif as shown in Figure 
25C. However, for the 76 plasma N-glycoproteins, a greater proportion of the 283 
identified N-glycosites (143 representing ~ 50%)  were identified as valid N-glycosites 
(Figure 25D). 
4.3.3 SIL HepG2 secretome protein levels versus plasma 
This present study involves the characterization of the stable isotope labeled (SIL) HepG2 
secretome with downstream applications including plasma analysis. Consequently, we 
Figure 26 - Plasma Protein Secretion Changes over 72 hours in HepG2 Cells 
A) Median heavy:light (H/L) ratios for 143 proteins quantified in 2 replicates of at least one sample as a function of 
time. B) Extracted median H/L ratios of apolipoproteins and SERPINs identified and quantified in the HepG2 
secretome 
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spiked the SILAC heavy labeled HepG2 secretome into an 
ethylenediaminetetraaceticacid (EDTA) plasma sample. Here, three SILAC 
secretome:plasma samples were prepared by spiking an equal volume (35.60 µL) of each 
secretome sample (24 h – 2.976 µg/mL, 48 h – 3.596 µg/mL, and 72 h – 4.213 µg/mL) 
into 150 µg of plasma (6.607 µg/mL) in three different 1.5 mL centrifuge tubes. The SILAC 
mixtures were subsequently processed and analyzed via nLC-MS/MS before and after 
PNGase F treatment, with and without lectin enrichment of N-glycoproteins.  
For the samples analyzed without PNGase treatment, an additional 10:1 heavy to light 
mixture (300 µg:30 µg) was prepared by combining 71.21 µL of the 72 h HepG2 
secretome with 4.54 µL of plasma, resulting in twelve sample replicates representing four 
sample groups (24 h, 48 h, 72 h 1:1, and 72 h 10:1). This was done to assess linearity of 
the nLC-MS/MS method. In the plasma spike-in study 1405 proteins in total were 
identified and of these 143 proteins were quantified with ≥ 2 valid H/L ratios in at least 
one group (Figure 26A). Consistent with the total protein concentration at 280 nm, LFQ 
intensity and 1D gel results of the secretome only analysis, heavy:light (H/L) ratios of 
identified proteins in the spike-in study revealed increasing protein ratios from 24 to 72 
hours. Figure 26B shows that for apolipoproteins and protease inhibitors (quantified with 
valid H/L ratios in all replicates of all samples), secretion was generally trending upwards. 
H/L ratios were seen to increase by approximately ten-fold from the 72h 1:1 sample to 
72h 10:1 sample. However, this was not observed for all proteins due to the presence of 
proteins for which valid H/L ratios were obtained for the 72h 1:1 sample but not for the 
72h 10:1 sample. 
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In a proof of concept study [82] showing the potential for using the SILAC-labeled HepG2 
secretome as an internal standard for comparative LC-MS/MS analysis of plasma, the 
potential impact of glycosylation on the quantitative value of this approach was 
demonstrated. In that study, carried out without enzymatic deglycosylation, the heavy 
isotope labeled peptide QNQCFYNSSYLNVQR from alpha-1-acid glycoprotein 2 (ORM2) 
was identified in the HepG2 secretome sample whereas the light-labeled peptide from 
plasma was not identified. We predicted that this might have been a result of differential 
glycosylation at the 93 position of the protein between the HepG2 secretome and plasma. 
Thus, we incorporated PNGase F cleavage of N-glycans into the workflow for the present 
study. Manual data analysis and interpretation of the secretome:plasma mixture without 
PNGase F treatment revealed the same observation wherein the QNQCFYNSSYLNVQR 
was identified in the HepG2 secretome but not plasma (Figure 27). However, both the 
heavy and light isotopes of the peptide were detected and quantified in the PNGase F-
treated mixture (Figure 27). That the peptide was not identified in plasma without 
Figure 27 - Peptides from alpha-1-acid-glycoprotein 2 (ORM2) 
Heavy and Light isotopes of the peptide QNQCFYNSSYLNVQR ORM2. Heavy isotope was identified with 
or without PNGase F treatment of the SILAC combined sample whereas the light isotope from plasma was 
only identified with PNGase F treatment. 
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PNGase F treatment is suggestive of differential glycosylation between the HepG2 and 
plasma forms of the protein. Additionally, this finding is indicative of the effect of 
glycosylation on the quantitation of certain peptides.  
Figure 28 - The effect of lectin enrichment on N-glycoprotein levels between proteins in the HepG2 
secretome and plasma 
Proteins that were quantified with valid H/L ratios in ≥ 2 replicates of at least one sample group were extracted 
and their Log
2
 H/L ratios computed; missing values were imputed. The graphs were then plotted to illustrate 
the changes in protein levels due to enrichment using lectins with different specificities (Con A and WGA). 
Graphs are shown for A) Alpha Fetoprotein (AFP), B) Anti-thrombin III (SERPINC1), C) Serotransferrin (TF), 
and D) Apolipoprotein A1 (APOA1). 
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4.3.4 Differential glycosylation of SIL HepG2 secretome versus plasma 
glycoproteome 
Complex glycopeptides and/or glycan identification can be improved using glycoprotein 
enrichment strategies including lectin affinity capture[80, 81, 366] and solid phase 
extraction[107]. Several lectins exist with widely differing binding affinities for different 
glycan moieties. Wheat germ agglutinin (WGA) and Concanavalin A (Con A) are two of 
the most widely lectins for glycoprotein/glycopeptide enrichment. Despite the general 
knowledge in glycomics that there is some overlap between WGA and Con A binding 
preferences, the degree of overlap is generally not known. It is widely accepted however, 
that WGA binds preferentially to glycoproteins with N-acetylglucosamine residues and 
sialic acid residues (e.g. N-acetylneuraminic acid) whereas Con A binds to mannose[81, 
123, 367]. Consequently, we pursued lectin enrichment of the 72 h secretome:plasma SILAC 
sample and explored, where present, glycan differences in major plasma proteins 
including apolipoproteins and SERPINS using WGA and Con A. 894 proteins were 
identified in the lectin enrichment study with 119 proteins quantified with valid H/L ratios 
in at least one of the groups. Among the 119 proteins are many apolipoproteins, 
complement factors, and serine protease inhibitors identified with sequence coverages 
as high as 70%. H/L protein ratios were transformed to Log2 values following which 
missing values were computed. We then determined median Log2 H/L ratios for each 
protein in each group. While protein glycosylation plays a vital role in various molecular 
processes in the body, the microheterogeneity of glycans found on a single site of 
glycosylation in proteins poses challenges [368]. 
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It is important to note that when the same types of glycan structures are present at a given 
glycosite of both the heavy (HepG2 secretome) and light (plasma) isotopes of a given 
protein, the H/L ratios determined for the Con A or WGA lectin-enriched samples would 
be expected to largely be similar, if not equal. Furthermore, this ratio will not be different 
from the unenriched sample. However, when a given glycosites harbors different kinds of 
glycans in the secretome compared with the plasma, the H/L protein ratio determined for 
the unenriched sample will differ from the ratios determined for either Con A- or WGA-
enriched samples. For example, AFP shows similar ratios for the unenriched sample and 
the Con A-enriched sample but a significantly different ratio for the WGA-enriched sample 
(Figure 28A) signifying that the heavy- and light-labeled isotopes of AFP have similar 
types of mannose-containing glycans but different sialic acid or N-acetylglucosamine 
residues. While AFP has two possible sites of N-glycosylation, only one known site is 
reported in Uniprot. Although controversial, serum AFP levels have been used as a 
marker for hepatocellular carcinoma (HCC) and nonseminomatous germ cell tumors 
(NSGCT) [369, 370]. Johnson et al. reported, in 1999, the isolation and structural elucidation 
of eleven glycan structures from HCC and NSGCT patients including seven N-linked 
glycans with different levels of sialylation, fucosylation, and galactosylation[369]. The 
authors stated that the glycans present on AFP may be useful for diagnosis as the glycan 
structures may be related to the type of tumor present in the patient. A study by Kim et 
al.[370] then showed that the glycosylated (or deglycosylated) form of AFP performed 
better as a diagnostic tool for HCC than the un-glycosylated form of the protein. 
Ajdukiewicz et al.[371] also reported abnormal glycosylation of AFP in some HCC making 
it plausible that the glycosylated heavy-labeled AFP in the secretome differs from that 
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present in the plasma sample due to the different origin of the samples. Moreover, this 
highlights the value of the SILAC HepG2 secretome as an internal standard for the 
analysis and detection of differential glycosylation in patient plasma. 
Again, SERPINC1 showed similar ratios for the unenriched and WGA-enriched samples 
but a different for the Con A-enriched sample as illustrated in Figure 28B suggesting 
similar sialic acid residues but different mannose residues between the HepG2 secreted 
protein and its plasma isotope. As a necessary factor for the inhibitory effect of heparin 
on thrombin and factor Xa in the clotting cascade, the discovery of potential differences 
Figure 29 - Deglycosylated Peptides from serotransferrin (TF) 
Heavy and Light isotopes of two peptides from serotransferrin (TF), CGLVPVLAENYNK and 
QQQHLFGSNVTDCSGNFCLFR showing distinct differences in the amounts present in the Con A-
enriched and WGA-enriched samples. Heavy peptides are shown in red font and light peptides in black. 
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in SERPINC1 glycosylation between the HepG2 secretome and human plasma is very 
relevant. Moreover, it is known that differences between the alpha and beta forms of 
SERPINC1 regarding the glycan composition is responsible for the approximately ten-
fold difference in heparin binding affinity[372]. We also observed differing H/L ratio for 
various proteins including serotransferrin (TF), and APOA1 between the Con A- and 
WGA-enriched samples compared to samples that were not enriched (Figures 28C-D). 
N-glycan analysis of TF by Fu et al. resulted in the identification of trisialylated 
carbohydrate species [373]. The higher H/L ratio of TF following WGA enrichment 
Figure 30 - Differential enrichment of 68 SIL HepG2 glycoproteins relative to human plasma 
Glycoproteins enriched by more than ±1.5 are indicated in red. SIL glycoproteins were enriched primarily 
with WGA lectin affinity relative to ConA lectin affinity.  
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compared to the unenriched sample suggests an overexpression of sialylated glycan 
residues in the HepG2 secretome relative to plasma. It is still largely unknown, for most 
major proteins, how glycosylation differs between healthy and disease patients. 
Consequently, the interaction of under- or overexpression of certain glycans with patient 
disease remains unclear [374]. Using our SILAC HepG2 secretome as an internal standard 
approach for comparative plasma studies, these interactions can be delineated to provide 
some insight into these very pertinent questions. The results of the quantitative analysis 
showed that of the two known N-glycopeptides from TF that were identified and quantified 
in the unenriched PNGase F-treated SILAC sample, CGLVPVLAENYNK was quantified 
only in the Con A-enriched sample and QQQHLFGSNVTDCSGNFCLFR only in the 
WGA-enriched sample. However, further manual data interpretation revealed that both 
peptides were present in both lectin-enriched samples albeit the light peptide was always 
more abundant in the Con A-enriched sample while the heavy peptide was always more 
abundant in the WGA-enriched sample (Figure 29). In addition, the lack of quantitative 
information on CGLVPVLAENYNK in the WGA-enriched sample is attributable to the low 
quality of the spectra compared to the spectra seen in the Con A-enriched sample. 
Finally, in Figure 30, we evaluated the general relationship between all proteins with 
sufficient quantitative information in the Con A and WGA-enriched samples. Except for a 
few proteins, the results indicate that there is a general bias towards WGA enrichment in 
the HepG2 secretome compared to plasma. This observation is consistent with previous 
reports in the literature that tumor cells present with hypersialylation [375, 376]. 
4.4 Conclusion 
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The extension of the applications of the SILAC labeled proteome to the analysis of 
biospecimen has been demonstrated in different studies. We provided, in a previous proof 
of principle study, evidence to show that these applications can be extended to plasma, 
the most abundant biospecimen in clinical settings. Apolipoproteins (e.g. APOA1, and 
APOE) and serine protease inhibitors (e.g. SERPINA1, SERPINA3, and SERPINA5) 
serve as biomarkers in various diseases in the clinic. In this present study, we have 
identified and quantified many of these usually difficult to measure apolipoproteins and 
SERPINs, demonstrating the utility of the SILAC HepG2 secretome as a spike-in internal 
standard for the analysis of clinical specimen such as plasma. Moreover, in comparison 
to our previously published proof-of-principle study, we have improved upon the total 
number of proteins quantified in the secretome:plasma sample from 62 to 143. 
Furthermore, we have successfully characterized the temporal SILAC-labeled HepG2 
secretome particularly as it relates to similarities and differences in glycosylation 
compared to human plasma. In so doing, we have further demonstrated the applicability 
and value of mass spectrometry-based proteomics, using the SILAC-labeled HepG2 
secretome as an internal standard, in comparative analysis of clinical samples. We have 
showed differences in the glycosylation of proteins e.g. AFP, SERPINC1, TF, and APOA1 
between the HepG2 secretome and plasma. Lastly, our results suggest an 
overrepresentation of sialylated glycans in the HepG2 secretome relative to plasma. 
Ongoing studies in our lab aim to demonstrate further applications of this approach and 
the potential to use the SILAC-labeled library of proteins generated from the HepG2 
secretome in identifying different glycan-binding ligands in plasma. 
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Chapter 5: Overall Conclusions 
 
 
 
Mass spectrometry-based proteomics has contributed enormously to research efforts that 
have led to many important discoveries that have resulted in improved understanding of 
cellular function and disease states over the past two decades [377]. With the current focus 
on the bridging the gap between clinical practice and basic science research, research 
efforts are directed at findings that can be easily transferred to the clinic to guide both 
clinical practice – early disease detection and diagnosis – as well as patient management 
[378, 379]. At the forefront of the clinical translation research paradigm is the search for 
novel, faster, and simpler ways of carrying out point-of-care tests. For this reason, MS-
based proteomics leads the search for biomarkers of disease aimed towards helping in 
early detection, diagnosis, and prognosis of disease and treatment. In addition, current 
MS-based efforts are aimed at the extension of traditional sample analysis to more 
complex and detailed analysis of biomolecular species including complex carbohydrates 
often found bound to proteins and sometimes lipids. 
Plasma represents the primary biospecimen for disease diagnosis and prognosis in the 
clinic and is therefore the sample of choice in the search for clinical biomarkers [93, 130, 380]. 
Initial research efforts however, benefit from looking into secreted proteins (secretome) 
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in cell culture. This approach is due, in part, to the complexity of plasma with protein levels 
spanning more than 10 orders of magnitude, as well as the analytical challenges involved 
in its LC-MS/MS analysis [82, 130]. As part of the normal homeostatic mechanism of the 
body and/or in response to different types of injury, cells secrete various proteins and 
other macromolecules into the extracellular environment. These secreted proteins may 
be found in the interstitial fluid, blood, cerebrospinal fluid (CSF), and bronchoalveolar 
lavage (BAL) fluid [130, 381]. Cell secretions contain many proteins with described function 
in cell-cell signaling and communication, immunity, and coagulation [93]. 
The cell culture secretome represents a surrogate for blood useful for early discovery and 
development research [93, 96] due to a combination of decreased complexity, more control 
of the experimental sample, and the relatively lower heterogeneity of samples compared 
to plasma [382, 383]. The secretome represents a great resource for these studies due also 
to the depth of information contained therein.  
5.1 H1299 NSCLC Study  
As has been demonstrated using MS-based proteomics, the secretome holds great 
experimental value as a model for biomarker discovery and development. In Chapter 3, 
the suitability of the secretome of the isogenic H1299 NSCLC cell line in biomarker 
discovery involving radiation-induced autophagy was demonstrated by the discovery of 
candidate biomarkers with potential use for diagnostic and prognostic purposes. Having 
been established, in previous studies in the Gewirtz lab, that cytoprotective and non-
cytoprotective autophagy are induced in response to ionizing radiation treatment in p53-
wt and p53-null H1299 cells respectively, this study aimed to explore the differences in 
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protein expression and secretion between p53-wt and p53-null cells before and after 
ionizing radiation treatment. The study was to delineate the value of different proteins as 
candidates for distinguishing between patients for whom autophagy modulation in 
addition to radiotherapy would or would not be beneficial. Initial data analysis revealed 
that the H1299 secretome was enriched for proteins associated with exosomes (~5.3 fold, 
p-value = 4.52 × 10-66) and chaperone activity (~15.1 fold, p-value = 5.12 × 10-13). An 
analysis of variance was conducted to determine protein differences across samples and 
yielded 25 proteins. Hierarchical clustering subsequently revealed that differential protein 
secretion was primarily dependent on p53 status. We then compared the protein levels in 
each sample to the mean protein level across all samples as a means of expressing 
protein secretion per sample/condition as a function of a population value. Levels of 
CHGB, SCG2, GPI, TXNRD1, FAM3C, CANX, and EIF5A were determined to be differ in 
the secretome based on radiation treatment and/or p53 status.  
Overall, we demonstrated differences in protein secretion and discovered the above-
mentioned candidate biomarkers that may serve a diagnostic purpose in early disease 
detection or prognostic role following radiotherapy. 
5.1.1 Future Studies 
While we have successfully developed MS-based proteomics methods for global protein 
analysis in the H1299 for biomarker discovery, it is necessary to recognize that more work 
may be done to build on the results of these studies.  
First, the study may be replicated in different NSCLC cell lines to determine if the protein 
secretion response observed in our study is generalizable or limited to only H1299 
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NSCLC cells. Following the identification of candidate biomarkers, it is essential to screen 
and validate the panel of proteins. Consequently, the H1299 radiation-induced autophagy 
biomarker study will benefit from further studies involving immunoassay (Western blot or 
ELISA) analysis of the proteins, both in the secretome and in cell lysates, to verify the 
increased or decreased protein levels observed in our MS-based proteomics study. 
Furthermore, it would be appropriate to explore the effect of pharmacological and genetic 
inhibition of autophagy on the levels of these proteins before and after radiation treatment. 
Indeed, if the secretion of the candidate proteins is altered significantly in autophagy-
competent versus autophagy incompetent cells, that would offer more support to their 
potential roles as biomarkers of radiation response in these H1299 cells. Finally, studies 
may be conducted to validate the presence and differential levels of these candidate 
proteins in the plasma of NSCLC patients before and after radiotherapy.  
5.2 HepG2 Study  
In Chapter 4, secreted proteins from HepG2 hepatocellular carcinoma cells were 
characterized as part of a larger effort in the generation of a library of intact SIL internal 
standards for comparative proteomics. HepG2 cells were cultured in serum-free 
conditions for 24h, 48h, and 72h and the conditioned media collected and analyzed via 
nLC-MS/MS. Protein secretion was generally observed to increase from 2.88 mg/mL (± 
0.11) at 24 hours to 3.46 mg/mL (± 0.08) at 48 hours and 4.02 mg/mL (± 0.08) at 72 hours. 
Expectedly, the increasing protein secretion over time translated into increasing protein 
intensities (LFQ) from 2.38E11 (± 3.20E9) at 24 hours to 2.63E11 (± 2.78E9) at 48 hours 
and then to 3.03E11 (± 2.55E9) at 72 hours. Among the Gene Ontology (GO) terms found 
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to be highly enriched in the HepG2 secretome are extracellular exosomes (~3.57 fold, p-
value = 3.13 × 10-257), and membrane (~1.90 fold, p-value = 1.27 × 10-27). 
A total of 1635 proteins were identified in the HepG2 secretome out of which 491 were 
determined to be plasma proteins through comparative analysis with the plasma proteins 
database curated by Nanjappa et al [365]. Despite known difficulties in LC-MS/MS analysis 
of apolipoproteins, the study showed the identification and quantification of many 
apolipoproteins including APOA1, APOA2, APOB, APOC1, and APOM. Serine protease 
inhibitors including SERPINA1, SERPINC1, and SERPIND1 were also among the major 
plasma proteins identified and quantified with high sequence coverage. 67 proteins were 
determined to increase consistently with time whereas 29 proteins decreased consistently 
over 72 hours. A Uniprot cross reference of the 491 plasma proteins revealed that 163 
proteins were N-glycosylated at 707 unique N-X-S/T sites. Of the Uniprot N-glycoproteins, 
76 were identified with 143 N-glycosites in the PNGase F-treated HepG2 secretome.  
A plasma spike in study was conducted, with and without lectin (Con A and WGA) 
enrichment of glycoproteins, in comparison of protein glycosylation between the SIL 
HepG2 secreted proteins and plasma. Differential glycosylation of proteins including AFP, 
SERPINC1, TF, and APOA1 was observed between plasma and the HepG2 secretome 
using the difference in levels of the Con A-enriched samples and WGA-enriched samples. 
Taken together, this study validated the HepG2 cell line as a good source for the 
generation of a library of intact SILAC labeled plasma proteins. Moreover, it demonstrated 
the extended applicability of the SILAC labeling strategy to plasma and other bodily fluids. 
5.2.1 Future Studies 
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In bottom-up MS-based glycomics, three essential pieces of information are necessary 
for a complete understanding and elucidation of glycoprotein structure. These are the 
sites of glycosylation, the intact glycopeptide sequences, and the types and numbers of 
different glycan species occupying the determined glycosites. Currently however, one of 
the major bottlenecks in glycomics is the successful elucidation of the glycans occupying 
specific glycosites on a protein on a global scale. Issues of the number of possible glycan 
structures combined with the paucity of reliable software necessary to automate the 
structural elucidation of glycan species contribute to this bottleneck.  
Future studies may focus on the identification of glycopeptide sequences from the HepG2 
secretome alone and in combination with plasma. Furthermore, it will be necessary to 
determine the structures of the glycans shown in the lectin enrichment study to differ 
between plasma and the HepG2 secretome. Information obtained from determining intact 
glycopeptide sequences may then be utilized in the determination of glycan structures; 
the glycopeptide weight minus the weight of the deglycosylated peptide gives the weight 
of the glycan(s) that inhabit the N-glycosite(s) on the peptide sequence. This offers a good 
starting point for beginning to elucidate the structure of the glycans. Through glycan 
structure elucidation, it will be possible to conclusively determine the differences in 
sialylation between plasma and the HepG2 secretome. 
In conclusion, the results of the studies outlined in this dissertation support the use of the 
cancer cell secretome for biomarker discovery as demonstrated in the H1299 NSCLC 
study as well as the extension of the SILAC proteome to comparative plasma studies. 
Furthermore, the HepG2 study offers a foundation for building on the glycomics of the 
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HepG2 secretome as a platform for the generation of plasma proteins capable of use as 
internal standards. 
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